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Recombinant Human Lactoferrin Injectable Hydrogel as an Osteogenic Biomaterial

Ashley Ali Amini, PhD
University of Connecticut, [2014]

The bidirectional signaling of lactoferrin (LF) that suppresses osteoclastogenesis
and enhances osteoblast proliferation and survival supports the notion that LF is a strong
candidate for bone tissue engineering. The proposed studies were aimed to increase our
understanding of the effect of recombinant human LF (rhLF) in modulating skeletal cells
and further establish rhLF crosslinked gel as an excellent candidate for a skeletal
regenerative biomaterial.
In situ formation of injectable biomaterials has several advantages as cell delivery
vehicles. In this study, the biological properties rhLF were utilized as the building block,
to develop the engineered cell delivery system. These studies reported the development
of a novel injectable cell delivery vehicle that can significantly improve cell survival and
osteogenic functions by serving as a biomaterial ligand to induce receptor mediated cell
signaling of encapsulated cells. Furthermore, the bioactive rhLF gel matrix was shown to
promote cell survival, proliferation and differentiation. The positive effects of rhLF gel
on cellular processes supports the notion that rhLF gel is a strong candidate for bone
tissue engineering.
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1 Synopsis
The pursuit for bone tissue engineering has been prompted by clinical demands
that may occur as a result of congenital anomalies, trauma and skeletal diseases (Geckil
et al. 2010, Huang et al. 2011). The current gold standard for skeletal repair is autografts
(Laurencin et al. 1999).

However, this treatment has limitations, which include donor

site morbidity and limited availability. Allografts are commonly used as an alternative
option to autografts, however, it too is associated with significant limitations – delayed
vascular penetration, slow bone formation, high incidence of non-union or delayed union
and possibility of disease transmission (Delloye et al. 2007). A new avenue, namely
bone tissue engineering, is currently being explored to overcome the limitations of these
biological grafts. Tissue engineering uses cells, scaffolds, and biological factors alone or
in combination toward the repair, restoration and replacement of bone tissues (Laurencin
et al. 1999).
A major modality in tissue engineering is cell-based therapeutics, and its
efficiency is based on successful delivery of cells to sites of repair or regeneration.
Recently, various biomaterials have been employed to mediate localized cell delivery. In
situ—forming gel scaffolds (i.e., injectable, crosslinked polymeric networks) are of great
interest since they can be implanted simply by injection to fill irregularly shaped defects.
These crosslinked networks allow for the accomadation of homogeneous incorporation of
cells and bioactive molecules in a three-dimensional (3D) microenvironment. Moreover,
protein-based gels are especially attractive since their bioactivity may encourage
encapsulated cells to recognize and bind to specific sites within proteins. Recently,
significant interest has grown towards developing biologically active gels that could
modulate the functions of encapsulated cells for better regenerative outcome. Our lab has
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previously developed a novel, in situ—forming, lactoferrin (LF) – based gel system that
may utilize the biological functions of the native protein for the development of a
bioactive biomaterial in order to modulate encapsulated cell functions. The rationale for
developing a LF-based gel is multi-fold. 1) The gel is in situ forming, which allows for
non-invasive implantation through injection. 2) The injectable gel may also be used as a
cell delivery vehicle as it provides a mild water rich environment. 3) Due to the potential
bioactivity of LF, the gel might present a bioactive environment for enhanced cellular
performance.
Our preliminary studies discussed here demonstrated the bioactivity of bovine LF
(bLF) gel. bLF was used to evaluate the bioactivity of the novel biomaterial since there
is significant literature on the bioactivity of soluble bLF protein. The advent of the
recombinant human protein technology, however, offers a cost-effective alternative and a
foundation for producing consistent and predictable results for potential clinical
applications. The goal of the present study aimed to evaluate the bioactivity of rhLF
towards osteoblast cells, and develop a bioactive injectable cell delivery system based on
rhLF.
We hypothesize that injectable rhLF gel can be formulated and this biomaterial
will possess osteogenic activities. We further hypothesize that the cell survival activities
of the rhLF gel are regulated upstream of PI3K/Akt and the osteogenic activities will be
transduced via a β-catenin—dependent signaling pathway.
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Figure 1. Crystal structure of (A) bLF of (B) hLF.
Each protein binds to two Fe3+ atoms (pink spheres) – one in each lobe of the protein.
Image taken from (Vogel 2012).

Since there is only 69% species homology between the bLF and human LF (hLF)
(van Berkel et al. 2002b) (Figure 1), we first confirmed the bioactivity of rhLF protein
using in vitro cell models. We also investigated the biological effects of the various iron
saturation forms of rhLF (apo-, pis- and holo-) on MC3T3 pre-osteoblast cells to
understand the effect of iron concentration on rhLF bioactivity and identify the suitable
polymer to develop injectable hydrogels for bone tissue engineering application. We
performed a global gene analysis using microarrays to examine the effect of LF iron
saturation on MC3T3 cells. MC3T3 cell line was selected to evaluate the bioactivities of
rhLFs since it is a well-characterized murine osteoblast cell line (Sudo et al. 1983) that
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has been used extensively as a model for osteoblasts in vitro. Next, we compared the
effect of holo-rhLF on two in vitro culture systems: clonal MC3T3 cells and primary
NHOst cell cultures. These comparative experiments were designed to confirm whether
MC3T3 could act as a good model cell line to demonstrate the potential future clinical
efficacy of the system. Further, the biological effects (cell survival, proliferation and
osteogenesis) of holo-rhLF were tested using standard cell culture system. Molecular
mechanism underlying LF’s anti-apoptotic and osteogenic effects were probed using
western blot analysis and PCR arrays, and confirmed using pharmacological inhibitor
studies. Finally, after establishing the biological effects and molecular mechanisms of
holo-rhLF protein on MC3T3 cells, our next aim was to characterize the physical
properties of crosslinked holo-rhLF gel based on gelation time, water uptake, mechanical
properties and morphology properties to be further employed as a regenerative skeletal
biomaterial. In all these studies, enzyme-crosslinked injectable gelatin gel was used as
the control. Biological effect of holo-rhLF on MC3T3 pre-osteoblasts was evaluated
based on its ability to promote cell survival, proliferation and differentiation compared to
the gelatin gel.
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2 Literature review
2.1 Injectable hydrogels for skeletal repair
The pursuit to engineer bone and cartilage microenvironments are prompted by
the clinical demand for skeletal tissue repair and replacement, which occur as a result of
congenital anomalies, trauma and skeletal diseases (Geckil et al. 2010, Huang et al.
2011). Autografts, the current gold standard for bone and cartilage repair, presents itself
with limitations, including donor site morbidity and limited availability. Although the
use of allografts can overcome these limitations, they also have substantial limitations,
which include delayed vascular penetration, slow bone formation, high incidence of nonunion or delayed union and possibility of disease transmission (Burchardt 1987, Wozney
et al. 1988). The avenue of tissue engineering explores the use of cells, scaffolds, and
biological factors alone or in combination toward the repair, restoration and replacement
of tissues (Laurencin et al. 2001).

The opportunities and challenges for tissue

engineering are extensive for both bone and cartilage.
The extracellular matrix (ECM) in natural tissue provides the structured
microenvironment with mechanical, biochemical and physical cues that enable the cells
to interact with each other and with the ECM to allow optimal cell function. ECM is a
dynamic structure that consists mainly of fibrous proteins and some glycosaminoglycans,
which self-assemble into nanofibrillar supramolecular networks (collectively called
structural/physical signals) to provide structural architecture to support the resident cells
(Nair, Laurencin 2006).

The native microenvironment is not only composed of ECM,

but also biomolecules (growth factors, chemokines and cytokines) and ions that are
bound to the ECM. Growth factors bind to target cell receptors and induce intracellular
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signal transduction that reaches the cell nucleus and determines the biological response
(Devescovi et al. 2008). The main growth factors acting on the skeleton are bone
morphogenetic proteins (BMPs), transforming growth factor β (TGFβ), fibroblast growth
factor (FGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor
(VEGF) and insulin-like growth factors (IGFs) (Linkhart, Mohan & Baylink 1996,
Baylink, Finkelman & Mohan 1993). Each biological growth factor has specific roles in
the growth, maintenance and repair of the skeleton. In summary, the multifunctionality
of ECM is achieved through the biochemical signaling from the soluble factors along
with the unique tissue specific matrix composition and hierarchical structural features. It
is therefore pertinent to consider the structural features of ECM along with the biological
principles that govern cell-cell and cell-matrix interactions while developing novel
strategies to promote tissue regeneration. Successful fabrication of a biomimetic scaffold
requires

the

biomaterial

to

be

finely

tailored

toward

the

dynamic

native

microenvironment and to mimic the intricate and organized meshwork of extracellular
matrix (ECM).

2.1.1 Hydrogels as skeletal ECM mimetic scaffolds
Hydrogels are cross-linked, porous networks that exhibit high tissue-like water
content and elastic properties. The potential of hydrogels as unique biomaterials was
reported in the later half of the 20th century when non-degradable methacrylate gels were
used for developing soft contact lenses. Subsequently, a wide range of hydrogels were
developed using synthetic and natural hydrophilic polymers that are biodegradable or
non-degradable for various biomedical applications in the form of drug/gene/and protein
delivery, as unique wound dressing materials as well as scaffolds for tissue engineering
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(Peppas, Sahlin 1996). Synthetic hydrogels provide more chemically programmable and
reproducible

platform

to

systematically

understand

cell-matrix

interactions.

Poly(ethylene glycol) (PEG) is one of the most extensively investigated non-degradable,
synthetic, hydrophilic polymer for biomedical applications due to its hydrophilicity, good
tissue compatibility, non-toxicity and availability of reactive end groups for chemical
functionalization.

Several degradable synthetic polymeric systems have also been

developed to form hydrogels. These include co-polymers of PEG with a variety of
synthetic degradable polymers such as poly(lactic co-glycolic) acid (PLGA),
poly(propylene fumarate) (PPF), poly(vinyl alcohol) (PVA), poly(propylene oxide)
(PPO), polyanhydrides and polyphosphazenes (Joa, Engelb & Mikos 2000, Lee et al.
2007). Among the natural biodegradable hydrophilic macromolecules investigated for
hydrogel formation, proteins and polysaccharides form the most prominent members
(Coviello et al. 2007).

This is due to various advantages such as non-toxicity,

biocompatibility, availability in large variety of composition and properties, widely
present in living organisms as well as due to the fact that they can be produced using
recombinant DNA techniques (Coviello et al. 2007).

Hydrogels made of naturally

derived, polysaccarides for skeletal repair include agarose, alginate, chitosan and
hyaluronic acid (Burdick, Prestwich 2011). Protein-based scaffolds, such as collagen,
gelatin and fibrin, are very attractive for building bioactive scaffolds due to their ability
to mimic the extracellular environment, biodegradability and inherent biochemical
properties (Stenzel, Miyata & Rubin 1974, Dreesmann, Ahlers & Schlosshauer 2007, Liu
et al. 2009, Spotnitz, Burks 2008). These biocompatible and biodegradable matrices due
to their highly swollen three-dimensional environment with large pore sizes, porosity and
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high water content provide temporary support for cell growth and maintenance as they
facilitate the transfer of nutrients, gases, metabolic waste and cell signaling molecules.
Furthermore, convenient tunability of these scaffolds allows for the incorporation of
sophisticated biochemical cues in these networks to better mimic the native
microenvironment.
In addition to preformed hydrogels, injectable in situ forming hydrogels are of
significant interest for therapeutic and diagnostic applications. The ability to introduce
the injectable in situ forming hydrogels via simple injection significantly increases
patient compliance relative to preformed hydrogels, which must be crosslinked in vitro
and then surgically implanted in vivo. The injectable hydrogels can be processed in the
operating room, can be used to fill irregularly shaped defects as the implants are formed
in situ at the defect site, can shorten surgical time, minimize surrounding tissue damage
and reduce postoperative pain and scar size. Moreover, with injectable gels, the gelation
takes place under very mild physiological conditions allowing for the successful
encapsulation of cells and biologically active proteins or peptides for regenerative
applications (Nguyen, Lee 2010).
The biological properties of bone and cartilage tissue are highly distinguished
from each other with regards to physical structure, vascularity, growth factors and cell
types.

As a result of this uniqueness, there are distinct demands for design and use of

biomaterials for the regeneration of these tissues. For cartilage regeneration, hydrogels
may effectively able to serve as ECM mimics. However, due to the high mechanical
strength and structural complexity of bone, hydrogels may be effectively used as carriers
for biological growth factors and cells to aid bone regeneration.
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2.1.2 In situ gelling hydrogel systems
Several criteria need to be met to develop an ideal in situ-forming injectable gel
for biomedical applications. These include: 1. Solubility in aqueous media with gelation
occurring in physiological conditions (temperature, pH and ionic concentration); 2. No
release of harmful by-products upon gelation; 3. Gelation occur at a sufficiently rapid rate
for clinical efficacy, however allow adequate time for proper mixing and injection of the
solution in the presence of additives such as cells and/bioactive molecules (Ma, Elisseeff
2005).
Hydrophilic polymers that can undergo gelation in response to different types of
stimuli have been developed either by modifying existing polymers or by specifically
designing polymers with stimuli sensitive units along the polymer chain. The various
stimuli of interest for biomedical applications include light (photo-polymerizing/photogelling systems), chemical agents (chemical and ionic crosslinking systems) as well as
environmental stimuli from the physiological environment (temperature, pH and ionic
strength). Physical and chemical crosslinking methods can be used to develop hydrogels.
Physical crosslinking of the polymers is generally considered to be milder than chemical
crosslinking reactions. Hydrogels formed by ionic and thermogelation are examples of
those formed via physical crosslinking. On the downside, the instability and reversibility
of many of these systems yields low mechanical properties (Nguyen, Lee 2011).
Chemical crosslinking generally yields more stable hydrogels with better mechanical
properties relative to those formed by physical crosslinking. The main drawback of
chemical crosslinking is the need to incorporate reactive compounds and/or
photoirradiation, which may lead to toxicity problems. However, recent advances in
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chemical crosslinking methods led to the development of systems that undergo gelation
under mild reaction conditions.

Examples of various hydrogel materials and their

crosslinking mechanism are listed in Table 1.
Table 1. Various hydrogel materials, crosslinking initiators and mechanism.
Material

Gel Precursors

Crosslink
Mechanism

Reference

Pluronics

Macromer(s): PEO-PPO-PEO
Initiator: temperature (37°C)

Physical

(Ruel-Gariepy,
Leroux 2004)

Chitosan-Pluronics

Macromer(s): chitosan and pluronics
Initiator: temperature (37°C)

Physical

(Weng et
al. 2001)

Chitosan–AHP

Macromer(s): chitosan and AHP
Initiator: temperature (37°C)

Physical

(Nair et al. 2007)

Chitosan-glycerol
phosphate

Macromer(s): Chitosan and glycerol phosphate
Initiator: temperature (37°C)

Physical

(Ahmadi, de Bruijn
2008)

PPF-co-ethylene
glycol

Macromer(s): hydrophobic PPF and hydrophilic
PEG
Initiator: light

Covalent

(Fisher et al.
2004)

Hyaluronic acid

Macromer(s): tyramine substituted hyaluronic
acid
Initiator: HRP enzyme

Covalent

(Darr, Calabro
2009)

Hyaluronic AcidPluronics

Macromer(s): Hyaluronic Acid and pluronics
Initiator: temperature (37°C)

Physical

(Jung, Park & Han
2010)

SMO-PCLA-PEGPCLA-SMO
copolymer hydrogel

Macromer(s): pH-sensitive SMOs and thermosensitive PCLA-PEG-PCLA
Initiator: temperature (37°C) and pH (7.4)

Physical

(Shim et al. 2006)

oxidized alginate,
gelatin and biphasic
calcium phosphate

Macromer(s): oxidized alginate, gelatin and
biphasic calcium phosphate

Covalent

(Nguyen, Lee
2011)

2.1.2.1 Physically crosslinked hydrogels

Thermo-gelation is one of the most extensively investigated strategies to develop
physically crosslinked in situ gelling polymers. N-isopropyl-acrylamides (NIPAAm),
pluronics and various PEG based polymers are some of the most widely used nondegradable thermo-gels (Ruel-Gariepy, Leroux 2004). Aqueous solutions of triblock
copolymers composed of PEO and PPO (PEO-PPO-PEO) exhibit sol-to-gel phase
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transitions at physiological temperatures and are commercially known as Pluronics.
Chondrocytes suspended in Pluronics "painted" onto a tissue engineered osseous surface
resulted in a bone-cartilage interface for mandibular condylar reconstruction (Weng et al.
2001). Even though pluronics has advantages such as mild gelation, ability to increase
the stability of encapsulated proteins, and good biocompatibility, the low mechanical
integrity of the gel, non-degradability, limited gel stability with quick dissolution and
high permeability limits its biomedical applications (Liu et al. 2007). This led to the
development of several degradable block co-polymers with hydrolytically sensitive
blocks

such

as

poly(lactic

acid/glycolic

acid)

or

poly(caprolactone)

and

pluronics/PEG/NIPAAm units as potential candidates for biomedical applications (Cohn
et al. 2006, Jeong, Bae & Kim 2000, Chen, Singh 2005). Thermosensitive chitosan–
pluronic hydrogel has proven itself to be a successful injectable cell delivery vehicle for
cartilage regeneration (Park et al. 2009). Composite thermosensitive hydrogel using
pluronic derivatives and crosslinked hyaluronic acid (X-HA) loaded with TGFβ1 have
been shown to increase benefits in the induction of chondrogenic differentiation of
human adipose-derived stem cells in a full-thickness defect of rabbit knee articular
cartilage model (Jung, Park & Han 2010).
A pH- and temperature-sensitive hydrogel of sulfamethazine oligomer, poly(εcaprolactone-co-lactide)-poly(ethyleneglycol)-poly(ε-caprolactone-co-lactide)

(SMO-

PCLA-PEG-PCLA-SMO) pentablock copolymer was synthesized by adding pH-sensitive
SMOs to either end of a thermo-sensitive PCLA-PEG-PCLA block copolymer. This
copolymer solution forms stable gel under physiological conditions (pH 7.4 and 37°C),
but not at high pH (pH 8.0) or at increased temperatures (ca. 70°C) (Shim et al. 2006).

	
  

36

pH/temperature-sensitive hydrogel of poly(beta-amino ester)-poly(ε -caprolactone)-poly
(ethylene glycol)-poly(ε-caprolactone)-poly(beta-amino ester) (PAE-PCL-PEG-PCLPAE) pentablock copolymer was evaluated as a sustained injectable insulin delivery
system (Huynh et al. 2009).

Insulin was ionically linked forming an insulin-PAE

complex and was steadily released for 15 days in a Sprague-Dawley rat subcutaneous
model (Huynh et al. 2009). The ability of these systems to undergo gelation under
physiological conditions (pH 7.4 and 37°C) makes them strong candidates for therapeutic
applications.
Apart from synthetic polymers, several natural polymers have also been used to
develop thermogels mostly due to their innate thermo-sensitivity. Methyl cellulose, a
biocompatible polysaccharide can undergo thermogelation around 37°C due to the
hydrophobic interactions between molecules containing methoxy substitution. Ghanaati
et al. evaluated the efficacy of an injectable composite bone substitute composed of β tricalcium phosphate (β-TCP), methyl cellulose and hyaluronic acid.

The presence of

the polymeric phase decreased the degradation time of β-TCP and at the same time
increased the vascularization of the construct (Ghanaati et al. 2011). Chitosan is another
polysaccharide that is attracting significant attention as a biomaterial due to its
biodegradability, biocompatibility and wound healing properties. We have developed an
injectable thermo-gelling system based on chitosan using inorganic phosphate salts as the
neutralizing and thermo-gelling agent (Nair et al. 2007). The in situ gelling system was
developed by adding ammonium hydrogen phosphate (AHP) to chitosan solution at low
temperature. The system has been found to be highly versatile with gelling time varying
from 5 minutes to several hours at 37°C by varying the concentration of the phosphate
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salt. The injectability of the system as well as the feasibility of using chitosan–AHP
thermogels as a cell delivery vehicle has been demonstrated (Nair et al. 2007).
Biocompatible, chitosan-glycerol phosphate hydrogels have also been demonstrated to
stimulate mesenchymal stem cell proliferation as a potential vehicle for cell
encapsulation (Ahmadi, de Bruijn 2008). Furthermore, chitosan molecules, which share
glycosaminoglycan (GAG) structural features, have been crosslinked with proteins or
other GAGs to promote chondrogenesis (Suh, Matthew 2000). Various reagents such as
β-glycerophosphate, genipin and glyoxal have been investigated to develop composite
injectable hydrogels of chitosan with proteins such as collagen (Wang, Stegemann 2010,
Wang, Stegemann 2011).

Hydroxy butyl chitosan (HBC), a water-soluble

thermosensitve polysaccharide, can undergo physical gelation under physiological
conditions and has also been investigated as a cell delivery vehicle (Dang et al. 2006).
Agarose, a polymer isolated from red algae and seaweed, crosslinked via
hydrogen bonds has been shown to be well suited for 3D cell encapsulation, especially
for chondrocytes (Benya, Shaffer 1982, Buschmann et al. 1992). BMP2-transduced
mesenchymal stem cells (MSCs) form more cartilage-like tissue in agarose gels than in
other matrices, such as collagen and alginate. This has been attributed to the tendency of
agarose gel to resist blood vessel invasion resulting in low oxygen tension that facilitate
cartilage tissue formation (Xu et al. 2005).
Alginic acid, another polysaccharide present in brown algae has also been
extensively investigated for cell encapsulation. Alginic acid can undergo rapid ionotropic
gelation in the presence of various divalent cations, including calcium, zinc and strontium
(Wee, Gombotz 1998, Rowley, Madlambayan & Mooney 1999, Place et al. 2011).
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Calcium-alginate gels are studied as a scaffold for encapsulating non-adherent cells such
as chondrocytes as it does not mediate mammalian cell adhesion due to its poor binding
of serum proteins (Smetana 1993).

This will allow for maintaining the spherical

morphology of chondrocytes in alginate gels. In comparison with the native cartilage
tissue, the calcium-alginate hydrogels display slightly lower water content and
compressive modulus but the tensile modulus of these hydrogels match well with that of
the tissue (Wan et al. 2008). On the other hand, since osteoblasts may not thrive in a
non-adhesive hydrogel environment, the chemistry of hydrogels may further be amended
(i.e., covalent grafting of adhesion peptides (Hern, Hubbell 1998, Mann et al. 1999,
Rowley, Mooney 2002) and tethering growth factors (Mann, Schmedlen & West 2001)).
Hydrogels modified with cell surface adhesion peptides, such as arginine-glycine-aspartic
acid (RGD), can improve osteoblast adhesion and matrix synthesis within the 3D
polymer network (Burdick, Anseth 2002, Alsberg et al. 2001).
Gelatin is the denatured form of the ECM’s main component, collagen, and has
been used successfully as a cell vehicle in chondrogenesis studies (Ponticiello et al. 2000)
and bone tissue engineering (Payne et al. 2002). Crosslinking of gelatin polymer has
been demonstrated in various ways including physical crosslinking due to its
thermosensitivity. However, the use of these biodegradable matrices formed via physical
crosslinking is limited due to their weak structure at physiological temperature (Landers
et al. 2002).
Self-assembled peptide-amphiphile (PA) molecules, which consist of a peptide
segment coupled to a fatty acid chain, into 3D nanofiber networks have been shown to
support cell processes, including cell migration, proliferation and differentiation within
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the hydrogel (Paramonov, Jun & Hartgerink 2006, Silva et al. 2004, Hosseinkhani et al.
2006b). The formation of self-assembling gels is driven by the hydrophobic core, which
is composed of closely packed alkyl tails, and the fibrous strands that build-on via
hydrogen bonds between the amino acids of adjacent PA molecules. Self-assembly can
be triggered upon mixture of PA solutions with cell culture media or other physiological
fluids that contain polyvalent metal ions (Zhang 2002, Zhang 2003). The PA system
presents a versatile platform, where in molecules can be designed and developed for
specific applications. PA system has been developed that allows for mineral deposition
(Hartgerink 2004), optimized cell adhesion (Harrington et al. 2006, Guler et al. 2006) and
supports ectopic bone formation (Hosseinkhani et al. 2006b).

Another interesting

variation of PA systems includes the in situ hydrogel formation through ionic interactions
between negatively charged PAs and a positively charged basic fibroblast growth factor
(bFGF) (Hosseinkhani et al. 2006a). Although these types of self-assembling systems are
inherently biocompatible and versatile, they may present difficulties for precisely
controlling the gelation and mechanical properties.
2.1.2.2 Covalently crosslinked hydrogels

Visible or near ultra violet light induced photo-polymerization is one of the most
extensively investigated in situ gelation process for developing injectable covalently
cross-linked hydrogels. Biodegradable photocurable polymers form a versatile class of
injectable biomaterials as the aqueous polymer solution can be introduced to the desired
site via injection followed by photo curing in situ using fiber optic cables. The most
extensively investigated route involved water-soluble polymers with acrylic/methacrylic
side groups that can undergo photo-polymerization via a radical chain polymerization
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mechanism initiated by appropriate photo-initiators. Moreover, photopolymerization
allows for temporal and spatial control over scaffold formation, enabling the implantation
of complex structures such as multilayered hydrogels in a minimally invasive manner
with minimal heat production. Multilayered photopolymerizable hydrogels facilitate the
encapsulation of multiple cell types in a stratified organization and also control of spatial
presentation of bioactive factors within the scaffold.

Zonal organization of articular

cartilage is of structural and functional importance. To achieve zonal distribution of
multiple cell types, researchers have combined cells with photosensitive polymers that
could be injected and gelled in situ or photopolymerized in layers, reproducing the
structures of articular cartilage and osteochondral tissue (Hunziker, Quinn & Hauselmann
2002, Hu et al. 2001).
Poly(propylene fumarate) (PPF), a biocompatible and biodegradable polyester
that can be crosslinked through its fumarate double bond, undergoes cell-friendly
biodegradation as one of its degradation products include fumaric acid, a substance which
occurs naturally as a part of the Kreb’s cycle (Kasper et al. 2009). Peter et al. used PPF
to successfully produce chemically crosslinked hydrogels in vivo capable of acting as an
injectable bone cement (Peter et al. 1997).

Furthermore, a polymer-based system of

copolymer PPF-co-ethylene glycol, formed from hydrophobic PPF and hydrophilic PEG,
support chondrocyte survival and ECM production (Fisher et al. 2004). The versatility of
PPF and its ease of modification lend itself to be an excellent candidate for bone and
cartilage replacement. The material property allows it to be injected into irregularly
shaped bone voids in vivo and provide good mechanical stability to support bone
regeneration. Recently, osteoblasts have been added to the PPF construct to improve the
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rate and extent of new bone formation (Payne et al. 2002). TGFβ-loaded PPF composite
scaffolds was shown to act directly on cell migration and differentiation within the
material (Peter et al. 2000, Lu, Stamatas & Mikos 2000, Lu, Yaszemski & Mikos 2001).
Porter et al. has developed porous composites from PPF and tricalcium phosphates as
scaffolds for bone regeneration. The moduli of the composites are on the order of
magnitude of trabecular bone indicating that these composites are attractive candidates
for use as a replacement scaffold for trabecular bone (Porter et al. 2000).
Photo-crosslinkable dendrimers, which are highly branched and regularly
structured macromolecules composed of natural metabolites (i.e., succinic acid, glycerol,
and beta-alanine), and non-immunogenic PEG have been synthesized using ester and
carbamate forming reactions. Histological analysis of the photo-crosslinked macromer
solutions in a rabbit osteochondral defect showed good attachment in the defect site and
presence of collagen II and GAGs in contrast to the contralateral unfilled defects. The
strong potential of these dendrimer-based, photocrosslinked hydrogels as scaffolds for
osteochondral defect repair was illustrated by its good mechanical properties, lower water
absorption, good adhesion to the defect site, and positive in vivo performance (Degoricija
et al. 2008).
Even though degradable injectable photo crosslinkable systems presents unique
advantages, the gelation process does present some limitations such as residual high
molecular weight kinetic chains upon gel degradation, mild toxicity associated with the
photo-initiators, limited control over the network evolution mechanism during chaingrowth and also light attenuation by the initiators restricting the maximum attainable cure
depth of only a few millimeters (Rydholm, Bowman & Anseth 2005).
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To circumvent the limitations of photo-polymerization, crosslinking using
thiolated polymers have been proposed.

The thiolated polymers form degradable

networks through Michael-addition type reaction when reacted with polymers containing
acrylate, acrylamide or vinyl sulfone groups (Lutolf, Hubbell 2003, Vernon et al. 2003).
The thiol based systems has shown to form crosslinked networks with better control over
the crosslink density, eliminate high molecular weight degradation products as the
degradable segments get incorporated throughout the network and allow samples to be
cured to depths exceeding 10 cm and therefore have significant potential as an in situ
gelling system for cell encapsulation (Rydholm, Bowman & Anseth 2005).
Polymeric aldehydes derived from polysaccharides having vic-diols using
periodate chemistry are potential candidates for developing injectable fast gelling systems
due to their chemical reactivity. An in situ gelling non-toxic system via the crosslinking
of oxidized alginate and amino groups of gelatin has been reported (Balakrishnan,
Jayakrishnan 2005). Recently, Nguyen et al. fabricated a composite gel consisting of
oxidized alginate, gelatin and biphasic calcium phosphate as a bone graft substitute
(Nguyen, Lee 2011).

Covalent crosslinking of the composite was achieved via Schiff-

base reaction between the aldehyde groups of oxidized alginate and amino groups of
gelatin (Boanini et al. 2010, Liao, Zhang & Chen 2009). The osteogenic properties of the
composite have been attributed to the calcium phosphate ceramics, which release calcium
and phosphate ions upon degradation that are beneficial to bone formation. Furthermore,
the system presents excellent tunability wherein the degree of crosslinking, water uptake
and mechanical strength may be controlled by the degree of alginate oxidation.
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With

excellent biocompatibility and biodegradability, this composite is an example of a
promising injectable biomaterial for bone regeneration.
2.1.2.2.1 Enzymatically crosslinked hydrogels
Another emerging technique for developing in situ gelling system for biomedical
applications is based on enzyme-catalyzed crosslinking reactions due to the mild, cellfriendly and natural crosslinking process involved (Table 2, Figure 3).

Enzymatic

crosslinking of hydrogels is an innovative alternative to other crosslinking methods, such
as the photo-polymerization or physical crosslinking. Drawbacks to other crosslinking
methods include cytotoxicity in photo-polymerized gels and insufficient mechanical
strength in physically crosslinked gels. These limitations may be overcome through the
use of enzymes to covalently crosslink polymers to form hydrogels. Transglutaminases
and horseradish peroxidases (HRP) are highlighted as enzyme systems involved in
hydrogel crosslinking.
Transglutaminase has been investigated as a biocompatible catalyst to crosslink
polymers containing glutamine and lysine residues in a calcium-dependent reaction
(McHale, Setton & Chilkoti 2005a, Yung, Bentley & Barbari 2010, Davis et al. 2010b).
Tissue transglutaminase is naturally found in vivo during wound healing for the purpose
of stabilization and organization of the ECM (Greenberg, Birckbichler & Rice 1991).
Members of the transglutaminase family have been used to crosslink polymers, including
PEG (Hu, Messersmith 2003, Ehrbar et al. 2007) and elastin-like protein polymers
(McHale, Setton & Chilkoti 2005a) to form gels.
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Figure 2. Enzymatically crosslinked recombinant protein by transglutaminase (TG)
enzymatic crosslinking.
(A) Schematic of the protein hydrogel formation by tissue transglutaminase enzymatic
crosslinking. (B&C) Photograph of the precursor solution before and after enzymatic
gelation with tTG. (D) Photograph of a transparent hydrogel crosslinked by TG. Image
taken from (Davis et al. 2010a)

Several synthetic and natural polymers functionalized with tyramine, tyrosine or
aminophenol side groups are currently under development that can form in situ gels by
phenol or aniline derivative coupling using hydrogen peroxide as an oxidant catalyzed by
HRP (Kurisawa et al. 2005, Kobayashi, Uyama & Kimura 2001, Jin et al. 2007a, Lee,
Wagoner Johnson & Murphy 2010).

HRP-mediated crosslinking takes place at

physiological pH and temperature and the gelation time can be modulated to a great
extent by varying the reagent concentrations, making this a potential route to form
injectable cell and protein delivery vehicles (Sakai et al. 2009, Hu et al. 2009). For
example, tyramine substituted hyaluronic acid was developed to form injectable gels in
the presence of HRP (Darr, Calabro 2009). The injectable system has several advantages
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as the gelation time, equilibrium swelling and storage modulus of the gel may be adjusted
by varying the degree of substitution of tyramine residues and polymer concentration.
Furthermore, the mild enzymatic crosslinking has shown to be highly suitable for
chondrocyte encapsulation as it allow for high viability of encapsulated chondrocytes,
maintenance of the encapsulated cells’ round morphology, increased production of
glycosaminoglycans and collagen type II (Jin et al. 2010a).

Table 2. Enzyme-catalyzed crosslinkable hydrogels and potential applications.
Table adapted from (Teixeira et al. 2012)
Gel	
  type/composition	
  

Enzyme	
  type	
  

Potential	
  applications	
  

References	
  

Fibrin	
  gel	
  

Factor	
  Xllla	
  
(transglutaminase	
  
isoenzyme)	
  

Angiogenesis	
  

(Eyrich	
  et	
  al.	
  2007,	
  Hall,	
  
Baechi	
  &	
  Hubbell	
  2001)	
  

8-‐arm	
  PEG-‐peptide	
  
conjugates	
  

Factor	
  Xllla	
  
(transglutaminase	
  
isoenzyme)	
  

Drug	
  delivery	
  systems	
  

(Ehrbar	
  et	
  al.	
  2007,	
  Sala	
  
et	
  al.	
  2010)	
  

Elastin-‐like	
  polypeptide	
  
gels	
  

Tissue	
  
transglutaminase	
  

Cartilage	
  tissue	
  repair	
  

(McHale,	
  Setton	
  &	
  
Chilkoti	
  2005b)	
  

Surgical	
  tissue	
  adhesives	
  

(Hu,	
  Messersmith	
  2005)	
  

PEG-‐peptide	
  conjugates	
  

Bone	
  and	
  cartilage	
  tissue	
  
repair	
  

Cartilage	
  tissue	
  repair	
  
Gelatin	
  

Microbial	
  
transglutaminase	
  

Scaffolds	
  for	
  tissue	
  
engineering	
  

(Yung	
  et	
  al.	
  2007)	
  

Gelatin	
  

Calcium-‐independent	
  
microbial	
  
transglutaminase	
  

Microfluidic	
  biosensor	
  
systems	
  

(Chen	
  et	
  al.	
  2003b)	
  

Gelatin-‐chitosan	
  
conjugates	
  
Gelatin-‐chitosan	
  
conjugates	
  
Coil-‐chitosan	
  
bioconjugate	
  

Tyrosinase	
  

Tissue	
  glue	
  

(Chen	
  et	
  al.	
  2003a)	
  

Film	
  biofabrication	
  

(Wu,	
  Bentley	
  &	
  Payne	
  
2011)	
  
(Demolliens	
  et	
  al.	
  2008)	
  

Coenzyme	
  A-‐
functionalized	
  PEG	
  

Phosphopantetheinyl	
  
transferase	
  (surfactin	
  
synthetase)	
  

	
  

Protein	
  immobilization	
  
Cell	
  biology	
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(Mosiewicz,	
  Johnsson	
  &	
  
Lutolf	
  2010)	
  

Supramolecular	
  tyrosine-‐
based	
  hydrogel	
  

Alkaline	
  phosphatase	
  

Assay	
  platform	
  for	
  enzyme	
  
inhibitors	
  

(Li	
  et	
  al.	
  2010)	
  

Chitosan-‐glycolic	
  acid	
  
conjugates	
  modified	
  with	
  
phloretic	
  acid	
  

Horseradish	
  
Peroxidase	
  

Cartilage	
  tissue	
  repair	
  

(Jin	
  et	
  al.	
  2009)	
  

Protein	
  delivery	
  

(Lee,	
  Chung	
  &	
  Kurisawa	
  
2009b,	
  Kim	
  et	
  al.	
  2011)	
  

Hyaluronic	
  acid-‐tyramine	
  

Cartilage	
  tissue	
  repair	
  

Carboxymethylcellulose	
  

Biomedical	
  applications	
  

Dextran-‐tyramine	
  
conjugates	
  
Dextran-‐hyaluronic	
  acid	
  
conjugates	
  

Protein	
  delivery	
  

(Ogushi,	
  Sakai	
  &	
  
Kawakami	
  2007)	
  
(Jin	
  et	
  al.	
  2007b)	
  

Cartilage	
  tissue	
  repair	
  

(Jin	
  et	
  al.	
  2010b)	
  

Dextran-‐heparin	
  

Cartilage	
  tissue	
  repair	
  

(Jin	
  et	
  al.	
  2011)	
  

Tyramine-‐terminated	
  
PEG	
  

Drug	
  delivery	
  

(Tran	
  et	
  al.	
  2010)	
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Figure 3. Schematic mechanism of the enzyme-mediated crosslinking systems.
A) Transglutaminase, B) horseradish peroxidase, C) tyrosinase and D) oxidase
enzymatically crosslink polymer to form gels. Figure modified from (Teixeira et al. 2012)
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2.1.3 Application of hydrogels
Hydrogels may be utilized as localized delivery vehicles by homogenously
incorporating cells, growth factors and other bioactive compounds while concomitantly
allowing diffusion of nutrients and metabolites. Hydrogels may serve as a transient
biomimetic scaffold with suitable mechanical and viscoelastic properties in many
applications such as cartilage regeneration, serve as a suitable vehicle to locally deliver
appropriate growth factors and cells to facilitate regeneration of tissues such as bone.
Physical, chemical and biological properties of hydrogels can be modulated by chemical
and biological modifications by the incorporation of functional groups, cells or growth
factors to facilitate tissue regeneration (Figure 4).
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Figure 4. Examples of hydrogels as growth factor, gene and cell delivery systems.

2.1.3.1 Enhancing mechanical properties and mineralization of hydrogels

As viscoelastic solids, hydrogels characteristically possess low static and dynamic
moduli due to their high water content and high permeability for oxygen, nutrients and
other water-soluble metabolites. Due to the limited mechanical strength of hydrogels,
they have been widely considered to be excellent therapeutic delivery devices of cells and
growth factors for soft-tissue engineering and ideal porous scaffolds when load-bearing
support is unnecessary. The challenge of tissue-engineered grafts is to also match the
mechanical properties of native bone or cartilage tissue (Hutmacher 2000).
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Recent

advances in polymer synthesis and processing made it possible to increase the mechanical
strength of hydrogels in various ways, including addition of covalent crosslinks,
increasing the crosslinking density, increase of monomer content, addition of fillers and
biodegradable fibers and preculturing to allow embedded cells to generate functional
tissue before implantation (Anseth, Bowman & Brannon-Peppas 1996, Kloxin et al.
2010, Salinas, Anseth 2009).
One approach commonly used to increase the mechanical properties of hydrogel
for bone tissue engineering is to develop mineralized composite systems. Various
strategies have been employed to induce mineralization in inert, non-mineralizing
hydrogels for the use of bone tissue engineering (Gkioni et al. 2010). Major strategies for
hydrogel mineralization include (1) the addition of inorganic particles, (2) the creation of
nucleation sites by biomimetic methods, and (3) the derivatization of the polymeric
hydrogel backbone with anionic functional groups. The addition of inorganic phase
allows for the dispersed minerals to promote nucleation, subsequent hydroxyapaptite
formation and provides cell adhesion sites that enable integration with surrounding bone
tissue (Rea, Best & Bonfield 2004). Finally, as the temporary hydrogel degrades the ongoing mineralization will allow for replacement by new bone formation and thus increase
mechanical stability.
2.1.3.2 Enhancing biological properties by growth factor loading

Bone regeneration is a coordinated cascade of spatio-temporal events regulated by
several cytokines and growth factors. Biomaterial scaffolds are used to retain growth
factors at the orthopedic defect site for an appropriate period of time to allow native cells
to migrate to injury site, then proliferate and differentiate.
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A recent study used a

biopolymer chitosan/ β–tricalcium phosphate (TCP) composite hydrogel loaded with 150
µg recombinant human BMP2 (rhBMP2) in a 15 mm critical-size defect in the radius of a
rabbit to demonstrate successful osteoinduction (Luca et al. 2011).

However, many

other studies have demonstrated that osteogenic factors alone may not be sufficient for
optimal bone regeneration due to inadequate vascularization. Therefore, the combined
delivery of osteogenic and angiogenic factors have been studied to enhance bone
regeneration.

Since VEGF and BMPs are key regulators of angiogenesis and

osteogenesis during bone regeneration, various studies have investigated the effect of
dose and temporal release of these growth factors from hydrogels on bone formation.
Dual delivery of VEGF and BMP2 from gelatin microparticles for bone
regeneration in rat model having an 8 mm rat critical size defect led to synergistic effects
on bone formation and enhancement of bone bridging and union of the critical size
defect. At 12 weeks, the dual VEGF/BMP2 release showed bone formation within the
scaffold pores and along the outer surfaces of the scaffold; osteoid secretion and
mineralization were apparent, and new bone was often in close or direct contact with the
scaffold interface (Patel et al. 2008). A supporting study demonstrated the delivery of
VEGF and BMP2 to osteoprogenitor cell populations of human bone marrow stromal
cells (HBMSC) positively effecting bone formation.

HBMSCs seeded onto

VEGF/BMP2 releasing, biodegradable composite composed of alginate and P(DL)LA
significantly enhanced new endochondral bone matrix in a critical sized femur defect
(Kanczler et al. 2010).
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Since angiogenic growth factors are predominantly expressed during the early
phases of regeneration for vascularity, whereas osteogenic growth factors are
continuously expressed during bone formation and remodeling, the effect of sequential
delivery of VEGF and BMP2 on bone formation was also investigated (Kempen et al.
2009).

A composite scaffold which consisted of poly(lactic-co-glycolic acid)

microspheres loaded with BMP2 embedded in a poly(propylene) scaffold surrounded by
a gelatin hydrogel loaded with VEGF was used for the sequential release of the growth
factors. The implantation of this scaffold resulted in a large initial burst release of VEGF
within the first 3 days and a sustained release of BMP2 over the full 56-day implantation
period. In the orthotopic defects, no effect of VEGF on vascularization was found, nor
was bone formation higher by the combination of growth factors, compared to BMP2
alone. Contradictory to the previously mentioned growth factor delivery studies, this
study demonstrates that a sequential release of VEGF followed by the sustained release
of BMP2 may not be beneficial for bone regeneration relative to just BMP2 alone.
Similarly, dual delivery of VEGF and BMP2 from porous PPF scaffolds incorporating
gelatin microparticles on bone regeneration in a rat critical-size cranial defect model did
not demonstrate that the addition of VEGF increased bone formation over BMP2 delivery
alone (Young et al. 2009). An in vivo dose-dependent decrease in percentage of bone
regeneration was observed for BMP2. The addition of VEGF was unable to reverse this
decrease in bone formation, although improvements in the number of bridged defects did
occur in some groups.
A significant shortcoming of hydrogel based growth factor delivery is high burst
release leading to growth factor inactivation. To overcome this shortcoming and better
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control the release kinetics, natural and synthetic materials have been functionalized with
anchoring sites with affinity for the loaded growth factors.

The repeated

binding/interaction of growth factors to the functionalized recognizing species slows
down their diffusion and prolongs release rate from the biomaterial. Key determinants of
the growth factor release rate include the number of binding sites, the affinity of growth
factor for the immobilized recognizing species, and the degradation rate of the hydrogel
(Quaglia 2008). Heparin has been widely used as an interacting site due to the presence
of heparin-binding domain on many growth factors. Heparinized collagen gels (Wissink
et al. 2000, Steffens et al. 2004) and heparin-immobilized hydrogels based on thiolfunctionalized PEGs (Nie et al. 2007) were synthesized and tested as growth factor
delivery platform. More recently, heparin-immobilized macroporous PLGA scaffolds for
the release of bFGF have been developed (Yoon et al. 2006). Another study utilized
poly(L-lactide) and sucrose acetate isobutyrate-based coating around rhBMP2 – loaded
collagen-chondrotin sulfate to extend rhBMP2 release period from 24 hour to 12 days
(Keskin et al. 2005).

The extended release of rhBMP2 from the biomaterial allowed for

histologically well-organized bone formation.
As discussed before, articular cartilage has a poor healing capacity, and thus
healing does not always entail cartilage regeneration. Studies have shown that controlled
release of various pro-chondrogenic growth factors using hydrogel scaffolds may support
articular cartilage regeneration.

Intra-articular administration of collagen scaffolds

loaded with BMP2 induces chondrogenic differentiation of marrow-derived MSCs
(Mimura et al. 2011). RT-PCR results showed that the BMP2 administration enhanced
chondrogenic differentiation. Another study demonstrated that the incorporation of
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recombinant connective tissue growth factor (CTGF), a hypertrophic chondrocytespecific gene product, in a gelatin hydrogel possessed the ability to repair damaged
articular cartilage in monoiodoacetic acid (MIA)-induced experimental rat osteoarthritis.
The repaired cartilage histologically looked similar to that of normal articular cartilage.
Similar results were obtained using a 2 mm diameter, full-thickness rat articular cartilage
defect treated with CTGF-loaded gelatin gel. At 4 weeks post treatment, new cartilage
was found filling the defect (Nishida et al. 2004). The combined use of cells and growth
factors loaded on to injectable hydrogels has proven to be constructive in the quest for
optimal skeletal regeneration. PLGA microspheres loaded with IGF1 and TGFβ1 and
bovine articular chondrocytes were photoencapsulated in PEO-based hydrogels
demonstrated statistically significant changes in GAG production and cell content
compared to control gels either without microspheres or with blank microspheres after a
14 day incubation (Elisseeff et al. 2001). These studies suggest that localized delivery of
growth factors, such as BMP2, CTGF, IGF1 and TGFβ1 via porous hydrogel scaffolds
may be useful in therapeutic regeneration of articular cartilage.
2.1.3.3 Enhancing biological properties by drug delivery

Hydrogels may also be utilized to enhance the delivery and therapeutic efficacy of
drugs. Biodegradable hydrogels have the potential to deliver a wide range of waterinsoluble drugs. Recent studies have demonstrated that a biodegradable gelatin hydrogel
can be used for the sustained release of water-insoluble simvastatin at a bone defect site
(Tanigo, Takaoka & Tabata 2010). The release of biologically active simvastatin was
accompanied by the biodegradation of hydrogel. In this study, simvastatin was watersolubilized by gelatin grafted with
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acid oligomer and mixed with gelatin,

followed by chemical crosslinking to obtain gelatin hydrogels incorporating simvastatin.
Bone healing of critical-sized nasal defects in rabbits by simvastatin in hydrogels has also
been investigated (Mukozawa et al. 2011).

At 2 and 4 weeks post-implantation,

increased bone healing and BMP2 expression was seen in the animal groups with
simvastatin delivered in the hydrogels.

Other studies have also demonstrated the

increased expression of BMP2, along with VEGF and Cbfa1 upon treatment with statinloaded hydrogels (Wong, Rabie 2006). Thus, the delivery of drugs, such as statins, may
be achieved via hydrogel delivery to enhance bone regeneration.
2.1.3.4 Enhancing biological properties by gene delivery

Another promising method of growth factor delivery in the field of bone-tissue
engineering is the application of gene therapy (Caplan 2000, Chen 2001), which presents
a simple approach to evade the difficulties involving the delivery of multiple growth
factors. The transfer of genetic material into the genome of the target cell allows for high
expression of bioactive factors from the local cells in the defect and delivering a more
biologically active product that can be achieved by exogenous application of recombinant
proteins. Gene therapy has the potential to provide control over the timing, distribution
and level of multiple growth factors that can be either simultaneously or sequentially
expressed in a tissue-specific manner; this approach may also provide a cure to diseases
or offer transient growth and regeneration (Franceschi 2005).
The possibility of achieving osteogenic differentiation as a result of prolonged
presence of BMP2 was investigated using plasmid DNA-based gene therapy.

The

delivery of BMP2 cDNA in an alginate hydrogel resulted in an increasing amount of
biologically active BMP2 released from endogenous cells after 6 weeks of implantation
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(Wegman et al. 2011). Combinatorial gene therapy has also been explored; human
BMP2 and VEGF165-transfected rabbit bone marrow stromal cells (BMSCs) loaded on
coral scaffold resulted in increased new bone formation, compared with any single factor
in a critical-sized orbital defect rabbit model (Xiao et al. 2011).

2.1.3.5 Enhancing biological properties by cell encapsulation

Numerous studies have utilized hydrogels as cell delivery vehicles for skeletal
regeneration. Although hydrogels lack mechanical strength, they are extremely valuable
and efficient in encapsulating and maintaining viable cells.
available for engineering organized skeletal tissues.

Various cell types are

However, when selecting the

optimal cell type for therapeutic application, one must consider a few different factors,
including the ex vivo proliferative capacity of the cells, phenotypic stability and
immunogenicity.

Cell types that are currently considered for skeletal regeneration

include fully differentiated cells, mesenchymal stem cells and embryonic stem cells.
Photoencapsulation of rat calvarial osteoblasts in injectable, non-adhesive PEG
hydrogel modified with Arg-Gly-Asp (RGD) peptide for bone tissue engineering
demonstrated increased mineral deposition (Burdick, Anseth 2002). However, a decrease
in osteoblast viability of approximately 25% and 38% was seen after 1 day of in vitro
culture when the macromer concentration was increased to 20 and 30wt%, respectively.
A later study demonstrated collagen type I hydrogel allowed for the migration,
proliferation and finally adoption of the osteoblastic fate of rat bone marrow stromal cells
(rBMSCs) (Hesse et al. 2010). However, only about one third of the entire rBMSC
population had the ability to actively migrate. Although this study contributes to the
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development of novel bone grafts, it also presents current drawbacks of hydrogels as cell
delivery vehicles for bone tissue engineering.

A recent study investigated the need for smart matrices in bone tissue-engineered
grafts to provide an optimal environment for cells and retain osteoinductive factors for
sustained biological activity. Slow-degrading, heparin-incorporated HA hydrogel loaded
with primary osteoblasts and BMP2 facilitated the increase of bone-related genes after 8
weeks in rat femor.

An arterio-venous loop provided an angiogenic stimulus and

supported axial vascularization to provide nutrition for a bio-artificial bone graft.
However, no significant increase in bone formation was observed histologically which
might be explained by the absence of biomechanical stimulation as a result of the
heterotopic isolation chamber.

This suggests that optimization of osteogenic and

angiogenic conditions are necessary to generate sufficient amounts of vascularized bone
grafts for reconstructive surgery. This study also clearly demonstrated that the HA
hydrogel supported growth and differentiation of osteoblasts in vitro and in vivo and
allowed sustained release of BMP2 (Rath et al. 2011).
Also, while designing a cell delivery system, it must be noted that tissues are
generally not homogenous from a cell perspective; they consist of multiple cell types in
highly organized frameworks – termed microscale heterogeneity. For example, skeletal
tissue consists of various cell types including osteocytes, osteoclasts, endothelial cells
and chondrocytes. Engineering osteochondral tissues to have regulatory effects with each
other, in turn, encourages more functional tissue development. Co-culture models of
multiple cell types is especially exciting since different cells act cooperatively and
bioactive factors secreted by one cell type provides cue for the action of its neighboring
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cells. An important study that showed promise in bone regeneration and angiogenesis
using a vascular endothelial cell/bone marrow MSC co-culture model (Sun et al. 2007).
A later study went on to demonstrate the patterned microscale capability of 3D coculturing endothelial cells and osteoblastic cells in a microchannel (Chueh et al. 2010).
This simple and reversible hydrogel patterning method for 3D cell culture allowed for
alginate gel to be formed in select regions of a microfluidic device through light-triggered
release of caged calcium. Since microscale heterogeneity is central to cellular niches and
tissue development, microscale engineering of hydrogels has proven to be a useful tool
for tissue engineering (Sands, Mooney 2007). Furthermore, techniques to mimic the
microscale heterogeneity of the ECM in vitro improve how scientists examine the
interaction of cells.
Toti-potent embryonic stem cells possess the potential to differentiate into an
unlimited array of cell types. Cartilage repair was seen using hyaluronan hydrogelencapsulated human embryonic stem cell (hESC)-derived chondrogenic cells (Toh et al.
2010).

In this study, hESC-derived chondrogenic cells produced ECM-enriched

cartilaginous tissue construct when cultured in HA-based hydrogel. Furthermore, the use
of this hydrogel/hESC sytem for the repair of rat critical-sized osteochondral defect
resulted in an orderly spatial-temporal remodeling over 12 weeks into osteochondral
tissue with good surface regularity and complete integration with the adjacent host
cartilage. This study demonstrated the feasibility of using hESC-derived chondrogenic
cells for cartilage tissue engineering.
Multi-potent mesenchymal stem cells have the ability to differentiate into several
cell types to form new repair tissue. Bone marrow is a major source of mesenchymal

	
  

59

stem cells (BMSCs), which may contribute to the regeneration of bone and cartilage.
Studies have investigated the biocompatibility of thermoresponsive copolymer composed
of hyaluronic acid-g-chitosan-g-poly(N-isopropylacrylamide) (HA-C-NIPAAm) and its
efficacy as a cell carrier for bone marrow stem cells (BMSCs).

After 4 months of

composite hydrogel/BMSCs implantation subcutaneously in nude mice, significant
ectopic bone formation was confirmed via microCT analysis (Liao, Chen & Chen 2011).
The most widely studied synthetic gels for MSC encapsulation and cell delivery
are based on PEG and PVA. PEG is biocompatible polyester that has been approved by
FDA for many medical applications.

Non-toxic, biodegradable PEG hydrogels are

promising matrices for cell encapsulation (Sims et al. 1996, Chen et al. 2003) and has
been shown to support BMSC chondrogenesis in vitro (Williams et al. 2003). Successful
application of photopolymerizable PEG hydrogels towards the engineering of
multilayered articular cartilage has been demonstrated (Alhadlaq, Mao 2005).

MSCs

were treated ex vivo for 3-4 days with either chondrogenic or osteogenic supplements and
loaded into two hydrogel layers and cured via photopolymerization. Stratified layers of
chondrogenesis and osteogenesis were observed after 4 weeks of implantation. In a
recent study, swine auricular chondrocytes were photoencapsulated into two PEG
dimethacrylate (PEGDM) copolymer hydrogels of different degradation profiles:
degradable (PEG-4,5LA-DM) and nondegradable (PEGDM) macromers in molar ratios
of 60:40 and 70:30.

The less degradable PEGDM hydrogel supported higher

glycosaminoglycan and hydroxyproline contents in the neotissue.

This study

demonstrated that PEGDM copolymer hydrogels can support in vivo chondrogenesis by
photoencapsulating auricular chondrocytes (Papadopoulos et al. 2011). The control of
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biomaterial degradation rate is essential for proper matrix synthesis of the encapsulated
cells.
Autologous chondrocyte implantation is an established, FDA-approved method of
treatment for cartilage repair. This treatment requires the removal of the chondrocytes
from the patient’s knee, expansion of the chondrocytes and subsequent implantation into
the defect site. This procedure entails disadvantages such as donor site morbidity and
also loss of chondrogenic phenotype during the cell expansion step. A recent study has
utilized autologous chondrocyte implantation in a novel alginate-agarose hydrogel to
demonstrate significant clinical improvement at follow-up at two years with
predominantly hyaline cartilage-like repair tissue (Selmi et al. 2008). Another supporting
study encapsulated bovine chondrocytes from corresponding zones of the femoral
articular cartilage in photopolymerizing hydrogels to regenerate cartilage with zonal
organization (Kim et al. 2003).

However, the encapsulation of growth factors for

modulation of chondrogenesis and osteogenesis may be necessary for further phenotypic
maintenance of chondrogenic and osteogenic cells derived from MSCs in vivo (Lu,
Yaszemski & Mikos 2001, Elisseeff et al. 2001).
Thusfar, no hydrogel biomaterial has been presented in literature to inherently
increase cell survival, proliferation or osteogenesis (without the use of drugs, gene
therapy or growth factors). Such bioactive biomaterial is warranted since these processes
are necessary for successful bone formation and regeneration. The bioactivity of proteinbased hydrogels in cell-based therapeutics may encourage encapsulated cells to recognize
and bind to specific sites within proteins.

The key for a successful regenerative

biomaterial lies in its ability to interact with the surrounding environment and induce a
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multitude of cell signaling pathways, including cell survival, proliferation and
mineralization.
2.1.4 Conclusions
For optimal tissue regeneration, biomaterial scaffolds should not serve as a simple
inert substrate; instead should serve as three-dimensional mediums for the dynamic
extracellular signaling and facilitators for progenitor cell recruitment, growth and
differentiation. Hydrogels may serve as excellent scaffolds for skeletal regeneration
since their biomimetic properties and high water content presents a cell-friendly, natural
microenvironment to support cell functions. The ability to conveniently control the
chemistry and functionality of the hydrophilic polymers allow tailoring the physical and
mechanical properties of hydrogels for bone and cartilage regeneration. The use of
enzymatically-crosslinked hydrogels provides a mild, in situ-forming biomaterial system
for the localized delivery of cells to support tissue regeneration.

Our ability to

incorporate specific and controlled biological activities in these hydrogels to modulate
encapsulated cell performance can significantly increase their efficacy as scaffolds for
skeletal tissue regeneration. Attempts have been made to increase the bioactivity of
hydrogels by incorporating one or more growth factors in the gels. However, it is to be
noted that tissue regeneration/healing is a complex process involving several bioactive
molecules expressed under very tight spatio-temporal control. Since encapsulated cells
are capable of producing these bioactive molecules, one attractive strategy will be to
design and develop bioactive materials as injectable cell delivery vehicles that can induce
the encapsulated cells to produce appropriate bioactive molecules for regeneration. We
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explore the feasibility of developing such a novel injectable biomaterial system in the
present study.

2.2 Lactoferrin as a biologically active molecule for bone
regeneration
LF is described as a “moonlighting” protein as it possesses multifold functions
(Gonzalez-Chavez, Arevalo-Gallegos & Rascon-Cruz 2009) (Figure 5) and its bioactivity
is dependent on the specific physiological environment (Baker, Baker 2009).

The

regulation of LF synthesis, secretion and spatio-temporal distribution in vivo collectively
play a part in determining its specific biological functions. Since successful skeletal
tissue engineering requires concerted efforts of different cell types, the modulatory effect
of LF on pluripotent cells, osteoblasts, osteoclasts and immune-modulating cells makes
this glycoprotein a potential molecule to support skeletal tissue regeneration.

Figure 5. The wide range of beneficial functional properties decribed for LF.
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Image taken from (Vogel 2012).

2.2.1 Molecular structure and composition
The structure and composition of a protein play very important roles in
determining its biological functions. LF is a highly cationic protein with an isoelectric
point of 8.0-8.5 (van et al. 2001). Structurally, it is a bilobal globular glycoprotein with a
molecular weight of approximately 80 kDa.

Anderson et al., reported the three

dimensional structure of human diferric LF as comprising of two highly homologous
globular lobes (N and C lobes), each containing one canonical trivalent ferric ironbinding site and one glycan, linked by an extended α-helix (Anderson et al. 1987). The
globular lobes of LF can bind to variety of cations such as trivalent Fe3+, Ga3+ and Al3+
and di- and trivalent transition metal ions VO2+, Mn3+, Co3+, Cu2+, and Zn2+. However, as
the name suggests, LF has very high affinity for and is most commonly associated with
trivalent ferric iron (Harrington 1992). For each cation bound to LF, one bicarbonate
anion binds concomitantly and synergistically to the iron-binding crevice. The presence
of the bicarbonate anion bound to LF is essential for metal binding and greatly increases
the saturation of iron (Anderson et al. 1989).
Because of its ability to reversibly bind iron, LF can exist free of iron (apo-LF) or loaded
with iron (holo-LF) (Schanbacher, Goodman & Talhouk 1993). As in the case of
transferrins, the bound iron from LF can be released by the destabilization of the protein,
which can be triggered perhaps by receptor binding in vivo and by lowering of the pH,
reduction or the use of small-molecule chelating agents in vitro. The iron binding induces
substantial structural changes of the globular lobes of LF, consistent with the closure or
opening of the inter-domain cleft (Grossmann et al. 1992). The binding of the protein
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ligands to the ferric iron and bicarbonate leads to the highly compact conformation of
iron saturated-LF (Anderson et al. 1989). The presence of iron can also possibly affect
the stability of the protein towards proteases.

Studies have shown that the protein is

more resistant to proteolysis, especially in its iron-saturated holo form (Brines, Brock
1983, Brock et al. 1976). However, species differences do exist and human apo-LF has
been found to be more stable compared to bovine apo-LF (Brines, Brock 1983). It is
important to note that the vast majority of the molecular surface remains the same when
LF is “open” or “closed” state, therefore the surface receptor binding sites are likely to be
unaffected by iron status. However, the structural dynamics of the open binding cleft of
apo-LF provides additional sites for molecular interactions compared to holo-LF which
implies possible differences in their biological functions (Baker, Baker 2009).
Another important structural component of LF is the nature and extent of
glycosylation. All LFs are glycosylated although the glycosylation profile (the number
and location of potential glycosylation sites and sites actually used) is species-specific.
Bovine LF (bLF) has five potential glycosylation sites (Goodman, Schanbacher 1991),
out of which only four sites are known to be glycosylated. Native human LF (hLF)
contains three potential N-glycosylation sites, located at Asn138, Asn479, and Asn623.
Two sites are glycosylated by complex-type N-glycans and the third putative site
(Asn623) is unglycosylated (Spik et al. 1982, van Berkel et al. 2002a). Natural hLF
contains complex highly branched, highly sialylated and highly fucosylated structures.
The glycosylation patterns of LF have also been shown to be tissue/cell – specific. LF is
often associated with secretion of mucosal tissues and with neutrophilic granules. Even
though no significant differences in protein moiety have been reported between the
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mucosal and neutrophilic LF, they show difference in molecular weight (Levay, Viljoen
1995b). It has been reported that the digestion of the two forms with N-glycanase
resulted into a single protein band of approximately the same apparent molecular weight
indicating that the difference in molecular weight is mainly due to difference in
glycosylation (Hurley et al. 1993). Human milk lactoferrin glycan differs from the
neutrophilic protein in the presence of α-1,6 and α-1,3 fucose residues and in the degree
of sialylation (Levay, Viljoen 1995b).

The recombinant forms of LF also show

differences in the composition of carbohydrate chains and vary according to the specific
species expression system. The glycosylation patterns of rhLF have been investigated in
forms that were expressed in maize, tobacco, rice and cattle transgenic systems (Fujiyama
et al. 2004, Samyn-Petit et al. 2003, Samyn-Petit et al. 2001, Yu et al. 2010). The
recombinant form produced in the milk of transgenic clone cattle has been found to be
approximately 2 kDa smaller than that of native form, due to the differences in Nglycosylation (Yu et al. 2010). As discussed before, neutrophilic LF, unlike the milkderived protein, is not fucosylated – however, the difference in the molecular structure
and functions of the two naturally occurring forms are not completely understood. On
the other hand, rhLF, obtained from rice, contains N-glycans that are of high mannose,
hybrid structures with low sialic acid and fucose, which are common post-translational
modification patterns (van Berkel et al. 2002a, Nandi et al. 2005). A recent study
investigated the difference in properties of glycosylated and non-glycosylated human LFs
showed that deglycosylation did not affect its iron-binding and/ release as well as thermal
stability (Baker, Baker 2009).
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possible that the glycosylation pattern of LF might affect some of the biological activities
of the protein such as immune-regulatory functions (Yu et al. 2010).
2.2.2 Role of lactoferrin in ferrokinetics
LF is a pleiotrophic factor that exhibits a vast range of biological functions,
including anti-microbial, anti-inflammatory, iron homeostasis, osteogenesis, angiogenesis
and immuno-modulation (Gonzalez-Chavez, Arevalo-Gallegos & Rascon-Cruz 2009).
Of the many biological functions credited to LF, the protein was initially well recognized
for its ability to bind iron. Among the members of the transferrin family, LF has the
ability to retain iron over a wide pH range.

LF’s possible role in ferrokinetics is

attributed to its great affinity for free iron (Brock 2002). Homeostasis of iron is required
at specific concentrations for metabolic functions of cells including cell proliferation and
host defense. Elevated biological concentrations of iron are potentially deleterious;
consequences include support of microbial growth, suppression of various defense
mechanisms and cell injury induced by excessive hydroxyl or ferryl radicals.

Iron

loading conditions, such as hemochromatosis, have been positively correlated with a
suppression of osteoblast formation and new bone synthesis (Weinberg 2006).
It is consensual that LF influences the iron availability (Levay, Viljoen 1995a),
however, it is still not proven to be essential for normal iron homeostasis or intestinal iron
delivery (Brock 2002, Ward, Paz & Conneely 2005). LF knockout (LFKO-/-) mice,
which develop normally and display no overt abnormalities, demonstrated that LF is not
essential for iron delivery during the postnatal period. Analysis of adult mice on a basal
or a high-iron diet revealed no differences in transferrin saturation or tissue iron stores
between wild-type and LFKO-/- mice on either diet, although the serum iron levels were
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slightly elevated in LFKO-/- mice on the basal diet (Ward, Uribe-Luna & Conneely 2002).
Collectively, these results support the notion that LF does not play a major role in the
regulation of iron homeostasis unlike transferrins. However, the iron-binding function of
LF may contribute to alterations in iron metabolism during infection, inflammation or
other physiological functions (Brock 1995).
Among LF’s physiochemical properties, which collectively contribute to its
myriad of functions, are its reversible affinity for iron and resulting three-dimensional
changes in structural conformation. Biological properties of LF have been described
relative to its iron binding states, which differ significantly in structural conformation
(Baker, Baker 2004). Apo-LF, the predominating in vivo form, is an “open” molecule
that has been reported to increase VEGFA-mediated angiogenesis in vivo (Norrby 2004)
and strongly modulate inflammatory response (Baveye et al. 1999). Holo-hLF has been
reported to stimulate cell cycle progression through PI3K/Akt pathway (Lee et al. 2009).
However, iron (FeCl3) supplementation did not significantly promote cell cycle
progression indicating that the iron content does not induce the proliferative ability of
holo-hLF, but instead holo-hLF possesses a noble growth regulatory function (Lee et al.
2009). Physiological concentrations of apo-LF and holo-LF have been demonstrated to
result in a suppression of osteoclastogenesis (Cornish et al. 2006, Cornish et al. 2004,
Lorget et al. 2002). Cornish et al. assessed the effects of iron-binding of bLF, compared
to similar size cations (chromium and magnesium), in primary rat osteoblast-like cell
cultures on cell proliferation. The rate of proliferation of cells exposed to chromium- and
manganese-loaded LF was similar to iron-loaded and iron-unloaded LF. These studies
indicate that the proliferative effect of LF on osteoblast is independent of cation type and
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saturation (Cornish et al. 2006). Further studies are needed to elucidate the molecular
mechanisms regarding potential differences in response to iron saturation of LF. Aside
from its metal bound state, the potent activity of LF on bone cells at peri-physiological
concentrations indicate that LF might have a physiological role in bone growth and thus
may serve as a novel bone repair therapeutic.
2.2.3 Positive skeletal regulator
Bone is continuously remodeled by the sequential activities of osteoclastmediated bone resorption and osteoblast-mediated bone formation (Parfitt 1976). LF, as
a multifunctional glycoprotein, is also shown to be a potent anabolic effector of the
skeleton. LF’s anabolic effect in bone morphongenesis is attributed to its strong dosedependent proliferative and anti-apoptotic actions on osteoblasts and inhibition of
osteoclastogenesis (Cornish et al. 2004) (Figure 6 & 7). At physiological concentrations,
LF promotes proliferation of osteoblasts and cartilage cells in vitro at a magnitude that
exceeds the response observed relative to other skeletal growth factors such as IGF1 and
TGFβ (Cornish 2004).
A recent study analyzed the immuno-expression of LF in human bone tumors in
comparison to normal fetal and adult bone tissue (Ieni et al. 2009). Immunoreactivity of
this glycoprotein was seen in neoplastic fibroblast like stromal cells as well as
multinucleated giant cells (MNGCs). Positive LF immuno-expression was found in
osteoid osteomas, adamantinomas and chondroblastomas.

Normal fetal bone tissue

exhibited positive LF immuno-expression, where it was primarily localized in the
osteoblasts, in the calcified cartilage area as well as the nucleus of chondrocytes in the
cartilage matrix adjacent to the calcified area. No LF expression has been found in any
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of the adult bone tissue samples most likely due to the decrease in osteoblast metabolic
activity. The high LF immuno-expression in the human osteoblastic lineage or bone
forming tumors as well as in human fetal bone supports its significant role in promoting
bone formation.
The potency of LF’s anabolic actions on the skeleton requires better understanding of its
molecular mechanisms. However, the mechanisms and cell signaling pathways involved
in the transduction of LF’s growth-modulating effects on osteoblasts have not yet been
comprehensively studied. Presently, LF’s potent mitogenic effect is accredited to lowdensity lipoprotein receptor-related protein (LRP) 1, which signals the activation of
mitogen-activated protein kinases (MAPKs) to confer increased cell mitogenesis (Grey et
al. 2004, Naot et al. 2005). LRP1 and 2 are among the putative LF receptors (Ji, Mahley
1994, Meilinger et al. 1995, Vash et al. 1998, Willnow et al. 1992). LRP is a membrane
glycoprotein that spans the cell membrane and consists of an extracellular 515 kDa heavy
chain and an 85 kDa light chain (Herz, Gotthardt & Willnow 2000). The extracellular
domain of LRP contains four ligand-binding clusters, where hLF interacts with the
second and fourth cluster of class A cysteine-rich repeats (Neels et al. 1999). LRPs,
found on hepatocytes, fibroblasts, immune cells, osteoblasts, and endothelial cells,
functions as both endocytic receptors and signaling receptors (Herz, Gotthardt &
Willnow 2000, Neels et al. 1999, Li, Cam & Bu 2001, Strickland, Gonias & Argraves
2002). The expression of LRP1 by human osteoblasts was demonstrated as a mechanism
for delivery of lipoproteins and vitamin K1 to bone (Niemeier et al. 2005). Although
LRP1 is classically known for its involvement in the endocytic pathway, LF has also
been demonstrated to transduce cell signaling pathways mediated by LRP1 independent
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of the receptor’s endocytic properties (Grey et al. 2004). LF’s proliferative actions on
osteoblastic cells via LRP1–dependent phosphorylation of p42/44 MAP kinases (Grey et
al. 2004) suggests that this receptor may also mediate its anabolic effects in skeletal
tissue.
LRP5 and 6, are multiligand, nonendocytic members of LRP receptor family and
have been widely identified as crucial regulators of osteoblast function (Gong et al. 2001,
Babij et al. 2003). Thus, it is of question whether these receptors possess overlapping
functions with LRP1 in the increase of skeletal mass. Previous reports indicate that
LRP1 cannot substitute LRP5/6 in the transmission of the Wnt canonical pathway (Tamai
et al. 2000) and even represses the canonical Wnt pathway (Zilberberg, Yaniv & Gazit
2004).

LRP1 cytoplasmic domain plays a crucial role in LRP1-mediated signal

transduction (Howell, Herz 2001). Thus, to elucidate whether LRP1-mediated signaling
events directly or indirectly leads to the repression of the canonical Wnt pathway,
Zilbergerg et al. demonstrated that mLRP4T100, a mini-receptor of LRP1, tailless mutant
preserved its repressive effect on Wnt signaling. The study demonstrated that LRP1mediated signaling events directly lead to the repression of the canonical Wnt pathway.
Furthermore, this study excludes the possibility that this repression is attributed to LRP1affected signaling pathways that cross-regulate the canonical Wnt pathway. On the
contrary, another study has reported that LF causes the significant down-regulation of
dickkopf homolog 1 (DKK1) mRNA, a Wnt antagonist, in human primary osteoblasts
(Cornish, Naot 2010) possibly indicating the on-state of the canonical Wnt signaling
pathway.
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LF has been demonstrated to have potent anti-apoptotic effects on osteoblast cells,
which may also contribute to its anabolic skeletal actions.

At peri-physiological

concentrations (1-10µg/ml), LF protects both primary rat osteoblast cells and SaOS2 cells
from serum withdrawal-induced apoptosis (Grey et al. 2006). Studies have demonstrated
that LF induce LRP1-dependent phosphorylation of Erk and PI3K-dependent
phosphorylation of Akt (Grey et al. 2004, Grey et al. 2006). However, the ability of LF
to promote osteoblast survival was found to be independent of both of these activities
(Grey et al. 2006). Although studies indicate the activation of LRP1 can lead to the
activation of both PI3K and Erk (Orr et al. 2003), this study clearly indicates the
existence of unique signaling transduction pathways mediated by LF that subserve its
anti-apoptotic actions on osteoblasts (Grey et al. 2006).

Thus, collective studies

demonstrate that LF’s anti-apoptotic activities are not sufficiently explained by signaling
via LRP1 and most likely mediated by more than one of LF’s putative cell membrane
bound receptors.

This notion is further be supported by the cationic nature of LF

allowing it to interact with a heterogenous array of receptors, cells and anionic molecules,
including DNA (Elass-Rochard et al. 1995, Appelmelk et al. 1994b, Shimazaki et al.
1998, Mann, Romm & Migliorini 1994, Hutchens, Magnuson & Yip 1989).
Through the use of microarrays and low-density arrays to investigate the changes
in gene expression induced by LF treatment in osteoblasts, a recent study indicate the
significant upregulation of IGF1 mRNA (Cornish, Naot 2010). As an endocrine and
paracrine regulator of skeletal homeostasis, IGF1 has been demonstrated to promote
survival and proliferation in osteoblasts through parallel PI3K and p42/44 MAPK
signaling pathways (Grey et al. 2003). IGF binding proteins (IGFBPs) modulate IGF
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action by inhibiting or enhancing IGF binding to IGF receptors. Furthermore, LF has
been indicated to be a high affinity, IGFBP3 binding protein (Baumrucker, Gibson &
Schanbacher 2003). Interestingly, holo-LF showed slightly greater binding to IGFBP3
than the apo form (Baumrucker, Gibson & Schanbacher 2003). This interaction will free
IGFs (both IGF1 and IGF2) from their association with IGFBP. Much remains to be
learned about the interactions involving IGFs, IGFBPs and LF. The connections between
the various regulatory signaling pathways need to be further explored to help elucidate
LF’s effects on modulating skeletal growth.
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Figure 6. Through bidirectional signalling, LF enhances osteoblast activity and
suppresses osteoclastogenesis.
A) Effects of lactoferrin on rat primary osteoblast proliferation and differentiation.
Thymidine incorporation in primary cultures of rat osteoblast-like cells treated for 24
hours with increasing concentrations of rhLF. The effect of rhLF on areas of mineralized
bone nodules as determined in primary cultures of rat osteoblast-like cells cultured over
a period of 3 weeks. Cells were stained for mineral using Von Kossa stain. Image was
adapted from (Cornish et al. 2004, Grey et al. 2004).
B) RAW264.7 cells, induced to differentiate to osteoclasts by the addition of 50ng/ml
RANKL to the culture media, were treated with increasing concentrations of bLF (x
µg/ml). TRAP positive multinucleated cells were counted on day 5. Osteoprotegerin
(OPG) (0.02 µg/ml) was used as a positive control. Image was adapted from (Cornish,
Naot 2010).
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Figure 7. Anabolic effect on mouse hemi-calvaria in response to bLF after 10 days
treatment.
Photomicrographs of calvariae from animals treated with lactoferrin bLF) (4 mg) (A) and
vehicle (B) for 5 days. Animals were killed 10 day later. Fluorochrome labels used:
green, calcein; red, alizarin. Two calcein labels were given 13 day apart. The increased
new bone growth in the 13-d period (i.e. distance between the two green calcein labels,
arrowed) can be appreciated in the calvaria from the lactoferrin-treated animal. It can
also be noted that there is new bone marrow formation occurring within the recently
formed bone in the lactoferrin-treated calvaria. New bone formed on the injected side of
the lactoferrin calvaria is partially woven (*). This was seen only in the animals treated
with the highest dose of lactoferrin and probably reflects the very high rate of matrix
deposition. Horizontal bar, 50 µm. Figure was taken from (Cornish et al. 2004).

2.2.4 Lactoferrin as an immunomodulatory protein
LF is a potent modulator of inflammation, innate and adaptive immune response
(Legrand et al. 2005, Spadaro et al. 2008). The presence of LF in neutrophil granules
indicates its important role in host defense.

High affinity LF receptors have been

identified on cells such as lymphocytes, monocytes and macrophages. The modulatory
effects of LF have been attributed to its ability to interact with pro-inflammatory bacterial
components as well as through interactions with epithelial and immune cells via specific
cellular receptors even though the exact mechanisms have not been fully elucidated yet.
At the cellular level, LF is known to modulate antigen presenting cells (monocytes,
macrophages, dendritic cells) migration and activation as well as affects the expression of
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soluble immune mediators such as cytokines, chemokines and other effector molecules.
Several factors such as concentration of LF, iron content and composition have shown to
have an effect on its immune-modulatory function.
The immunotropic regulation of LF in the innate immune system includes a
multitude of host-protective effects against microbial infections, septic shock,
inflammation, allergy and cancer (van Hooijdonk, Kussendrager & Steijns 2000).
Supporting data indicates that patients with congenital or acquired LF deficiency are
subjected to recurring infections (Breton-Gorius et al. 1980). Enhanced Th1 response to
Staphylococcus aureus (S. aureus) infection was demonstrated in transgenic mice
expressing human LF (Guillen et al. 2002). Oral LF administration demonstrates a
protective effect during lethal bacteraemia and septic shock (Lee et al. 1998, Zagulski et
al. 1989). Degree of iron saturation of LF has been demonstrated to play an interesting
role in LF’s ability to inhibit or promote L. pneumophila intracellular multiplication in
mononuclear phagocytes at sites of inflammation (Byrd, Horwitz 1991).

Apo-LF

completely inhibited L. pneumophila multiplication in non-activated monocytes, whereas
iron-saturated LF had no effect on the already rapid rate of L. pneumophila multiplication
in non-activated monocytes. Increased levels of LF during inflammatory and immune
responses target the monocytic cell line with high affinity (4.5 x 1O-9M) through a
receptor-mediated mechanism (Bennett, Davis 1981, Birgens et al. 1983). However,
lower affinity of LF is demonstrated for adherent mononuclear cells (Bennett, Davis
1981, Birgens et al. 1983) and alveolar macrophages (Campbell et al. 1992).
Furthermore, LPS-induced TNFα, IL1β, IL6, and IL8 production is inhibited by LF in
various human monocytic cell lines (Haversen et al. 2002). LPS-induced endotoxaemia
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is associated with an up-regulation of nitric oxide synthase (Lauw et al. 2000). However,
the inducible nitric oxide synthesized in response to E. coli infection is inhibited by the
administration of LF (Zagulski et al. 1989). LF also promotes lytic cell activity by
increasing the number of natural killer cells (Shimizu et al. 1996, Yamauchi et al. 1998),
which results in a phagocytosis-enhancing effect (Szuster-Ciesielska, Kamiaska &
Kandefer-Szerszea„ 1995, Wakabayashi et al. 2003). LF activating effect is also due to
the modulation of natural killer cell cytotoxicity and an increased sensitivity of target
cells to lysis (Damiens et al. 1998). LF-enhanced phagocytosis of pathogens could be
due to its direct binding to PMNs and opsonin-like activity (Miyauchi et al. 1998). The
adjuvant effect of LF in the generation of delayed-type hypersensitivity due to its binding
on the mannose receptor of immature antigen-presenting skin cells is further supportive
of its immunotropic activity (Zimecki, Kocieba & Kruzel 2002). The ability of LF to
directly activate macrophages (Actor et al. 2002, Sorimachi et al. 1997) and also inhibit
effector phases of cellular immune responses (Zimecki, Machnicki 1994) are
contradictory and therefore require greater knowledge of the conditions during the
administration of LF.
The anti-inflammatory properties of LF have been extensively studied. LF’s antiinflammatory properties may be partially explained by its iron-independent regulatory
role during cytokine response to decrease pro-inflammatory cytokines, such as tumor
necrosis factor α (TNFα), M-CSF, IL1β, IL6 and IL8 (Sawatzki, Rich 1989, Broxmeyer
et al. 1987, Machnicki, Zimecki & Zagulski 1993, Kruzel et al. 2002) and to increase
anti-inflammatory cytokines, such as IL4 and IL10 (Legrand et al. 2005, Togawa et al.
2002).
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The anti-inflammatory activity of LF is applicable to infectious and noninfectious pathologies, such as allergies, rheumatoid arthritis, inflammatory bowel
disorders and neurodegenerative disorders (Ward, Uribe-Luna & Conneely 2002). The
effects of exogenous pro-inflammatory molecules, such as bacterial lipopolysaccarides
(LPS)

(Miyazawa

et

al.

1991)

and

bacterial

unmethylated

CpG-containing

oligonucleotides (Britigan et al. 2001), are alleviated by LF. The binding of LPS to LF
inhibits LPS signaling, in turn blocking the activation of the serum LPS-binding protein
(LBP) and soluble CD14 (sCD14), as well as, membrane CD14 (mCD14) on monocytes
and L-selectins on PMNs (Elass-Rochard et al. 1998, Baveye et al. 2000b). The strong
interaction between LF and sCD14 interferes with the formation of the sCD14-LPS
complex and ultimately inhibits the expression of endothelial adhesion molecules, Eselectin and ICAM-1 and reactive oxygen species production in neutrophils (Baveye et
al. 2000a). Furthermore, the lactoferricin domain of LF was demonstrated as a highaffinity lipid A binding protein (Elass-Rochard et al. 1995, Appelmelk et al. 1994a). The
charge-charge interaction that occurs between LF and lipid A can result in exposure of
the unbound portion of lipid A to recognize LPS receptors, such as Toll-Like Receptor 4
(TLR4). This complex recognition would, in turn, activate macrophages. Potentially
separate pathways for LF-mediated macrophage activation events are demonstrated by
LF-induced, TLR4-dependent CD40 expression and the LF-induced, TLR4-independent
IL6 secretion (Curran, Demick & Mansfield 2006).
In addition to inducing systemic immunity, in vivo studies show promotion of
skin immunity and inhibition of allergic responses by LF (Elrod et al. 1997, Griffiths et
al. 2001).
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accumulation of dendritic cells in lymph nodes, LF is able to protect the immune system
against skin allergies. The overexpression of LF in patients with allergies (Zweiman et
al. 1990) involves mast cell and basophil activation and IL1β and TNFα- induced
migration of antigen-presenting cells. The interaction of LF and keratinocytes results in
the inhibition of TNFα release by keratinocytes (Kimber et al. 2002).
Furthermore, the iron-dependent anti-inflammatory activity is associated with iron
sequestration by apo-LF, which is released by neutrophils at the septic site.

LF

participates in detoxification by reducing the tissue-toxic hydroxyl radicals produced by
the granulocytes.

During inflammation, the Fenton/Haber-Weiss reaction produces

damaging hydroxyl radicals as a result of free iron accumulation reacting with the
reactive oxygen species released from the synovial macrophages. The chelation of iron
by LF limits the concentration of radicals at the inflammation site and thus decreases
lipid peroxidation and cell damage (Kruzel 2003).
Glycosylation patterns are known to impact immunogenicity and biological
activity of various glycoproteins (Dwek 1995, Walsh, Jefferis 2006). Granulocytic LF,
which is present in exocrine secretions and secondary granules of neutrophils, is known
to have potent immunomodulatory functions. The two forms of LF show similar amino
acid sequences and differ only in their glycosylation, indicating that glycosylation pattern
can significantly affect LF’s immunomodulatory functions. Recombinant human LF
identical in glycosylation pattern to natural neutrophilic counterpart was recently
bioengineered using Pichia pastoris expression system (Choi et al. 2008).

The

glycosylated recombinant protein showed potent immune regulatory properties and
effectively reduce methotrexate induced suppression of secondary humoral immune
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responses in sheep erythrocytes.

The study also suggests that the terminal N-

acetylneuraminic acid plays a significant role in LF mediated immune response. Even
though the mechanism is not fully understood, it is suggested that the milk-derived,
fucosylated LF has lower affinity to receptors that are responsible for signal transduction
in immune cells.
Similarly, talactoferrin alfa (TLF), a recombinant human LF that differs from
native human LF only in its glycosylation patterns, has been demonstrated to have potent
immune modulatory functions (Engelmayer, Blezinger & Varadhachary 2008, de et al.
2008). TLF has recently been used as a therapeutic agent for several cancers and healing
of diabetic wounds (Varadhachary et al. 2004, Wolf et al. 2007, Hayes et al. 2006). TLF
rapidly mounts responses to pathogens by chemoattracting monocytes, promoting
leukocytes and activating dendritic cells (de et al. 2008). The ability of TLF to recruit
and activate antigen-presenting cells and to enhance antigen-specific immune responses
are characteristic of alarmins, which are a group of endogenous mediators of the immune
system that link innate and adaptive immune systems (de et al. 2008). The effects of TLF
on macrophage function ultimately leads to attenuation of excessive inflammation and
stimulation of host response against pathogen threats (Puddu, Valenti & Gessani 2009).
Whether immunogenicity is affected by the different glycosylation pattern of rhLF as
compared with the native form should be investigated further.
2.2.5 Lactoferrins’s link to osteoimmunology
The emerging heuristic field of osteoimmunology poses the interesting question
of whether LF’s regulation of bone homeostasis is a consequence of its cytokine
modulation properties. The crosstalk and shared mechanisms between the skeletal and
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immune systems is complex and multifold with shared cytokines, receptors, signaling
molecules and transcription factors (Takayanagi 2005). For example, a mutation in
macrophage colony-stimulating factor (M-CSF) gene produces a defect in both
macrophage and osteoclast formation, indicating that immune and bone cells are derived
from the same cell origin (Yoshida et al. 1990). Thus, the effect of molecules with
osteoimmunological pleiotropy, such as LF, is not limited to modulation of inflammation
and immune function, but also directly involved with associated inhibition of
osteoclastogenesis.
LF has been shown to significantly decrease bone resorption (Lorget et al. 2002,
Cornish 2004, Blais et al. 2009). At a concentration of 100 µg/ml, LF completely inhibits
osteoclastogenesis in mouse bone-marrow culture. However, LF shows no effect on
calvarial organ culture, implying LF does not affect mature osteoclast function (Cornish
2004).

Collectively, data indicates that LF treatment decreases bone resorption by

reducing osteoclast number formed from precursor cells. LF is able to directly inhibit
osteoclastogenesis, independent of osteoblastic factors.

Differentiation of murine

macrophage RAW264.7 cells by the addition of receptor activator of NF-κβ ligand
(RANKL) to the cell culture medium allows for a controlled study of LF effects on
osteoclastogenesis independent of osteoblasts, as opposed to heterogeneous bone marrow
derived culture systems. LF inhibits RANKL-induced osteoclastogenesis in RAW264.7
in a dose-dependent manner (Cornish, Naot 2010) measured by a significant decrease in
TRAP positive multinucleated cells. Furthermore, the addition of LRP1-inhibitor RAP
did not significantly alter LF-induced inhibition of osteoclasts (Cornish, Naot 2010),
suggesting LRP1 is not involved in the LF-inhibition of osteoclasts.
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The OPG/RANK/RANKL molecular triad is known to be a main regulator of
osteoclastogenesis and osteoclast activity. Interestingly, it has been suggested that the
mode of action of bLF in CD14—selected cells undergoing osteoclast differentiation, is
independent of the RANK/RANKL/OPG molecular triad (Lorget et al. 2002).
Osteoprotegerin (OPG), the physiological antagonist of RANKL, and RANKL mRNA
was not detected either in the presence or absence of bLF. mRNA for RANK was
detected in the CD14—selected culture system, however its expression was not
modulated by bLF.
mediators,

other

This data is supported by previous studies that demonstrate
than

the

OPG/RANK/RANKL

triad,

are

responsible

for

osteoclastogenesis. Proinflammatory cytokines, such as TNFα or IL1, induce osteoclast
formation independent of the triad (Fox, Fuller & Chambers 2000, Fuller et al. 2002,
Kudo et al. 2002). On the contrary, LF has been linked to the triad through the downregulation of LPS-induced cytokine production in monocytic cells by NFκβ. Haversen et
al. demonstrated the capacity of LF to translocate to the nucleus and block NFκβ
activation, resulting in a decrease of the LPS-induced binding of NFκβ to the TNFα
promoter. This inhibition is also associated with LF’s ability to inhibit LPS-induced IL6
and IL10 secretion in monocytic cells (Haversen et al. 2002).
Recent reports revealed significant LF-induced stimulation of nuclear factor of activated
T cells 1 (NFATc1) transcription, which is critical for lineage selection in T-cell
differentiation, osteoblast differentiation and osteoclastogenesis (Cornish, Naot 2010,
Zhao et al. 2010). NFATc1 is a master regulator of osteoclasts and plays a pivotal role in
osteoclast activation via stimulation of various genes responsible for osteoclast adhesion,
migration, acidification, and degradation of inorganic and organic bone matrix. The
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calcineurin-NFAT signaling pathway is strongly implicated in osteoblast-mediated
osteoclast differentiation and also in promoting osteoblast proliferation and
differentiation (Stern 2006, Winslow et al. 2006).

Constitutively active nuclear

NFATc1nuc mutant mice showed an increase in osteoclast number and markers of
osteoclast activity and increased bone resorption (Winslow et al. 2006). This regulation
is independent of RANKL and OPG, which correlates to the negative osteoclast
regulation of LF, also independent of the RANKL/OPG pathway (Lorget et al. 2002).
Furthermore, mice expressing this NFATc1 variant displayed rapid Wnt-mediated
osteoblastogenesis, independent of Runx2.

The effect of rapid osteogenesis was

suggested by histological analysis, which revealed that bone in mutant mice had a less
organized appearance than normal tissue. The expression of the NFATc1 variant was
found exclusively in osteoblasts, and the bone phenotype was marked by a significant
increase in osteoblast number and bone volume. Furthermore, markers of osteoblast
activity, serum osteocalcin and serum alkaline phosphatase, were greater than doubled.
Other studies demonstrated NFATc1-activation of type 1 collagen through stimulation of
Osterix suggesting the possibility of the formation of a novel NFATc1-Osterix complex.
A contradiction in these sets of data includes LF’s stimulation of NFATc1 transcription,
but reported decreases in osteoclastogenesis by this protein.

Therefore, further

exploration to elucidate this regulation may provide useful knowledge for the application
of osteoclast-activated physiology and pathophysiology. These studies lend the question
of possible LF signaling mediating osteoblasts and osteoclastogenic pathways through
NFATc1.
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2.2.5.1 Lactoferrin and periodontitis-induced bone loss

The interplay between LF’s immuno-modulation and bone homeostatic properties
has recently been investigated using lipopolysaccaride (LPS)-induced periodontitis
models (Yamano et al. 2010) (Figure 8). Periodontitis is an inflammatory disease
instigated by infection with various oral plaque-associated periodontopathic bacteria,
which includes Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, and
Prevotella intermedia and bacterial LPS. The induced inflammation ultimately leads to
destruction of the periodontium, which includes the gingiva and the surrounding alveolar
bone. This destruction is induced by pro-inflammatory cytokines, including TNFα and
IL-1β, which subsequently leads to a significant increase receptor activator of NFκβ
ligand (RANKL)-induced osteoclastogenesis (Clowes, Riggs & Khosla 2005,
Weitzmann, Pacifici 2007).
.
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Figure 8. Comparison of periodontitis versus healthy/LF treated tissue.

LF is a component of exocrine secreted saliva and an important constituent of
neutrophilic granules of leukocytes. This glycoprotein is seen to be an important immune
defense factor against oral pathogens and periodontopathic bacteria and a good marker
for periodontitis (Wakabayashi et al. 2003), since it is not synthesized in healthy gingival
tissues and is produced by invading inflammatory cells in response to the inflamed
periodontal tissue (Eberhard et al. 2006). LF has been reported to inhibit the LPS
interaction with CD14 by competition with LPS-binding protein. Furthermore, LF may
also bind directly to soluble CD14 receptor (Baveye et al. 2000a), which is expressed on
the membrane of osteoclast precursors (Nicholson et al. 2000). In vitro assays have
demonstrated that bLF inhibits LPS-induced osteoclastogenesis through the reduction of
TNFα and RANKL expression and elimination of OPG suppression in osteoblastic cells
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with LPS stimulation. Through liposomalization of bLF, which acts to increase protein
stability, Yamano et al. demonstrated a significant inhibitory effect on LPS-induced
osteoclastogenesis through orally administering this stabilized form of the protein
(Yamano et al. 2010). Periodontal bone resorption occurs due to the significant increase
in RANKL-stimulated osteoclastogenesis; on the other hand, LF causes an increase in
osteoblast activity and inhibits osteoclastogenesis.
LF inhibits the growth of periodontopathic bacteria. As a major innate host
defense factor, LF binds and sequesters LPS, thus preventing pro-inflammatory pathway
activation, sepsis and tissue damage. LF may down-regulate LPS-induced cytokines
following its internalization, nuclear localization and interference with NFκβ activation
(Haversen et al. 2002).

Furthermore, this glycoprotein decreases pro-inflammatory

cytokines, such as IL1α and TNFα, and increases anti-inflammatory cytokines, IL4 and
IL10. LF inhibits the adhesion of bacteria to fibroblasts and epithelial cells. MMPs,
which are known to lead to periodontal ligament and tissue destruction in periodontitis,
which have been demonstrated to be inhibited by LF in rabbit preterm delivery model
(Mäkelä et al. 1994, Nakayama et al. 2008).

2.2.5.2 Lactoferrin and osteoporotic bone loss

Recent studies explored the crosstalk between LF’s regulation of bone homestasis
and immuno-modulatory characteristics using ovariectomized animal models (Figure 9).
Postmenopausal osteoporotic bone loss is regarded as a consequence of estrogen
deficiency, which in turn increases osteoclastogenesis. Estrogen deficiency is known to
increase pro-inflammatory cytokines, including TNFα, which, in turn, increases RANKL	
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induced osteoclastogenesis.

Due to the presence of LF in secretory granules of

neutrophils, the production of LF is understood to be predominantly influenced by
inflammatory stimuli.

LF possesses strong immunomodulatory effects, including a

decrease in the secretion of osteolytic cytokines, such as TNFα and IL1β. Therefore, it is
possible that this effect may contribute to its anabolic effects on the skeleton by
counterbalancing the catabolic osteoclastogenesis caused by some of the mediators in the
inflammatory bone turnover response.

Figure 9. Schematic representation of the role of estrogen deprivation and bLF on bone
loss and bone resorption markers through APC and T cell modulation.
bLF can prevent osteoclastogenesis directly or indirectly by modulation of: i) T cell
activation, ii) antigen presenting capacity (APC) and iii) Cytokines released in bone
micro-environment particularly through a down-regulation of TNFα release. Image was
taken from (Malet et al. 2011).

Recently, LF treatment was shown to improve bone status of ovariectomized mice
in vivo and in vitro (Blais et al. 2009). Oral supplementation of LF to the diet dosedependently improved bone mineral density and femoral failure load.
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Furthermore,

periphysiological concentrations of bovine LF treatment to primary cultures of murine
bone cells was demonstrated to stimulate cell growth and differentiation of osteoblastic
cells and inhibit the growth of preosteoclastic cells in vitro (Blais et al. 2009).
Milk basic protein (MBP) has been demonstrated to have positive bone effects in
vitro and in vivo (Toba et al. 2000).

Interestingly, a component of MBP that is

responsible for anti-osteoclastic activity has recently been demonstrated to also possess
pro-angiogenic activities due to its identical structure to 14 kDa milk angiogenin (Morita
et al. 2008). In a recent study, a ribonuclease (angiogenin)-enriched LF supplementation
improved bone-formation markers while reducing bone resorption markers in
postmenopausal women (Bharadwaj et al. 2009). Due to its strong anabolic bone effects,
LF can be considered as a potential molecule for bone regeneration.

2.2.6 Angiogenesis modulator
Angiogenesis is a complex physiological process whereby new blood vessels
form from pre-existing blood vasculature and is imperative for successful tissue
regeneration.

This complex process occurs during embryonic development, wound

repair, and tumor growth. Basic fibroblast growth factor (bFGF) and vascular endothelial
growth factor (VEGF) are two key mitogens involved in endothelial cell proliferation and
migration, which are important components of the angiogenic processes. VEGF-A is
stimulated during hypoxic condition and is key factor linking ischemia and collateral
compensatory angiogenesis (Schaper, Ito 1996). Angiogenesis is essential in a variety of
physiological and pathological processes, such as wound healing, tumor growth,
metastasis and hypoxia (Isner, Asahara 1999).
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Human and bovine LFs have been shown to modulate VEGF-A—mediated
angiogenesis in vivo. Apo-hLF and apo-bLF exert specific and contrary angiogenesismodulating roles in VEGF-A—mediated angiognesis in vivo. Apo-hLF significantly
enhances VEGF-A—mediated angiogenesis, but does not affect bFGF-mediated
angiogenesis (Norrby 2004). These studies indicate that this endogeneous protein by
itself lacks angiogenesis-modulating activity, but apparently is able to enhance VEGFA—mediated angiogenesis systematically. On the other hand, apo-bLF does not
significantly affect IL1α—mediated angiogenesis (Norrby et al. 2001), while it
significantly suppresses VEGF-A—mediated angiogenesis (Norrby 2004). Furthermore,
bLF administration, both orally and intraperitoneally, significantly suppressed tumorinduced angiogenesis in mice (Shimamura et al. 2004). The opposing effects of apo-hLF
and apo-bLF on VEGF-A—mediated angiogenesis could be due to the differences in the
three-dimensional structure of the protein, amino acid sequence and composition
(Goodman, Schanbacher 1991, Spik et al. 1982).
Mechanistically, the actions of bLF on angiogenesis have been described in
various lights. The investigation of bLF’s inhibition of tumor-induced angiogenesis lead
to the notion that bLF’s inhibition of angiogenesis can be explained by the blocking of
endothelial cell function and induction of IL18 production (Shimamura et al. 2004). In
this study, bLF potently suppressed bFGF- or VEGF-induced proliferation of mouse
endothelial KOP2.16 cells (Shimamura et al. 2004). Other studies have investigated
bovine lactoferricin (LfcinB), a peptide fragment of iron- and heparin-binding LF,
inhibits bFGF and 165-kd isoform of VEGF (VEGF165)-induced angiogenesis. LfcinB
inhibits receptor-stimulated angiogenesis by complexing with heparin-like binding sites
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on the endothelial cell surfaces that are involved in the binding of bFGF and VEGF165 to
their respective receptors (Mader et al. 2006).
VEGF-A is recognized by two receptors, KDR/Flk-1 and Flt-1, and thereby
induces angiogenesis. In an attempt to elucidate the molecular mechanism underlying the
effects of hLF on VEGF-A—mediated angiogenesis, Kim et al. (Kim et al. 2006)
demonstrated that apo-hLF stimulates VEGF-mediated human umbilical vein endothelial
cell (HUVEC) migration and proliferation through the up-regulation of KDR/Flk-1
mRNA expression and protein levels. Furthermore, exposure of apo-hLF to HUVECs
was also correlated with a significantly increased VEGF-induced Erk MAPK
phosphorylation and endothelial cell proliferation.
Pretreatment of endothelial cells with 5 µg/ml apo-hLF for 12 hours and
subsequent exposure to 10 ng/ml VEGF stimulated cell proliferation approximately 3fold over VEGF alone (Norrby 2004). However, it should be noted that apo-hLF did not
induce endothelial cell migration by itself, but did so with the concurrent administration
of VEGF-A. It was also observed that holo-hLF did not enhance HUVEC migration,
even in the presence of VEGF-A. This data is consistent with a previous claim that apohLF, not holo-hLF, enhanced VEGF-A—mediated angiogenesis in vivo (Norrby 2004).
LF treatment of rodent osteoblast was reported to cause increased transcription of
prostaglandin-endoperoxide synthase 2 (Ptgs2), which is also known as cyclooxygenase
2 (Cox2) (Cornish, Naot 2010). This transcription factor modulates angiogenesis by
increasing the production of angiogenic factors, such as VEGF (Tsujii et al. 1998).
However, it is important to note that the source and iron saturation of the LF used and the
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time course was not specified in the above study making it difficult to derive definitive
conclusion.
2.2.7 Candidate for bone regeneration applications
An important goal of bone regeneration therapy is directed differentiation of
heterogenous populations of undifferentiated pluripotent mesenchymal cells to the
osteoblastic lineage. Increased mRNA and protein expression of Runx2 and Sox9, tissuespecific differentiation markers for osteoblasts and chondroblasts, respectively, occurred
in LF-treated pluripotent C2C12 mesenchymal cells. Levels of MyoD, a differentiation
marker of skeletal muscle, and PPARγ, a critical transcription factor of adipocyte
differentiation, significantly decreased upon LF treatment in this undifferentiated
mesenchymal cell culture line (Yagi et al. 2009). This set of data suggests that LF
appears to positively regulate undifferentiated mesenchymal cell population toward the
osteoblastic and chondroblastic lineage, and inhibits myogenic and adipogenic
differentiation.
The production of rhLF provides vast benefit for its use in regenerative bone
tissue engineering, as it possesses similar physical, biochemical and biological
characteristics from the native protein. The similarities that have been reported include
anti-microbial and thermostability and ability to bind Fe3+ (van Berkel et al. 2002a,
Huang et al. 2008). The small difference in molecular mass between the recombinant and
native form of hLF is accounted for in differential glycosylation patterns (van Berkel et
al. 2002a).

This cost-effective alternative provides a great option for regenerative

therapeutic use of this protein. The use of the recombinant form of LF provides a
foundation for producing consistent and predictable results.
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Holo-rhLF, purified from rice, has been demonstrated to increase thymidine
incorporation in primary rat osteoblast cultures. Holo-rhLF concentration of 100 µg/ml,
almost doubled osteoblast proliferation over a 24 hour time course. A direct correlation
between rhLF iron saturation levels and cell proliferation has been reported. It has been
reported that holo-rhLF possesses stronger growth promoting effects compared to aporhLF (Huang et al. 2008) on HT-29 cells. On a commercial basis, this source of rhLF is
now used as a growth factor for media to promote cell growth and cell productivity.
Since rhLF technology has made its way to the commercialized world as a
nutritional supplement and as a clinical product with perceived benefits to the consumer.
rhLF, expressed in milk, rice and microorganisms is now used commercially as a dietary
supplement.

Talactoferrin, an immunomodulatory rhLF preparation, has been

demonstrated to be effective in the treatment of patients with diabetic neuropathic foot
ulcers (Spadaro et al. 2008), non-small cell lung cancer therapy in combination with
cisplatin treatment and renal cell carcinoma (Jonasch et al. 2008).
The potent modulating effects on the skeletal system support the prospect of rhLF
application for regenerative bone tissue regeneration. The use of various biomaterials,
such as type 1 collagen membrane (Takayama, Mizumachi 2009) and biodegradable
gelatin hydrogels (Takaoka et al. 2011), have been used as carriers to provide a sustained
localized release profile of LF.

LF-embedded collagen membrane has been shown to

promote osteogenic differentiation of MG63 human osteosarcoma-derived cells.
Increased alkaline phosphatase activity and osteocalcin production was induced by the
LF-embedded collagen membranes (Takayama, Mizumachi 2009).

A recent study

demonstrated significant bone regeneration at cranial defects following the implantation
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of LF-incorporated gelatin hydrogels (Mäkelä et al. 1994, Takaoka et al. 2011). These
studies concluded LF as a general osteogenic growth factor for bone tissue engineering.
2.2.8 Conclusions
The bidirectional signaling of LF that suppresses osteoclastogenesis and enhances
osteoblast proliferation and survival supports the notion that LF is a strong candidate for
bone tissue engineering. This candidacy of the glycoprotein is further supported by the
multifunctional ability of hLF to promote neovascularization and its key modulating role
in inflammation. Although LF osteogenic research has made great strides, shortcomings
of LF research includes the lack of detail in terms of procedure and specific forms of LF
(iron saturation and source). Furthermore, the variations in preparation, which includes
heat treatment and processing, may also account for in consistencies in the reported LF
data. Thus, it makes it difficult to compare and analyze published data thus far when
lacking such indispensable information. It is imperative to investigate the effects of LF
and report findings with specific details with regards to the molecular state of LF.
Investigations should focus on the mechanisms by which LF concomitantly regulates the
immune and skeletal systems.

Such advances will provide a comprehensive

understanding of LF’s role in bone regeneration.
The studies discussed thusfar, provided great insights on the potential bioactivity
of LF and well as its ability to increase bone regeneration. All these studies used soluble
LF protein to evaluate the biological functions of the protein. However, to exploit the
biological functions of the protein for regenerative application, it needs to be developed
as a biomaterial that can be localized at the defect site to present an osteogenic
microenvironment.
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developing an injectable biomaterial from LF, which might serve as an osteogenic
microenvironment to support bone regeneration.

3 Preliminary studies
3.1 Enzymatically—crosslinked bovine lactoferrin hydrogel
as an osteogenic cell delivery vehicle
3.1.1 Introduction
As discussed previously (section 2.2.3), the anabolic effect of bLF on osteoblasts
and its potent inhibition of osteoclastogenesis in vitro suggests that bLF may have
positive effects on bone mass in vivo. The administration of bLF over the right
hemicalvaria of adult male mice resulted in a dramatic increases in bone area in the
calvariae compared with PBS control. Four groups of mice were given daily injections of
one of 3 doses of bovine lactoferrin (0.04 mg, 0.4 mg or 4 mg) or vehicle over the right
hemicalvaria for 5 consecutive days.
increased by bLF.

New bone formation was dose-dependently

Both 0.4 mg and 4 mg of lactoferrin produced an increase in new

bone formation, however the 4 mg dose induced changes of 4-fold greater than those
observed in control animals.

Local injections of bLF also increased the mineral

apposition rate and the bone formation rate (Cornish 2004). However, repeated injections
of bLF over 5 consecutive days were used in this study to achieve the significant anabolic
effect demonstrating that retention of the protein at the defect site for prolonged time may
be required to activate the regenerative process.
In another recent study, murine preosteoblast MC3T3 cells revealed greater
proliferation rates by the repeated addition of bLF compared to single addition of the
	
  

94

protein at the same dose (Takaoka et al. 2011). Attempts have been made to retain the
protein at the defect site using a controlled protein delivery approach. Type 1 collagen
membrane was used as a sustained delivery vehicle for bLF. Approximately 27% of bLF
embedded on the collagen membrane was burst released within the first hour followed by
a slower release (Takayama, Mizumachi & Takezawa 2002).

The embedded bLF

collagen membranes promoted MG63 cell calcium deposition, ALP activity and
osteocalcin production (Takayama, Mizumachi & Takezawa 2002).
A recent in vivo study evaluated the efficacy of a sustained delivery vehicle in
promoting bone formation. The study used biodegradable gelatin hydrogel to allow bLF
release in vivo in a sustained fashion. Upon subcutaneous implantation into the dorsum
of mice, the gelatin hydrogel incorporated with bLF demonstrated an extended retention
of bLF at the site of implantation than that of bLF solution injection. The remaining
radioactivity on days 1 and 3 of 125I-labeled LF solution injected subcutaneously was 2.96
and 0.82%, respectively. In contrast, the remaining radioactivity on days 1 and 3 of 125Ilabeled LF in the hydrogel incorporated form was 10.14 and 5.26%. Upon implantation
of gelatin hydrogels incorporating bLF into rat cranial defects, improved bone
regeneration at the defect was observed than in control gelatin gel.

The study

demonstrated that the retention of bLF at the defect site enhanced bone regeneration
(Takaoka et al. 2011) (Figure 10).

However, a significant limitation of this study was

that approximately 90% of the bLF incorporated in the gelatin gel was released within 24
hours. This necessitates the encapsulation of high concentrations of bLF since much of
it will be lost due to burst release from the carrier gelatin gel. Furthermore, the high
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concentration (30 mg) of bLF needed to induce significant bone growth may further
induce negative systemic side effects.

Figure 10. (A) Promoting effect of bLF—embedded collagen membrane on ALP activitiy
and osteocalcin production in MG63 cells.
MG63 cells were plated onto a control collagen membrane (open bar) and a bLF
embedded collagen membrane (closed bar). Upon confluence, the cells were shifted to
osteogenic conditions for 2 weeks. ALP activity and osteocalcin production were
calculated per well and values are represented as mean ± standard deviation of three
separate measurements. *p< 0.05 significant difference. Image was adapted from
(Takayama, Mizumachi & Takezawa 2002). (B) X-ray radiographs of rat calvarial defect
8 weeks after implantation of gelatin hydrogels incorporating 0, 0.3, 3 and 30 mg bLF.
The lower stand value indicated the average percentage of area ossified in an 8 x 8 mm
square around the bone defect. No statistical significant differences were observed
between the bLF 0 and 0.3 mg group. * p< 0.05 significant difference from the
percentage of ossified area in a square around the defect implanted with gelatin
hydrogels without bLF (Takaoka et al. 2011).

A potential approach to overcome these limitations is to develop a biomaterial where in
LF is immobilized.

Such approach may significantly decrease the amount of LF

introduced in the body as it can be used to localize the molecule for a prolonged time to
induce maximum regenerative response. Considering the cell instructive properties of
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LF, the ideal immobilization method might be to develop an injectable hydrogel, wherein
cells can be encapsulated within the gel and can serve as a localized microenvironment
for modulating the cell response. However, several challenges exist while developing
such an approach. Even though the bioactivity of bLF is known, the mechanism of action
of bLF is not completely known.

Bioactive proteins may activate cellular processes

through two different phenomenas – cell internalization/endocytosis or receptor-mediated
signal transduction. It is therefore not known if an immobilized polymer, which is
incapable of being endocytosed, will be bioactive or not. One study that supported our
hypothesis determined that internalization of LF by osteoblastic cells is not necessary for
activation of mitogenic signaling and that the endocytic function of LRP1 is independent
of its signaling function (Grey et al. 2004).
For developing injectable biomaterials, we selected HRP-mediated, enzymatic
crosslinking method of protein due to the reasons summarized below. As discussed
before in section 2.1.2, hydrogels may be crosslinked through various mechanisms
including photo-polymerization, covalent, ionic and enzymatic crosslinking. Enzymatic
crosslinking, as previously discussed in section 2.1.2.2.1, involves a mild, cell-friendly
and natural crosslinking process. Polymers functionalized with tyramine, tyrosine or
aminophenol side groups can form crosslinked hydrogels by phenol derivative coupling –
this reaction is driven by H2O2, as the oxidant, and HRP, as the enzyme (Kurisawa et al.
2005, Kobayashi, Uyama & Kimura 2001, Jin et al. 2007a, Amini, Nair 2012). HRPmediated, enzymatic crosslinking was selected for developing LF-based injectable gels
since this enzyme-mediated crosslinking may take place at physiological pH and
temperature, making this a potential route to form injectable cell and protein delivery
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vehicles (Sakai et al. 2009, Amini, Nair 2012, Lee, Chung & Kurisawa 2009a).

Other

advantages of these hydrogel injectable systems include the flexibility of gelation time,
equilibrium swelling and storage modulus – which may be modulated by varying the
degree of substitution of tyramine residues and reagent concentrations.

The efficacy of

the reaction has been demonstrated by various systems listed in Table 2.
Standard carbodiimide-mediated coupling of amino groups of tyramine with the
carboxyl groups of LF was used to increase phenolic content of LF. Although LF
contains phenolic amino acids, such as tyrosine, the phenolic content of LF is much lower
than what is needed to develop an effectively cross-linked matrix via the enzymecatalyzed coupling (Figure 11 & 12).

The reaction of LF with tyramine increases

polymer crosslinking by increasing the number of phenolic groups (Figure 13). Similar
chemical reactions have been used to increase the phenolic content of other polymers
such as chitosan and hyaluronic acid (Darr, Calabro 2009, Sakai et al. 2009, Lee, Chung
& Kurisawa 2009a).
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Figure 11. (A) Structure of Human LF. (B) Tyrosine amino acid groups contained in
human LF. (C) Carboxylic acid containing amino acid groups (aspartate and glutamate)
in human LF. (D) Theoretically available crosslinking amino acid sites after tyramine
modification of human LF.
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Figure 12. Amino acid sequence of human lactoferrin.
Tyrosine (y) amino acids are highlighted as they represent the possible crosslinking sites
for LF gel. Glutamic acid (e) and aspartic acid (d) are also highlighted as they may be
modified with phenolic groups and also serve as additional crosslinking sites.
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Figure 13. Schematic showing the modification of LF’s acidic groups with tyramine to
yield greater enzymatic crosslinking sites. Addition of HRP and H2O2 yields a LF
crosslinked gel.

The objective of our preliminary studies was to test the feasibility of crosslinking
bLF using HRP-enzymatic reaction to be used as a localized delivery of bLF protein for
increased osteoblast function.

The second objective of the study was to test our

hypothesis that the immobilized bLF based gel will be bioactive.

3.1.2 Methods
3.1.2.1 Synthesis of bLF-tyramine conjugates (modified bLF)

bLF was tyramine modified for 1, 5, 15 and 24 hours (reaction time) as per the protocol
described in the Appendix of Protocols (section 7.9.2.1.1).
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3.1.2.2 Quantification of tyramine modification of bLF

Tyramine concentration of modified bLF was measured as described in Appendix of
Protocols (section 7.9.2.1.1.1). A tyramine standard curve was used to determine the
concentration of a tyramine in the modified bLF samples (Figure 77). Standard curve
stock was made by diluting 10.5 mg tyramine in 2 ml MES buffer.

0 - 40 µl of stock

solution was diluted in increments of 5 µl further in 900 µl MES buffer (n=4) and diluted
samples were measured by spectrophotomer at 275 nm.
3.1.2.3 Gelation time

Sol to gel time was determined via vial inversion method according to Appendix of
Protocols (Section 7.9.2.2.1). The effect of modified bLF (10 – 50 mg/ml), HRP (10 –
50 U/ml) and 0.25% H2O2 (1 - 10 µl) concentration on gelation time was investigated.
Variables were individually varied and tested for effect on gelatin time.
3.1.2.4 Morphology

The morphology of the bLF gels formed from modified bLF solutions of 10 mg/ml was
visualized by scanning electron microscope to evaluate the gel microstructure. 10 mg/ml
bLF gel was formed according to Appendix of Protocols (Section 7.9.2.1.2.2) on an SEM
stub, flash frozen the samples using liquid N2, lyophilized and then visualized according
to Appendix of Protocols (Section 7.9.2.2.3).
3.1.2.5 Protein expression analysis of encapsulated cells

3.1.2.5.1 Western Blot Analysis
Cells exposed to soluble bLF (2D studies): MC3T3 cells were plated on 10 cm2 tissue
culture plates (200,000 cells/plate), grown to 90% confluence in basal media and then
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serum starved for 6 hours. Cells were stimulated with 100 μg/ml of bLF or untreated
(control) for 24 hours. Cells encapsulated in bLF gel (3D studies): MC3T3 cells
(2,000,000 cells/ml) were encapsulated in 1 ml of 10 mg/ml bLF. After 24 hours of
incubation, total protein was lysed from cells and western blot analysis was performed as
described in Appendix of Protocols (Section 7.2.2.3).
3.1.2.5.2 Immunofluorescence
Cells exposed to soluble bLF (2D studies): 50,000 cells were plated on 35 mm sterile
glass bottom culture plates and then stimulated with 100 μg/ml of bLF or untreated
(control) for 24 hours.
Cells encapsulated in bLF gel (3D studies): MC3T3 cells were cultured on 35 mm sterile
glass bottom culture plates. For 3D cell encapsulation studies, 500,000 cells/ml were
encapsulated in 10 mg/ml bLF gels. bLF gel formation and cell encapsulation was
performed according to Appendix of Protocols (Sections 7.9.2.1.2.2 and 7.9.2.4). The
encapsulated cells were then maintained in basal media at 37ºC for 2 days. Protein
expression was analyzed via immunofluorescence according to Appendix of Protocols
(Section 7.2.2.5).

3.1.3 Results
3.1.3.1 Development of injectable gels from tyrosinated bLF

Figure 14a shows the phenolic content of tyramine modified and unmodified bLF
as a function of reaction time under the described reaction conditions. The phenolic
content of unmodified bLF is due to the presence of tyrosine. The study showed that the
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extent of phenol group substitution significantly depends on the reaction time. The
substitution of tyramine groups in bLF (modified bLF) and the phenolic content of the
modified bLF after 24 hours was approximately 1.5 times higher than the unmodified
bLF (0 hour reaction time).
bLF gels were prepared by the HRP-mediated oxidative coupling of modified bLF
in the presence of H2O2. Various concentrations of modified bLF ranging from 10 mg/ml
to 50 mg/ml were dissolved in 10 U/ml HRP (dissolved in H2O). Gelation was initiated
by the addition of 0.25% H2O2. Figure 14b shows the gelation time of modified bLF at
room temperature when treated with HRP and H2O2. As can be seen from the figure, the
reaction time significantly effects gelation time. The 1 hour reacted bLF was found to
behave similar to that of unmodified bLF, and unable to undergo gelation under the tested
reacted conditions. The 5 hours reacted bLF underwent gelation in ~15 minutes and the
gelation time significantly decreased for the 15 hours reacted samples. The 24 hours
reacted sample underwent gelation in about 2 minutes, which falls in the clinically
feasible injection time. This condition was therefore used for the rest of the studies.

Figure 14. Effect of modification time on (A) bLF phenolic content and (B) gelation time.
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The morphology of 10 mg/ml bLF gel after lyophilization was evaluated using
SEM. Figure 15 shows the morphology of the gel at three different magnifications. The
gels presented a flacky morphology with an open, irregular porous structure.

Figure 15. Morphology of 10 mg/ml bLF gel.

3.1.3.2 Bioactivity of bLF gels

Figure 16a (lane 2) is a western blot showing the expression of phosphorylated Akt by
MC3T3 cells when cultured in the presence of 100 µg/mL bLF compared to the untreated
control (Figure 16a, lane 1). Cells that were not treated with bLF did not show positive
expression of phosphorylated Akt, whereas, cells treated with bLF showed significant
expression of p-Akt. Since soluble bLF can significantly upregulate phosphorylated Akt
in MC3T3 cells after 24 hours in culture, the protein was used as a bioactive marker to
test the bioactivity of bLF injectable gels. Figure 16a (lane 3) is a western blot showing
the expression of phosphorylated Akt by MC3T3 cells encapsulated in injectable bLF gel
(10 mg/ml). As in the case of soluble bLF, the bLF injectable gel also showed significant
upregulation of phosphorylated Akt by the encapsulated MC3T3 cells indicating the
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retention of bioactivity by the gel. Equal protein loading in the above experiments were
confirmed by equivalent levels of tubulin in all lanes (Figure 16c).
The bioactivity of the injectable gel was further confirmed by following an
osteoblast osteogenic marker (active β catenin). Similar to phosphorylated Akt, increased
β catenin activation was seen in MC3T3 preosteoblast cells when treated with 100 µg/ml
soluble bLF after 24 hours of culture (Figure 16b; lane 2) relative to untreated MC3T3
cells (Figure 16b; lane 1). Due to the significant accumulation of β catenin in MC3T3
cells treated with soluble bLF, the same was tested in cells encapsulated in bLF gels.
Figure 16b (lane 3) is the western blot showing the expression of active β catenin by
MC3T3 cells encapsulated in injectable bLF gel (10 mg/ml). After 24 hours of culture,
the encapsulated cells showed positive expression of active β catenin.
Our lab and others have shown the ability of bLF to induce MC3T3 cells to
produce various osteogenic factors such as FGF2 and VEGF (Nakajima et al. 2011,
James et al. 2011). The production of these cytokines by MC3T3 cells was followed by
immunofluorescence. Figure 17 shows an immunofluorescence image of MC3T3 cells
treated with soluble bLF and control PBS for 24 hours stained for VEGF and IGF2
expression. As can be seen, treatment of MC3T3 cells with bLF led to significant
increase in expression of VEGF and IGF2 relative to untreated control. Figure 18 shows
the immunofluorescence image of MC3T3 cells encapsulated in bLF gel (10 mg/ml) for 2
days. As in the case of soluble bLF, the encapsulated cells showed significant expression
of these two proteins further confirming the cell instructive capability of bLF.
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Figure 16. Increased stabilization of β catenin and phosphorylation of Akt in MC3T3
after 24 hour treatment of 100 µg/ml bLF solution and encapsulation in 10 mg/ml bLF
gel.
100 µg/ml bLF treatment (lane 2) and 10 mg/ml bLF gel (lane 3) was compared to
untreated (lane 1) MC3T3 cells.

Figure 17. Effect of 100 µg/ml bLF solution on MC3T3 protein expression after 24 hours
treatment.
Expression of 100 µg/ml bLF treated cells were compared to that of untreated control.
Propidium iodide (red) was used to stain nuclei and FITC-tagged (green) secondary
antibodies were used to visualize positive expression of protein.
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Figure 18. Increased IGF2 and VEGFα expression in 10 mg/ml bLF gel encapsulated
MC3T3 cells after 2 days of culture.
Propidium iodide (red) was used to stain nuclei and FITC-tagged (green) secondary
antibodies were used to visualize positive expression of protein.

3.1.4 Discussion
The efficiency of cell-based therapeutics in tissue engineering is based on
successful delivery of cells to sites of repair or regeneration. Hydrogels allow for simple
implantation via injection to fill irregularly shaped defects and accommodation of
homogeneous incorporation of cells. Several hydrogel systems have been developed to
localize cells at the defect site. In addition to localizing the cells, our ability to modulate
cellular performance using these artificial matrices will be highly beneficial for positive
regenerative outcomes. One method commonly used to modulate cellular performance is
by encapsulating growth factors along with the cells as discussed before (section 2.1.3.2).
Growth factor encapsulation, eventhough it has showed improved performance, has
significant drawbacks. Hydrogels are highly permeable matrices and is associated with
subsequent burst release of these growth factors upon implantation, and growth factors
will not be available to the encapsulated cells for a prolonged time, which could
significantly decrease the efficacy.

Also, as discussed before, wound healing is a

complex process involving several bioactive molecules expressed in a temporal and
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spatial manner. Encapsulating one or two growth factors in the gel will not be able to
recapitulate such a complex microenvironment. Cells are capable of producing much of
the bioactive molecules required for the regenerative process. So the ideal approach will
be to develop a cell-instructive, injectable hydrogel that could induce the production of
these bioactive molecules by the encapsulated cells. Such a biomaterial does not exit so
far. The preliminary studies discussed here aims to evaluate the feasibility of developing
a cell instructive biomaterial using bLF, which has shown to have bioactivities to support
bone formation.
Natural bLF contains phenolic amino acids such as tyrosine. We first evaluated the
feasibility of crosslinking bLF using the HRP mediated enzymatic crosslinking using
H2O2. However, we found that the phenolic content of natural bLF is much lower than
what is needed to develop an effectively crosslinked matrix via the enzyme-catalyzed
coupling. Therefore, attempts were made to increase the phenolic content of the bLF by
chemically substituting the carboxyl groups of bLF with tyramine molecules to form
modified bLF (Figure 11 & 13). The extent of tyramine substitution was analyzed using
UV spectrophotometry at wavelength of 275 nm. The time of reaction was shown to
have a significant effect on the extent of tyramine substitution with extent of substitution
increases with increase in reaction time. For clinical application of injectable gels as
cells or factor delivery vehicles, a gelation time of 1-2 minutes is considered ideal
(Miljkovic et al. 2009).

Therefore, gelation time was used to determine the ideal

concentration of phenolic group in modified bLF that will give the injectable solution a
gelling time of ~1 minute. As indicated in Figure 14, the 24-hour modified bLF showed
a gelation time in that range and was therefore used for the rest of the study.
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The preliminary studies thus confirmed the feasibility of developing a clinicallyrelevant injectable hydrogel based on LF using the mild, enzymatic crosslinking method.
The gel also showed a porous structure that might be conducive to support cell
attachment and proliferation. However, before exploring the clinical applications of the
biomaterial, it is important to confirm the bioactivity of the injectable gel, even though it
is produced from a bioactive protein for reasons summarized below.
The bioactivities of the proteins are mostly governed by the composition as well as
the three dimensional structure of the protein.

Changes in the composition and or

structure of the protein can significantly affect their bioactivities. Since only a very small
amount of phenolic groups were substituted in modified bLF, we hypothesize that the
modification might not completely alter the bioactivity of the protein. Similarly, previous
studies have demonstrated the ability of bLF to improve osteoblast survival, proliferation
and differentiation – however, the mechanism behind bLF’s bioactivity is not completely
understood. The role of LRP1 in mediating the bLF-induced signal transduction in
promoting osteoblast proliferation has been shown to induce phosphorylation of MAP
kinase signaling transducution cascade (Grey et al. 2004). Ligand-induced, receptormediated signal transduction are known to occur in an avidity-controlled manner, where
1) the extracellular ligands can activate the receptors without internalization, 2) it is
consumption-controlled – meaning the extent of activation depends on the ability to
internalize surface-bound ligand and 3) dual-sensitivity where both the avidity and
consumption parameters are important.

In the case of bLF, even though the exact

mechanism is not known, a previous study revealed that the internalization of LF by
LRP1 is not necessary for activation of mitogenic signaling (Grey et al. 2004). Thus, if
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the internalization of bLF ligand is not required, then it is possible that the crosslinked
injectable gel from bLF could show the same bioactivity as soluble bLF. The bioactivity
of the injectable bLF was followed by determining the expression of several key signal
transduction molecules and cytokines in MC3T3 cells induced by soluble bLF.
Phosphorylated Akt is commonly considered as a marker for cell survival. Akt promotes
cell survival by inhibiting apoptosis through phosphorylation and inactivation of several
targets, including Bad, forkhead transcription factors, c-Raf, and caspase-9 (Cardone et
al. 1998, Brunet et al. 1999, Zimmermann, Moelling 1999). bLF is known to increase the
phosphorylation of Akt, however, a recent study demonstrated the anti-apoptotic action
induced by bLF is not dependent on the phosphorylation of Akt (Grey et al. 2006).
Although pAkt is known to play a critical role in cell survival and apoptosis, its function
has also been reported to play an important role in glycogen metabolism and cell growth
(Nave et al. 1999, Hajduch, Litherland & Hundal 2001). As shown in Figure 16a, similar
to solution bLF, injectable bLF gel significantly upregulated the expression of pAkt in
MC3T3 cells.

Even though bLF has shown to significantly increase osteogenic

differentiation markers, such as ALP, collagen 1, Runx2 and OCN (Ying et al. 2012), the
molecular mechanism of the osteogenic effect of bLF has not yet been demonstrated.
Our studies demonstrated the ability of soluble bLF to activate β catenin in MC3T3 cells.
This is interesting from the context of bLF’s ability to support osteoblast differentiation
since the de-phosphorylation and subsequent accumulation of β catenin is a key step in
osteogenic signaling pathway. The present study demonstrated that similar to soluble
bLF, the inejctable bLF gel may stabilize β catenin and promote its significant
accumulation.
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Bone regeneration is a coordinated cascade of spatio-temporal events regulated by an
array of cytokines and growth factors (Amini, Nair 2011b). Bioactive biomaterials that
are capable of locally inducing the production of endogenous cytokines and growth
factors necessary for bone regeneration could serve as an excellent microenvironment to
promote the regenerative process. These biomaterial scaffolds may serve as delivery
vehicles to introduce donor cells at the defect site or can be be used to allow native cells
to migrate to the injury site, then proliferate and finally differentiate to regenerate the
tissue. The combination of osteogenic and angiogenic growth factors have been shown to
enhance bone regeneration (Kanczler et al. 2010, Patel et al. 2008).
For example, our studies demonstrated that bLF-crosslinked gel increased IGF2
protein expression in MC3T3 encapsulated cells after 2 days. As a member of the IGF
signaling system, IGF2 plays an important role in prenatal growth and development
(Randhawa, Cohen 2005).

IGF2 activates various pathways including PI3K/Akt or

MAPK signaling transduction pathways, via IGF receptors (O'Dell, Day 1998). Recent
studies have also indicated that IGF2 potentiates BMP9-induced osteogenic
differentiation and bone formation (Chen et al. 2010).

Other studies reported that

stimulated bone turnover via increased osteoblast number and function is directly and/or
indirectly caused by local IGF1 and IGF2 production (Bouillon 1991). LF also activates
the PI3K/Akt signaling pathway and increases mRNA levels of IGF1, but the functional
significance of these remains to be determined (Cornish, Naot 2010).
Our studies also demonstrated a positive expression on VEGF in MC3T3 cells after 2
days of bLF gel encapsulation.

Furthermore, previous LF study has reported that apo-

hLF significantly enhances VEGF-A—mediated angiogenesis (Norrby 2004). VEGF is a
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key mitogen involved in endothelial cell proliferation and migration, which are important
components of angiogenesis (Schaper, Ito 1996).

Angiogenesis is a complex

physiological process whereby new blood vessels form from pre-existing blood
vasculature and is imperative for successful tissue regeneration. This complex process
occurs during embryonic development, wound repair, and tumor growth.

Human and

bovine LFs have been shown to modulate VEGF-A—mediated angiogenesis in vivo.
3.1.5 Conclusions
The preliminary studies discussed here demonstrate the feasibility of developing an
injectable biomaterial from bLF using the mild enzymatic crosslinking method. We also
showed initial evidence regarding the ability of injectable biomaterial in retaining the
bioactivities of soluble bLF. bLF, either in the soluble form or as injectable gel, was
capable of regulating signal transduction molecules as well as inducing cytokine
production which could play key roles in promoting osteoblast survival, proliferation and
differentiation.

These encouraging results formed the basis for exploring the

development of novel injectable biomaterials based on recombinant human LF as a cell
delivery vehicle, which will be discussed in sections 4 and 5.

4 Evaluation of the bioactivity of recombinant human
lactoferrins
4.1 Evaluation of the bioactivity of recombinant human
lactoferrins (apo-, pis- and holo-) towards murine MC3T3
preosteoblast cells
4.1.1 Introduction
LF protein, which belongs to the iron-binding transferrin family, is present in
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exocrine secretions and is an important regulator of the levels of free iron in the body
fluids (Gonzalez-Chavez, Arevalo-Gallegos & Rascon-Cruz 2009). LF harbors two ironbinding motifs, which are each responsible for the sequestration of a ferric Fe3+ molecule
(Anderson et al. 1990, Anderson et al. 1989).

The glycoprotein’s degree of iron

saturation has a pivotal influence on its physical structure (Baker, Baker 2009). When
fully iron saturated (holo), LF presents as a stable “closed” structure, as opposed to its
“open” iron-free state (apo) (Haridas, Anderson & Baker 1995, Grossmann et al. 1992).
Furthermore, the structure of this protein, although differs throughout species (Anderson
et al. 1989, Baker et al. 1991), retains essentially identical high affinity (KD ~10-22 M)
iron binding sites (Aisen, Leibman 1972).
The role of iron concentration and the resulting changes in protein conformation
in modulating the bioactivity of LF is not clearly understood.

Jiang et al. investigated

the effect of apo- and holo-hLF on Caco-2 cell proliferation under standard cell culture
conditions. The study demonstrated that even though both the proteins were internalized
by LF receptor they differentially affected Erk-signaling and cell proliferation. Apo-hLF
showed significant increase in cell proliferation and activation of Erk cascade compared
to holo-hLF (Jiang et al. 2011). Similarly, a study using mouse crypt cells demonstrated
the differential effects of apo- and holo-hLFs on cell functions. The proliferation of crypt
cells was significantly enhanced by apo-hLF compared to holo-hLF. Moreover, different
signaling pathways were involved in holo and apo-hLF mediated activation of the cells.
Only apo-hLF was capable of activating the Erk signaling pathway, and both apo and
holo-hLFs were capable of activating the PI3K/Akt pathway to modulate crypt cell
proliferation (Jiang, Lonnerdal 2012). Francis et al. studied the iron dependent effect of
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hLF on neutrophil survival (Francis et al. 2011) and concluded that only apo-hLF and not
holo-hLF is capable of inhibiting neutrophil apoptosis. These studies indicate the
possibility that iron concentration may play a significant role in LF bioactivity.
Cornish et al. investigated the effects of bLF’s structure-activity relationship
(Cornish et al. 2006) and reported that the degree of bLF iron saturation did not
significantly affect the proliferation of primary rat osteoblasts.

Furthermore, the

substitution of bLF’s iron with cations of similar size (i.e., magnesium and chromium)
did not significantly change the extent of cell proliferation compared to iron (Cornish et
al. 2006). Compared to the previous studies this data indicates that the iron content of
bLF may not significantly affect the biological activities of this glycoprotein towards
osteoblast. However, most of the studies reported thus far to understand the effect of LF
on osteoblasts and osteoclasts were performed using LF isolated from bovine milk (bLF).
Another important factor that may play an important factor in LF’s bioactivity is its
degree of glycosylation, as discussed in section 2.2.1.
Transgenic, rice-derived recombinant human LF (rhLF) has recently been made
commercially available in three different iron saturation forms, ranging from apo-rhLF
(iron depleted, <10% iron), pis-rhLF (partially iron saturated, ~50% iron), holo-rhLF
(>90% iron saturated) (Huang et al. 2008). The advent of the recombinant human protein
technology offers a cost-effective alternative and a foundation for producing consistent
and predictable results for potential clinical applications. Biochemical and biophysical
analyses indicate that rhLF is similar to native hLF and supports mammalian cell
proliferation (Huang et al. 2008, Tang et al. 2010). Huang et al. reported a “bell shaped”
dose response curve for the proliferative effect of apo-, pis- and holo-rhLF on HT-29
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intestinal cells after 24-hour treatment. The maximal stimulatory effect was seen at a
concentration of 1000 μg/ml for all three forms of rhLF. However, of the rhLF forms,
holo-rhLF showed approximately 3.5 times greater proliferation as indicated by [3H]thymidine incorporation over apo- and pis-rhLF. Furthermore, a dose-dependent increase
in cell growth was seen in rat osteoblast with the treatment of holo-rhLF up to 100 μg/ml
(Huang et al. 2008).
The objective of this study is to investigate the biological effect of apo-, pis- and
holo-rhLFs on MC3T3 cells to understand the effect of iron concentration on rhLF
bioactivity in order to identify the suitable polymer to develop injectable hydrogels for
bone tissue engineering application.

MC3T3 cell line was selected to evaluate the

bioactivities of rhLFs since it is a well-characterized murine osteoblast cell line (Sudo et
al. 1983) that has been used extensively as a model for osteoblasts in vitro. The dose and
iron concentration dependent mitogenic activity of rhLF toward MC3T3 cells was
evaluated using thymidine assay. The ability of rhLF to induce MC3T3 cells to activate
transcription factors, signaling molecules, chemokines and cytokines were determined by
following β-catenin activation, phosphorylation of Akt, VEGF and IL-6 expression.
Protein

and

phosphorylation

levels

were

followed

using

western

blot

and

immunocytochemical analysis. Moreover, a global microarray analysis was performed to
study the overall pattern of gene regulation in MC3T3 cells when cultured in the presence
of different rhLFs for 24 hours.
4.1.2 Methods
4.1.2.1 Cell proliferation

The effect of varying concentrations of apo-, pis- and holo-rhLF on MC3T3–E1 cell
	
  

115

proliferation was measured through thymidine incorporation. MC3T3 cells were
maintained in basal MEMα medium for 6 hours to allow proper cell adhesion and
maintained in serum-free medium overnight. The cell culture was then performed upon
supplementation with 0, 10, 100, and 1000 μg/ml of apo-, pis- and holo-rhLFs and [3H]
thymidine for 24 hour incubation at 37°C. Incorporation of [3H] thymidine radioactivity
was performed as described in Appendix of Protocols (Section 7.6.2.2). Data was then
normalized to untreated control sample and expressed as fold change over control.
4.1.2.2 Protein expression analysis

4.1.2.2.1 Western blot analysis
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to
90% confluence in basal media and then serum starved for 6 hours.

Cells were

stimulated with 100 μg/ml of apo-, pis-or holo-rhLF or untreated (control) for 24 hours.
Total protein was lysed from cells and western blot analysis was performed as described
in Appendix of Protocols (Section 7.2.2.3).
4.1.2.2.2 Immunocytochemistry
MC3T3 cells were plated on glass-bottom tissue culture plates (50,000 cells/plate) to
90% confluence in basal media and then serum starved for 6 hours. Cells were either
untreated (control) or stimulated with varying iron saturations of 100 μg/ml rhLF for 24
hours. Immunocytochemistry was performed as described in Appendix of Protocols
(Section 7.2.2.5).
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4.1.2.3 Microarray gene expression analysis

MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to
90% confluence in basal media and then serum starved for 6 hours.

Cells were

stimulated with 100 µg/ml of apo-, pis- or holo-rhLF or untreated (control) for 24 hours.
RNA extraction, purification and microarray analysis was performed as described in
Appendix of Protocols (Sections 7.3.2.1 and 7.3.2.3). The ratio of the signal intensity of
each experimental sample (100 µg/ml apo, pis, holo-rhLF treatment) and the signal
intensity of untreated control was represented as the fold change relative to control (
Table 3, 4 & 5).
4.1.2.4 Statistical data analysis

All data is presented as mean ± S.D. (standard deviation) for n = 3, unless stated
otherwise. Statistical analyses were performed by t-test; p < 0.05 was considered
statistically significant.
4.1.3 Results
Figure 19 shows the effect of rhLF and iron concentration on the proliferation of
MC3T3 cells after 24 hour treatment. Irrespective of the iron concentration, LF did not
show significant increase in MC3T3 cell proliferation compared to control culture at a
protein concentration of 10 µg/ml. However, significant increase in cell proliferation was
observed when cells were cultured in rhLFs at concentrations of 100 and 1000 µg/mL
rhLF treatment relative to untreated control. At any of the protein concentrations studied,
no significant differences in cell proliferation was observed when cells were treated with
apo-, pis- or holo-rhLF.
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Figure 19. Effect of rhLF concentration and iron saturation on MC3T3 cell proliferation
after 24 hour treatment measured by thymidine incorporation.
Data is expressed relative to control and astrices represent statistical significance
(p<0.05) relative to control and n=4 biological replicates.

LF is a pleotropic protein with multiple functions and is known to activate various
cell signaling pathways in cells including osteoblast cells. In addition to the mitogenic
effects, LF is known to increase cell survival, cause significant phosphorylation of Akt
and support osteogenic differentiation. Bovine LF has been demonstrated to activate
LRP1-independent, PI3K/Akt signaling in osteoblastic cells (Grey et al. 2006, Amini,
Nair 2011c).

Similarly, our studies demonstrated an increased Akt phosphorylation

(Figure 20) and LRP1 expression (Figure 21) relative to untreated control by rhLF
treatment in MC3T3 cells after 15 and 30 minutes irrespective of the iron concentration.
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Figure 20. Effect of rhLF iron concentration on Akt phosphorylation in MC3T3 cells.
Cells were treated for both 15 and 30 minutes in culture. Anti-tubulin was used as a gel
loading control.

Figure 21. Effect of rhLF iron concentration on LRP1 expression in MC3T3 cells.
Cells were treated for both 15 and 30 minutes in culture. Anti-tubulin was used as a gel
loading control.

The molecular mechanisms underlying the anabolic effects of LF have not yet
been clearly elucidated. β catenin-dependent signaling pathway has been well
documented as an osteogenic signaling pathway (Novak, Dedhar 1999).
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The

phosphorylation of Disheveled (Dsh) leads to the destabilization of the β catenin
destruction/ubiquitination complex – which includes a series of events including Gsk3β
phosphorylation. These actions ultimately lead to the stabilization of cytoplasmic β
catenin. Irrespective of the iron concentration, all the rhLFs showed significant increase
in phosphorylation of Dishevelled 2, Gsk3β and increased activation (dephosphosphorylation) of β catenin relative to untreated control (Figure 22).

Figure 22. Effect of rhLF iron concentration on Dishevelled 2, Gsk3β phosphorylation
and β catenin activation in MC3T3 cells.
Cells were treated for 24 hours in culture.
control.

Furthermore,

through

Anti-tubulin was used as a gel loading

immunocytochemistry,

we

demonstrated

that

the

accumulation of β catenin in the cytoplasm resulted in the translocation of β catenin to
the nucleus (Figure 23a) upon 100 μg/ml apo- and holo-rhLF supplementation for 24
hours.
We also investigated the effect of iron concentration of rhLF in inducing the
production of growth factors and chemokines by MC3T3 cells when cultured in the
presence of apo, and holo-rhLFs.
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confirm the production of IL6 and VEGF by MC3T3 cells in the presence of apo- and
holo-rhLF to evaluate whether the expression of the cytokines and chemokines is
dependent on iron concentration. Figures 20b and c show the immunofluorescence
images of MC3T3-E1 cells exposed to 100 μg/ml of apo and holo-rhLF indicating
positive stains for both IL6 and VEGF. The data demonstrates that rhLF is capable of
inducing the expression of IL6 and VEGF in MC3T3 cells and the effect is independent
of the iron concentration.

Figure 23. Immunocytochemistry analysis of (A) active β catenin, (B) IL6 and (C)
VEGFα of 100 µg/ml of apo- or holo-rhLF treated + or untreated (control).
Cells were treated for 24 hours in culture. Nuclei were detected using propidium iodide
(red) and protein expression was detected using FITC-labelled (green) secondary
antibodies.

Microarray gene expression analysis was performed on MC3T3 cells treated with
rhLF at the three varying iron saturations (apo, pis, holo) for 24 hours (Figure 24). Data
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quality and reproducibility is supported by the use of three biological replicates per
sample and also high level of bead-type redundancy (up to an average of 30 beads per
probe) on each array. Of the 45,200 gene transcripts present in the gene array only 251
genes were significantly regulated by rhLF. We compared the relative expression of 251
regulated genes by rhLF of different iron concentrations normalized to untreated control.
Approximately 94% of the 251 genes were regulated similarly by rhLFs irrespective of
the iron concentration. Only 6% genes of the 251 statistically significant genes were
found to be affected by rhLF iron concentration. For example, Ccl7 was up-regulated
1.77-, 4.75-, and 3.48- fold over control respectively by apo-, partial- and holo-rhLFs.
Ccl2, which is under the control of NFκβ and expressed by mature osteoclasts and
osteoblasts (Matsuo, Irie 2008), was up-regulated 1.46-, 3.69-, 2.74-fold over control,
respectively, by apo-, pis- and holo-rhLFs.

Nfkbiz, a gene that encodes for NFκB

inhibitor zeta, was also positively regulated by rhLF. Interestingly, this cluster of genes –
Ccl7, Ccl2 and Nfkbiz, were all more up-regulated upon treatment with rhLFs with higher
iron concentration (pis- and holo-) relative to the form with the lowest iron concentration
(apo-). Tfrc, a gene that encodes for transferrin receptor, was the only gene found to be
differentially regulated by the rhLFs with high (pis and holo) and low (apo) iron
concentration.

Iron-deficient (apo) rhLF up-regulated Tfrc 1.32-fold, whereas, pis- and

holo-rhLF down regulated the gene by 1.20- and 1.26-fold, respectively. Table 3, 4 & 5,
present the list of genes that were up-, down- or differentially-regulated in MC3T3 cells
by 100 μg/mL of rhLFs of three different iron concentrations after 24 hours in culture.

	
  

122

Figure 24. Global expression profiles in MC3T3 murine preosteoblasts treated with
varying iron saturations of rhLF.
Cultures were treated for 24 hours with 100 µg/ml apo-, pis- and holo-rhLF. Data is
expressed as fold change over 24 hour untreated control sample. Red signifies upregulation, and green signifies down-regulation. 251 genes had statistically significant
regulation by the three iron saturated rhLFs relative to the untreated control sample.

Table 3. Genes up-regulated by rhLF of different iron concentrations.

	
  PROBE_ID	
  
ILMN_1239230	
  
ILMN_1229455	
  
ILMN_1259564	
  
ILMN_1229827	
  
ILMN_2420939	
  
ILMN_1224855	
  
ILMN_2830661	
  
ILMN_1250410	
  
ILMN_1243129	
  
ILMN_2546272	
  
ILMN_2681232	
  
ILMN_2984828	
  
ILMN_1257771	
  
ILMN_2717127	
  
ILMN_2956102	
  
ILMN_2924419	
  
ILMN_2688075	
  
ILMN_1231392	
  
ILMN_2431619	
  
ILMN_2711401	
  

	
  

	
  Gene	
  Symbol	
  
Aurkb	
  
D11Ertd759e	
  
AI481100	
  
St7	
  
scl0002624.1_576	
  
AA175286	
  
Top2a	
  
Prkr	
  
Slc11a2	
  
Gng12	
  
D12Ertd647e	
  
Ly6e	
  
Ifi205	
  
Ddx58	
  
Ncapd2	
  
H2-‐Q7	
  
Cyp51	
  
Melk	
  
Ube2l6	
  
3200002M19Rik	
  

Fold	
  change	
  of	
  100	
  μg/ml	
  (x-‐rhLF)	
  
relative	
  to	
  untreated	
  control	
  
Apo-‐rhLF	
  
Pis-‐rhLF	
  
Holo-‐rhLF	
  
1.308	
  
1.161	
  
1.161	
  
1.272	
  
2.677	
  
1.166	
  
2.027	
  
5.613	
  
1.166	
  
1.237	
  
1.162	
  
1.174	
  
1.308	
  
1.182	
  
1.179	
  
1.26	
  
1.837	
  
1.186	
  
1.255	
  
1.196	
  
1.195	
  
1.367	
  
2.285	
  
1.198	
  
1.273	
  
1.454	
  
1.202	
  
1.191	
  
1.193	
  
1.206	
  
1.331	
  
1.175	
  
1.208	
  
1.321	
  
2.467	
  
1.213	
  
1.457	
  
2.709	
  
1.22	
  
1.462	
  
2.47	
  
1.222	
  
1.242	
  
1.18	
  
1.231	
  
1.518	
  
2.832	
  
1.234	
  
1.322	
  
1.304	
  
1.237	
  
1.232	
  
1.193	
  
1.238	
  
1.264	
  
2.154	
  
1.24	
  
1.299	
  
1.276	
  
1.244	
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ILMN_2770585	
  
ILMN_1230020	
  
ILMN_2661289	
  
ILMN_2593196	
  
ILMN_1243616	
  
ILMN_3161897	
  
ILMN_2511868	
  
ILMN_2630852	
  
ILMN_3083163	
  
ILMN_2739999	
  
ILMN_1248132	
  
ILMN_2708340	
  
ILMN_1229210	
  
ILMN_3096592	
  
ILMN_2816754	
  
ILMN_1238000	
  
ILMN_1221817	
  
ILMN_1234539	
  
ILMN_3135781	
  
ILMN_2944666	
  
ILMN_2625451	
  
ILMN_2757870	
  
ILMN_1256257	
  
ILMN_2832219	
  
ILMN_2755915	
  
ILMN_1216746	
  
ILMN_2737163	
  
ILMN_1237375	
  
ILMN_2588139	
  
ILMN_2693940	
  
ILMN_2773981	
  
ILMN_2657376	
  
ILMN_2696339	
  
ILMN_1224110	
  
ILMN_2919433	
  
ILMN_1257574	
  
ILMN_1233449	
  
ILMN_2636110	
  
ILMN_2711772	
  
ILMN_2878355	
  
ILMN_2866970	
  
ILMN_1225730	
  
ILMN_2914843	
  
ILMN_1223045	
  
ILMN_2711075	
  
ILMN_1260362	
  
ILMN_2531281	
  
ILMN_3122961	
  
ILMN_3006767	
  

	
  

BC027061	
  
Fmod	
  
Csprs	
  
Stat1	
  
Cdkn3	
  
Dync1li2	
  
2310002B06Rik	
  
Il7	
  
Cp	
  
B2m	
  
Stmn1	
  
1700029F09Rik	
  
2610318C08Rik	
  
Epb4.1l1	
  
Ndc80	
  
Srpx	
  
Ii	
  
Irgm	
  
Anxa3	
  
Ifit3	
  
Ankrd1	
  
Psmb10	
  
G1p2	
  
Cdca3	
  
Pet112l	
  
B2m	
  
Sqle	
  
Scd1	
  
H2-‐K1	
  
Psmb8	
  
0610007P14Rik	
  
Nipsnap3b	
  
Fgfr1op	
  
Bst2	
  
Cdc45l	
  
Esm1	
  
Ifi205	
  
Sgol2	
  
A930021H16Rik	
  
Kpna2	
  
Kif11	
  
Fdps	
  
Psmb10	
  
2810417H13Rik	
  
Mmp9	
  
LOC223594	
  
LOC271490	
  
Gbp2	
  
Mlkl	
  

1.194	
  
1.171	
  
1.334	
  
1.427	
  
1.228	
  
1.183	
  
1.184	
  
1.262	
  
1.369	
  
1.344	
  
1.404	
  
1.27	
  
1.245	
  
1.204	
  
1.317	
  
1.181	
  
1.706	
  
1.587	
  
1.213	
  
2.17	
  
1.359	
  
1.293	
  
3.222	
  
1.255	
  
1.212	
  
1.39	
  
1.318	
  
1.352	
  
1.575	
  
1.49	
  
1.211	
  
1.191	
  
1.42	
  
2.278	
  
1.257	
  
1.458	
  
1.344	
  
1.257	
  
1.289	
  
1.447	
  
1.337	
  
1.37	
  
1.196	
  
1.373	
  
1.303	
  
1.283	
  
1.427	
  
1.319	
  
1.264	
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1.24	
  
1.527	
  
2.892	
  
2.531	
  
1.165	
  
1.21	
  
1.159	
  
1.417	
  
2.168	
  
1.691	
  
1.277	
  
1.195	
  
1.175	
  
1.243	
  
1.242	
  
1.325	
  
3.788	
  
2.834	
  
1.237	
  
10.802	
  
1.367	
  
1.81	
  
14.31	
  
1.181	
  
1.37	
  
1.777	
  
1.213	
  
1.304	
  
3.047	
  
2.104	
  
1.164	
  
1.237	
  
1.491	
  
6.542	
  
1.187	
  
2.115	
  
2.391	
  
1.206	
  
2.022	
  
1.296	
  
1.27	
  
1.37	
  
1.693	
  
1.32	
  
1.672	
  
1.257	
  
1.265	
  
2.728	
  
1.602	
  

1.249	
  
1.249	
  
1.25	
  
1.257	
  
1.26	
  
1.267	
  
1.272	
  
1.277	
  
1.277	
  
1.278	
  
1.28	
  
1.282	
  
1.285	
  
1.287	
  
1.293	
  
1.3	
  
1.3	
  
1.304	
  
1.308	
  
1.309	
  
1.318	
  
1.318	
  
1.318	
  
1.324	
  
1.328	
  
1.331	
  
1.348	
  
1.35	
  
1.351	
  
1.353	
  
1.358	
  
1.36	
  
1.363	
  
1.365	
  
1.366	
  
1.381	
  
1.383	
  
1.387	
  
1.391	
  
1.409	
  
1.411	
  
1.413	
  
1.419	
  
1.429	
  
1.433	
  
1.439	
  
1.447	
  
1.454	
  
1.462	
  

ILMN_2687156	
  
ILMN_2711112	
  
ILMN_2612774	
  
ILMN_1225718	
  
ILMN_2738921	
  
ILMN_2737302	
  
ILMN_2709478	
  
ILMN_1230065	
  
ILMN_1256817	
  
ILMN_2701271	
  
ILMN_1216764	
  
ILMN_1226839	
  
ILMN_2732795	
  
ILMN_2528456	
  
ILMN_2638548	
  
ILMN_2662803	
  
ILMN_2960214	
  
ILMN_2811737	
  
ILMN_2652857	
  
ILMN_1235327	
  
ILMN_1217929	
  
ILMN_2662802	
  
ILMN_2930203	
  
ILMN_1254561	
  
ILMN_2618918	
  
ILMN_1248830	
  
ILMN_2459899	
  
ILMN_1238276	
  
ILMN_2725402	
  
ILMN_2594525	
  
ILMN_2856095	
  
ILMN_1219574	
  
ILMN_2759484	
  
ILMN_1228557	
  
ILMN_1231814	
  
ILMN_1255416	
  
ILMN_1222543	
  
ILMN_2493826	
  
ILMN_2795040	
  
ILMN_2896200	
  
ILMN_2755008	
  
ILMN_2835117	
  
ILMN_1245710	
  
ILMN_2771176	
  

Galm	
  
Shcbp1	
  
Hrbl	
  
Hmgcr	
  
2410187C16Rik	
  
Cxcl12	
  
Sh3kbp1	
  
LOC245892	
  
Slpi	
  
Plscr1	
  
Ier3	
  
Hist1h2ag	
  
Mylc2pl	
  
LOC219106	
  
Atoh8	
  
Ptx3	
  
8430423A01Rik	
  
Casp4	
  
Ifi47	
  
Rbbp4	
  
LOC328752	
  
Ptx3	
  
Ugt1a10	
  
Csf1	
  
Slc2a6	
  
Hist1h2an	
  
Tsrc1	
  
Hist1h2ai	
  
Nsdhl	
  
Nsdhl	
  
Zc3h12a	
  
Hist1h2af	
  
C3	
  
Id2	
  
Ccl5	
  
Ly6a	
  
Ugt1a9	
  
Ugt1a10	
  
Hist1h2ad	
  
Tnn	
  
Nfkbiz	
  
Ccl7	
  
Ccl2	
  
Ccl7	
  

1.347	
  
1.231	
  
1.31	
  
1.327	
  
1.432	
  
1.313	
  
1.211	
  
1.458	
  
1.277	
  
1.38	
  
1.232	
  
1.402	
  
1.443	
  
1.406	
  
1.428	
  
1.362	
  
1.266	
  
1.345	
  
1.608	
  
1.484	
  
1.259	
  
1.275	
  
1.345	
  
1.19	
  
1.532	
  
1.533	
  
1.392	
  
1.472	
  
1.353	
  
1.37	
  
1.458	
  
1.556	
  
3.17	
  
1.404	
  
4.426	
  
1.481	
  
1.564	
  
1.462	
  
1.742	
  
2.149	
  
1.758	
  
1.523	
  
1.463	
  
1.769	
  

1.342	
  
1.258	
  
1.231	
  
1.213	
  
1.65	
  
1.399	
  
1.283	
  
1.421	
  
1.903	
  
1.963	
  
1.564	
  
1.186	
  
1.473	
  
1.197	
  
1.417	
  
1.55	
  
1.17	
  
2.538	
  
2.837	
  
1.329	
  
1.187	
  
1.579	
  
1.972	
  
1.635	
  
2.227	
  
1.174	
  
2.178	
  
1.231	
  
1.329	
  
1.361	
  
2.131	
  
1.225	
  
9.662	
  
1.532	
  
26.037	
  
3.841	
  
2.528	
  
2.4	
  
1.302	
  
3.585	
  
3.666	
  
3.372	
  
3.685	
  
4.753	
  

1.465	
  
1.467	
  
1.472	
  
1.475	
  
1.509	
  
1.51	
  
1.513	
  
1.513	
  
1.515	
  
1.54	
  
1.556	
  
1.559	
  
1.567	
  
1.582	
  
1.583	
  
1.588	
  
1.594	
  
1.595	
  
1.621	
  
1.623	
  
1.635	
  
1.667	
  
1.706	
  
1.713	
  
1.719	
  
1.769	
  
1.781	
  
1.799	
  
1.799	
  
1.831	
  
1.849	
  
1.912	
  
1.993	
  
2.003	
  
2.045	
  
2.18	
  
2.248	
  
2.254	
  
2.276	
  
2.329	
  
2.599	
  
2.637	
  
2.736	
  
3.48	
  

Table 4. Genes down-regulated byrhLF of different iron concentrations
Fold	
  change	
  of	
  100	
  μg/ml	
  (x-‐rhLF)	
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relative	
  to	
  untreated	
  control	
  
PROBE_ID	
  

	
  

Apo-‐rhLF	
  

Pis-‐rhLF	
  

Holo-‐rhLF	
  

ILMN_1216322	
   Hmgcs2	
  

Gene	
  Symbol	
  

-‐2.41	
  

-‐2.60	
  

-‐3.04	
  

ILMN_1248998	
   Xpnpep2	
  

-‐1.61	
  

-‐2.03	
  

-‐2.49	
  

ILMN_2742426	
   Selenbp1	
  

-‐1.44	
  

-‐1.77	
  

-‐2.29	
  

ILMN_2944508	
   Bglap2	
  

-‐1.80	
  

-‐1.48	
  

-‐2.25	
  

ILMN_1220829	
   Bglap2	
  

-‐1.83	
  

-‐1.56	
  

-‐2.19	
  

ILMN_1233122	
   Bglap-‐rs1	
  

-‐1.71	
  

-‐1.40	
  

-‐2.16	
  

ILMN_2727309	
   Selenbp2	
  

-‐1.38	
  

-‐1.63	
  

-‐2.10	
  

ILMN_3101908	
   Bglap1	
  

-‐1.73	
  

-‐1.46	
  

-‐1.98	
  

ILMN_2445249	
   Krt1-‐5	
  

-‐1.25	
  

-‐2.05	
  

-‐1.97	
  

ILMN_2695085	
   Sorcs2	
  

-‐1.45	
  

-‐1.66	
  

-‐1.95	
  

ILMN_1245864	
   Ifitm5	
  

-‐1.48	
  

-‐1.94	
  

-‐1.93	
  

ILMN_1244099	
   LOC386192	
  

-‐1.56	
  

-‐1.38	
  

-‐1.88	
  

ILMN_2687165	
   Chst2	
  

-‐1.40	
  

-‐1.92	
  

-‐1.88	
  

ILMN_2724942	
   Ptgis	
  

-‐1.47	
  

-‐1.76	
  

-‐1.86	
  

ILMN_2816180	
   Lbh	
  

-‐1.44	
  

-‐1.37	
  

-‐1.85	
  

ILMN_2692244	
   Itga10	
  

-‐1.52	
  

-‐1.64	
  

-‐1.83	
  

ILMN_3162005	
   BC054438	
  

-‐1.48	
  

-‐1.57	
  

-‐1.81	
  

ILMN_1230648	
   Rerg	
  

-‐1.44	
  

-‐1.66	
  

-‐1.80	
  

ILMN_2479977	
   1110065P19Rik	
  

-‐1.39	
  

-‐1.68	
  

-‐1.79	
  

ILMN_2760254	
   Mrgprf	
  

-‐1.28	
  

-‐1.62	
  

-‐1.77	
  

ILMN_2980663	
   Aqp1	
  

-‐1.53	
  

-‐1.79	
  

-‐1.76	
  

ILMN_2633350	
   Mfap4	
  

-‐1.27	
  

-‐1.45	
  

-‐1.75	
  

ILMN_2643241	
   Accn2	
  

-‐1.31	
  

-‐1.59	
  

-‐1.74	
  

ILMN_1225348	
   C230093N12Rik	
  

-‐1.51	
  

-‐1.56	
  

-‐1.71	
  

ILMN_1229745	
   Sertad4	
  

-‐1.43	
  

-‐1.71	
  

-‐1.70	
  

ILMN_2980661	
   Aqp1	
  

-‐1.55	
  

-‐1.69	
  

-‐1.66	
  

ILMN_2829262	
   Ltbp4	
  

-‐1.32	
  

-‐1.62	
  

-‐1.64	
  

ILMN_1250569	
   B230105J10	
  

-‐1.37	
  

-‐1.36	
  

-‐1.62	
  

ILMN_2796472	
   Vldlr	
  

-‐1.27	
  

-‐1.64	
  

-‐1.61	
  

ILMN_2601833	
   Plcg2	
  

-‐1.30	
  

-‐1.61	
  

-‐1.61	
  

ILMN_1217102	
   Tpcn1	
  

-‐1.24	
  

-‐1.29	
  

-‐1.61	
  

ILMN_2746738	
   Htra1	
  

-‐1.20	
  

-‐1.37	
  

-‐1.60	
  

ILMN_2756486	
   Aqp1	
  

-‐1.34	
  

-‐1.79	
  

-‐1.56	
  

ILMN_2625197	
   Ptprv	
  

-‐1.40	
  

-‐1.41	
  

-‐1.56	
  

ILMN_3063340	
   Ibsp	
  

-‐1.49	
  

-‐1.75	
  

-‐1.55	
  

ILMN_1252294	
   Eef2	
  

-‐1.27	
  

-‐1.27	
  

-‐1.54	
  

ILMN_2695143	
   Capn6	
  

-‐1.23	
  

-‐1.33	
  

-‐1.52	
  

ILMN_2818294	
   Srpx2	
  

-‐1.32	
  

-‐1.49	
  

-‐1.52	
  

ILMN_2616164	
   Itga3	
  

-‐1.27	
  

-‐1.30	
  

-‐1.52	
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ILMN_2939012	
   1500012F01Rik	
  

-‐1.28	
  

-‐1.36	
  

-‐1.51	
  

ILMN_1237485	
   2310040A07Rik	
  

-‐1.32	
  

-‐1.55	
  

-‐1.51	
  

ILMN_2744603	
   2010323F13Rik	
  

-‐1.32	
  

-‐1.72	
  

-‐1.50	
  

ILMN_1218264	
   Vldlr	
  

-‐1.27	
  

-‐1.55	
  

-‐1.50	
  

ILMN_1221178	
   Pdlim2	
  

-‐1.33	
  

-‐1.39	
  

-‐1.50	
  

ILMN_2954195	
   Scyl1	
  

-‐1.45	
  

-‐1.34	
  

-‐1.50	
  

ILMN_1230152	
   Adamts4	
  

-‐1.22	
  

-‐1.19	
  

-‐1.50	
  

ILMN_2770088	
   Ibsp	
  

-‐1.47	
  

-‐1.69	
  

-‐1.48	
  

ILMN_2428931	
   4631426J05Rik	
  

-‐1.32	
  

-‐1.50	
  

-‐1.48	
  

ILMN_1221264	
   Klf4	
  

-‐1.32	
  

-‐1.36	
  

-‐1.48	
  

ILMN_1259339	
   Cdk5r1	
  

-‐1.25	
  

-‐1.50	
  

-‐1.48	
  

ILMN_1237421	
   scl0003519.1_175	
  

-‐1.27	
  

-‐1.35	
  

-‐1.48	
  

ILMN_1251301	
   1200014P03Rik	
  

-‐1.28	
  

-‐1.31	
  

-‐1.47	
  

ILMN_3139693	
   Rab11fip5	
  

-‐1.26	
  

-‐1.24	
  

-‐1.47	
  

ILMN_2438962	
   2900054C01Rik	
  

-‐1.34	
  

-‐1.39	
  

-‐1.47	
  

ILMN_1248099	
   Col16a1	
  

-‐1.22	
  

-‐1.28	
  

-‐1.46	
  

ILMN_2718096	
   Sema3b	
  

-‐1.30	
  

-‐1.39	
  

-‐1.46	
  

ILMN_1232884	
   Sphk1	
  

-‐1.20	
  

-‐1.31	
  

-‐1.45	
  

ILMN_2826816	
   Ppox	
  

-‐1.27	
  

-‐1.23	
  

-‐1.45	
  

ILMN_3141106	
   Ibsp	
  

-‐1.41	
  

-‐1.48	
  

-‐1.44	
  

ILMN_2911520	
   Hexdc	
  

-‐1.25	
  

-‐1.32	
  

-‐1.44	
  

ILMN_2457408	
   Zswim4	
  

-‐1.31	
  

-‐1.30	
  

-‐1.44	
  

ILMN_3112922	
   Hdac5	
  

-‐1.26	
  

-‐1.23	
  

-‐1.44	
  

ILMN_1255166	
   Ctxn	
  

-‐1.29	
  

-‐1.32	
  

-‐1.43	
  

ILMN_2592823	
   Cdc42ep5	
  

-‐1.19	
  

-‐1.18	
  

-‐1.43	
  

ILMN_2604029	
   Klf2	
  

-‐1.45	
  

-‐1.46	
  

-‐1.42	
  

ILMN_1228385	
   Itpr3	
  

-‐1.48	
  

-‐1.42	
  

-‐1.42	
  

ILMN_3064283	
   Pde4dip	
  

-‐1.26	
  

-‐1.31	
  

-‐1.41	
  

ILMN_2966104	
   Htra1	
  

-‐1.20	
  

-‐1.31	
  

-‐1.41	
  

ILMN_1260064	
   Pfn2	
  

-‐1.33	
  

-‐1.43	
  

-‐1.41	
  

ILMN_2620145	
   Plcd3	
  

-‐1.23	
  

-‐1.19	
  

-‐1.41	
  

ILMN_2920736	
   Bbc3	
  

-‐1.25	
  

-‐1.30	
  

-‐1.41	
  

ILMN_2418426	
   Wig1	
  

-‐1.22	
  

-‐1.29	
  

-‐1.41	
  

ILMN_2622500	
   B230208J24Rik	
  

-‐1.35	
  

-‐1.40	
  

-‐1.40	
  

ILMN_2698728	
   Srpx2	
  

-‐1.29	
  

-‐1.44	
  

-‐1.38	
  

ILMN_2602185	
   40795	
  

-‐1.43	
  

-‐1.35	
  

-‐1.37	
  

ILMN_2490252	
   Spred1	
  

-‐1.27	
  

-‐1.27	
  

-‐1.37	
  

ILMN_2592093	
   Ift20	
  

-‐1.25	
  

-‐1.32	
  

-‐1.37	
  

ILMN_2696592	
   C77080	
  

-‐1.24	
  

-‐1.18	
  

-‐1.36	
  

ILMN_1214899	
   Phospho1	
  

-‐1.36	
  

-‐1.56	
  

-‐1.36	
  

ILMN_2648098	
   Srgap2	
  

-‐1.39	
  

-‐1.36	
  

-‐1.36	
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ILMN_2909211	
   Msrb2	
  

-‐1.21	
  

-‐1.25	
  

-‐1.35	
  

ILMN_2618696	
   D15Ertd405e	
  

-‐1.34	
  

-‐1.24	
  

-‐1.35	
  

ILMN_2750258	
   Mea1	
  

-‐1.18	
  

-‐1.17	
  

-‐1.35	
  

ILMN_2753323	
   Eif4b	
  

-‐1.21	
  

-‐1.53	
  

-‐1.34	
  

ILMN_1215524	
   9330161C17Rik	
  

-‐1.22	
  

-‐1.19	
  

-‐1.34	
  

ILMN_2815138	
   Myom1	
  

-‐1.23	
  

-‐1.26	
  

-‐1.34	
  

ILMN_2664155	
   Pycr1	
  

-‐1.34	
  

-‐1.36	
  

-‐1.33	
  

ILMN_2615559	
   Dab2ip	
  

-‐1.34	
  

-‐1.32	
  

-‐1.33	
  

ILMN_2744492	
   D10Bwg0940e	
  

-‐1.29	
  

-‐1.44	
  

-‐1.33	
  

ILMN_2925711	
   Dusp6	
  

-‐1.41	
  

-‐1.39	
  

-‐1.33	
  

ILMN_2871628	
   Mapk8ip1	
  

-‐1.18	
  

-‐1.23	
  

-‐1.32	
  

ILMN_2734391	
   Ramp1	
  

-‐1.31	
  

-‐1.57	
  

-‐1.32	
  

ILMN_1227494	
   Egr3	
  

-‐1.46	
  

-‐1.42	
  

-‐1.32	
  

ILMN_1237579	
   1810062O18Rik	
  

-‐1.33	
  

-‐1.36	
  

-‐1.32	
  

ILMN_1234746	
   AI790298	
  

-‐1.31	
  

-‐1.26	
  

-‐1.32	
  

ILMN_1232621	
   Ank	
  

-‐1.23	
  

-‐1.31	
  

-‐1.31	
  

ILMN_2619767	
   Pdlim2	
  

-‐1.23	
  

-‐1.30	
  

-‐1.30	
  

ILMN_1226259	
   Adamts2	
  

-‐1.26	
  

-‐1.30	
  

-‐1.30	
  

ILMN_2907214	
   Tcea3	
  

-‐1.29	
  

-‐1.21	
  

-‐1.30	
  

ILMN_2650356	
   Pthr1	
  

-‐1.32	
  

-‐1.38	
  

-‐1.30	
  

ILMN_1241903	
   Klf4	
  

-‐1.29	
  

-‐1.34	
  

-‐1.30	
  

ILMN_2757916	
   2810037C14Rik	
  

-‐1.30	
  

-‐1.22	
  

-‐1.30	
  

ILMN_2450096	
   Zfp30	
  

-‐1.18	
  

-‐1.20	
  

-‐1.30	
  

ILMN_2617820	
   Ppp3cc	
  

-‐1.28	
  

-‐1.20	
  

-‐1.29	
  

ILMN_2483811	
   2210408F11Rik	
  

-‐1.25	
  

-‐1.29	
  

-‐1.29	
  

ILMN_1245549	
   6330404C01Rik	
  

-‐1.44	
  

-‐1.41	
  

-‐1.29	
  

ILMN_2701750	
   2310061J03Rik	
  

-‐1.36	
  

-‐1.23	
  

-‐1.29	
  

ILMN_2593774	
   1190002H23Rik	
  

-‐1.21	
  

-‐1.48	
  

-‐1.28	
  

ILMN_2643377	
   Slc24a6	
  

-‐1.26	
  

-‐1.19	
  

-‐1.28	
  

ILMN_2548010	
   1110018K11Rik	
  

-‐1.30	
  

-‐1.29	
  

-‐1.28	
  

ILMN_2594779	
   5430431G03Rik	
  

-‐1.20	
  

-‐1.22	
  

-‐1.28	
  

ILMN_1237061	
   Dm15	
  

-‐1.21	
  

-‐1.33	
  

-‐1.28	
  

ILMN_2509830	
   A730063M14Rik	
  

-‐1.23	
  

-‐1.24	
  

-‐1.28	
  

ILMN_2637714	
   Rasa3	
  

-‐1.24	
  

-‐1.33	
  

-‐1.27	
  

ILMN_2594031	
   BC011468	
  

-‐1.24	
  

-‐1.23	
  

-‐1.27	
  

ILMN_2443618	
   2900026A02Rik	
  

-‐1.21	
  

-‐1.22	
  

-‐1.27	
  

ILMN_1230145	
   Acvr2b	
  

-‐1.23	
  

-‐1.26	
  

-‐1.26	
  

ILMN_2476329	
   Whrn	
  

-‐1.26	
  

-‐1.20	
  

-‐1.26	
  

ILMN_1256950	
   1190009E12Rik	
  

-‐1.32	
  

-‐1.29	
  

-‐1.26	
  

ILMN_2599657	
   Fmnl3	
  

-‐1.27	
  

-‐1.24	
  

-‐1.25	
  

ILMN_2765047	
   Chrd	
  

-‐1.19	
  

-‐1.31	
  

-‐1.24	
  

128

ILMN_2732642	
   Kptn	
  

-‐1.18	
  

-‐1.17	
  

-‐1.23	
  

ILMN_1232146	
   1700021C14Rik	
  

-‐1.22	
  

-‐1.23	
  

-‐1.23	
  

ILMN_2799596	
   AI662250	
  

-‐1.29	
  

-‐1.33	
  

-‐1.23	
  

ILMN_2776619	
   Ltbp3	
  

-‐1.23	
  

-‐1.26	
  

-‐1.23	
  

ILMN_2490820	
   2310005L22Rik	
  

-‐1.29	
  

-‐1.19	
  

-‐1.22	
  

ILMN_1239386	
   5230401C23Rik	
  

-‐1.25	
  

-‐1.32	
  

-‐1.22	
  

ILMN_2890357	
   2610027C15Rik	
  

-‐1.19	
  

-‐1.28	
  

-‐1.21	
  

ILMN_2776283	
   Tcea3	
  

-‐1.28	
  

-‐1.29	
  

-‐1.20	
  

ILMN_2613306	
   Efhd1	
  

-‐1.19	
  

-‐1.33	
  

-‐1.20	
  

ILMN_2704822	
   Acaa2	
  

-‐1.27	
  

-‐1.23	
  

-‐1.19	
  

ILMN_2687032	
   Fbxo31	
  

-‐1.22	
  

-‐1.17	
  

-‐1.18	
  

ILMN_3106053	
   Slc39a7	
  

-‐1.24	
  

-‐1.23	
  

-‐1.18	
  

ILMN_2754027	
   Nit1	
  

-‐1.21	
  

-‐1.23	
  

-‐1.17	
  

ILMN_2674575	
   Mmd	
  

-‐1.20	
  

-‐1.21	
  

-‐1.17	
  

ILMN_2671755	
   Ceecam1	
  

-‐1.28	
  

-‐1.22	
  

-‐1.17	
  

ILMN_2528440	
   LOC380927	
  

-‐1.21	
  

-‐1.32	
  

-‐1.15	
  

Table 5. Genes differentially regulated by rhLF of different iron concentrations
Fold	
   change	
   of	
   100	
   μg/ml	
   (x-‐rhLF)	
  
relative	
  to	
  untreated	
  control	
  
	
  
PROBE_ID	
  

	
  
Gene	
  
Symbol	
  

ILMN_2619848	
   Tfrc	
  

Apo-‐rhLF	
  

Pis-‐rhLF	
  

Holo-‐rhLF	
  

1.32	
  

-‐1.20	
  

-‐1.26	
  

4.1.4 Discussion
In this study, the effect of iron concentration on the biological activity of ricederived rhLFs towards MC3T3 cells was examined. LF is a known pleiotropic factor
with unique antimicrobial, antiviral, immunomodulatory properties and anabolic effects
in bone at physiological concentrations. The molecular mechanisms behind the favorable
pleiotropic properties of LF are largely unknown, however, the role of various cell
surface receptors in mediating LF biological response have been identified. One of our
long-term goals is to develop bioactive biomaterials using unique ligand molecules that
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can activate specific receptor mediated signaling pathways.

We have previously

demonstrated the feasibility of developing LF-based biomaterials via an enzymatic
process irrespective of the iron content of the protein (Amini, Nair 2011a, Amini, Nair
2012a).

The aim of the present study was to evaluate whether the iron content of the

protein can make a significant difference in the bioactivity towards pre-osteoblast cells,
to determine the most effective protein to form LF based biomaterials to support bone
regeneration.
Bovine LF has been shown to induce the proliferation of primary ostoeblasts and
osteoblastic cell lines. rhLF derived from rice has shown to have mitogenic effects
towards a variety of cells types such as intestinal cells, hybridoma cells, osteoblast cells
and embryonic kidney cells (Huang et al. 2008). Based on LFs mitogenic activity on
different cell types two possible mechanisms have been suggested. The possibility of
iron acting as a nutrient to support cell proliferation and LF regulated gene expression in
cells through putative cell surface receptors.

Statistically significant dose-dependent

proliferation of MC3T3 cells cultured in the presence of 100 and 1000 μg/ml apo-, pisand holo-rhLFs relative to untreated control demonstrated the significant mitogenic effect
of rhLF towards MC3T3 cells. However, lack of difference in mitogenic effect between
apo-, partial- and holo LFs at all the concentrations studied indicates that the mitogenic
effect of rhLF towards MC3T3 is independent of iron concentration and therefore
potentially mediated by modulation of gene expression via cell surface receptors. The
observed results show a significant difference in behavior of rice-derived rhLFs towards
HT-29 intestinal cells which might be due to the different receptors involved in the
signaling cascade (Huang et al. 2008). The mitogenic effect of bLFs towards osteoblasts
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is known to be mediated at least partially via LRP1 receptors, whereas in the intestinal
cells, the ERK1/2 signaling cascades is mediated via lactoferrin receptor (LfR) (Jiang,
Lonnerdal 2012). Interestingly, LF receptor mRNA has been found to be undetectable in
osteoblastic cells (Naot et al. 2011).
Another unique bioactivity of lactoferrin is its ability to increase cell survival,
even though the mechanism behind the anti-apoptotic activity of LF is unknown.
Previous studies using osteoblasts have demonstrated the ability of bLF to induce PI3Kdependent Akt signaling independent of LRP1 receptor activation (Grey et al. 2006).
MC3T3 cells cultured in presence of rhLFs showed significant increase in Akt
phosphorylation irrespective of iron concentrations indicating that as in the case of
mitogenic activity Akt phosphorylation of rhLF is mediated by a mechanism independent
of iron concentration and potentially mediated through modulation of gene expression
induced by the protein LF.
The β catenin-dependent signaling pathway has been documented as a potential
osteogenic signaling pathway (Novak, Dedhar 1999). The phosphorylation of Disheveled
(Dsh) leads to the destabilization of the β catenin destruction/ubiquitination complex –
which includes a series of events including Gsk3β phosphorylation.

These actions

ultimately lead to the stabilization of cytoplasmic β catenin. Accumulation of β catenin
in the cytoplasm prompts its translocation to the nucleus, where it interacts with members
of the TCF/LEF family of transcription factors and induces the transcription of target
genes. Figure 19 demonstrates that, irrespective of the iron concentration, rhLF increases
phosphorylation of Dsh2, Gsk3β and activation (de-phosphosphorylation) of β catenin in
MC3T3 cells relative to untreated control. The translocation of the stabilized β catenin to
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the nucleus was confirmed by immunocytochemistry (Figure 20a). The stabilization of β
catenin has been known to occur via Wnt-dependent as well as Wnt-independent
pathways. Wnt and growth factor signaling can act through convergent pathways and
possibly synergistically on GSK3β and β catenin (Jin, George Fantus & Sun 2008).
Among Wnt proteins, Wnt3a has been extensively investigated as a potent molecule to
induce stabilization of β catenin, which then cooperatively regulate gene expression with
LEF/Tcf transcription factors (Mbalaviele et al. 2005, Chen, Alman 2009, Baron, Rawadi
2007). Signaling pathways affecting GSK3β (e.g. PI3K/Akt) can also modulate β catenin
transcriptional activity. LRP6 phosphorylation by various protein kinases is considered
another crucial factor for β catenin stabilization.

In summary, the data shown here

demonstrate the ability of rhLF to stabilize β catenin in preosteoblast cells and that the
effect is independent of the iron concentration. More details on the possible mechanism
of β catenin stabilization and the transcriptional activity will be discussed in section
4.3.3.2.1.
The pleiotropic functions of LF have also been attributed to its ability to induce
the synthesis of growth factors, cytokines and chemokines by the cells. Cell signaling
molecules, such as growth factors and cytokines, play an important part in the bone
regenerative process. IL6, a pleiotrophic cytokine, has been demonstrated to be an
important regulator for bone maturation during development (Yang et al. 2004). IL6, is
also known to be involved in initiating signaling cascades required for bone regeneration
following injury (Mountziaris, Mikos 2008). Immunofluorescence study demonstrated
the expression of IL6 protein in MC3T3 cells after 24 hours in culture in the presence of
100 μg/mL apo- and holo-rhLFs. The results concur with the up-regulation of IL6 mRNA
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in MC3T3 cells treated with 50 μg/ml bLF after 2 hours (Naot et al. 2011). Collectively,
the results demonstrate that rhLF is capable of inducing IL6 expression in MC3T3 cells
irrespective of the iron concentration.
VEGFα is another major angiogenic factor that has been demonstrated to be an
essential component of skeletal development and repair. Recent studies demonstrated the
ability of bLF in inducing the synthesis of the angiogenic factors VEGF and FGF2 in
MC3T3 cells via the p44/p42 MAPK pathway (Nakajima et al. 2011, James et al. 2011).
Other studies demonstrated the ability of hLF in stimulating VEGFα – mediated
endothelial cell proliferation and migration (Kim et al. 2006). It has been demonstrated
that exposure of human umbilical vein endothelial cells (HUVECs) to hLF significantly
increased VEGF-induced Erk MAPK phosphorylation (Kim et al. 2006). Similarly,
bovine milk LF induces synthesis of the angiogenic factors (VEGF) in MC3T3 cells via
the p44/p42 MAP kinase pathway (Nakajima et al. 2011, Amini, Nair 2011a). Studies
have also demonstrated that increased skeletal VEGF can enhance β catenin activity and
results in excessively ossified bones (Maes et al. 2010). The present study demonstrates
that rhLF is capable of inducing VEGFα expression in MC3T3 cells and the expression is
also independent of rhLF iron concentration.
The global whole-genome array study was performed to understand the effect of
iron concentration on the overall gene expression profile of MC3T3 cells. The regulated
genes cover a broad range of functional activities of LF ranging from immunity, cell
cycle progression and bone metabolism. The data reported to our knowledge is the first
genetic profile of rhLF treated MC3T3 cells and provide better understanding of the
molecular mechanism behind the pleiotropic effect of rhLF towards osteoblasts. Only a
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limited number of genes with known osteoblast relevant functions are discussed here. A
number of known genes regulated during osteoblast differentiation were found to be
down-regulated in MC3T3 cells for 24 hours when cultured in basal media in the
presence of rhLFs irrespective of the iron concentrations.

These include mature

osteoblast markers, osteocalcin (Bglap) and bone sialoprotein (Ibsp), transcription factors
parathyroid hormone receptor 1 (Pthr1) and prostaglandin 12 synthase (Ptgis). Adamts2
(A disintegrin and metalloproteinase with thrombospondin motifs 2), which is responsible
for processing several types of procollagen proteins (Wang et al. 2003), was also downregulated approximately 1.28-fold by all iron saturation forms. Interestingly, FGF2treated MC3T3 cells also showed similar results of significant down-regulation of
osteoblast differentiation-associated genes (i.e., BMP2, osteocalcin, Runx2 and collagen
1) at 24 hours in culture (Hughes-Fulford, Li 2011).

On the other hand, matrix

metalloproteinase 9 (MMP9), a key regulator in the development of the growth plate
during endochondral bone formation (Pratap et al. 2005), was stimulated by all iron
saturation forms (apo-, pis-, holo-) by 1.30-, 1.67-, 1.43-fold, respectively.
The gene array however, demonstrated an up-regulation of early osteoblastic
induction and proliferation markers. One example is Cxcl12 (chemokine (C-X-C motif)
ligand 12) or SDF1 (stromal cell-derived factor 1), which is an early marker of
ostoeblastic induction modulated by growth factors, which include VEGF, PDGF and
PTH (Jung et al. 2006). Cell division cycle associated 3 (Cdca3), which is required for
entry into mitosis, was also up-regulated an average of 1.25-fold across the three rhLF
concentrations above untreated control.
Three genes that are significantly stimulated by rhLFs with higher iron concentrations
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(pis and holo) are Ccl7, Ccl2 and Nfκβiz (NFκβ inhibitor zeta).

Studies have

demonstrated Nfκβiz to be an activator of IL6 production and also involved in the
induction of inflammatory genes activated through TLR/IL1 receptor signaling
(Yamamoto et al. 2004). Nfκβiz is a gene that encodes for a family of proteins known to
play a role in the inflammatory response to LPS by their interaction with NFκβ proteins
(Eto et al. 2003).

Ccl2 is expressed by mature osteoblasts and is under the control of

NFκβ (Li et al. 2007). Other studies demonstrated that Ccl2 mediates fibroblast survival
through IL6 (Liu et al. 2007). The regulation of Ccl7, Ccl2 and Nfκβiz were significantly
affected by high iron saturation of rhLF, however this differential effect of rhLF iron
saturation was not seen in IL6 protein expression. As discussed before, IL6 expression
was found to be stimulated by 100 μg/ml of both apo- and holo-rhLF treatments relative
to untreated control.

Perhaps, this occurrence is due to the change in molecular

confirmation in rhLF induced by iron saturation not significantly affecting the
upregulation of IL6.
The only gene found to be differentially regulated by the iron concentration of
rhLF is Tfrc (transferrin receptor) (Table 5). Interestingly, previous studies using cells
such as monocytes and intestinal cells have demonstrated a binding site for LF different
from the transferrin receptor. Only with high molar excess of both ligand proteins,
(lactoferrin and transferrin), did a small percentage of the ligands cross-react with the
receptor for the other. This most likely occur due to the structural similarity of the two
glycoproteins (Roiron et al. 1989, Birgens et al. 1983, Hu et al. 1988). With regards to
transferrin and iron, the transferrin family is known to be potent regulators of iron
homeostasis (Cairo et al. 2002), and transferrin receptor 1 is the primary target of
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transferrin in the iron transport system. It has been reported that low iron concentrations
can lead to up-regulation of this protein (Lambert 2012) which may explain why Tfrc was
differentially regulated by the iron unsaturated and saturated forms.
4.1.5 Conclusions
The present study investigated the effect of rhLF iron saturation on preosteoblasts. Recombinant human LF was found to have a significant effect on MC3T3
cell proliferation, Akt phosphorylation, β catenin activation, Dishevelled 2 and Gsk3β
phosphorylation at all iron concentrations studied over untreated control after 24 hour
treatment. Up-regulation of chemokines and cytokines, such as VEGF and IL6, was
induced by rhLF in MC3T3 cells independent of the iron concentration. Microarray
analysis of the effect of various iron saturated rhLF forms on MC3T3 cells demonstrated
only one gene, transferrin receptor, to be differentially regulated by the iron
concentration of rhLF. Since there wasn’t a significant difference of bioactivity of the
various iron saturation forms of rhLF, we choose to use holo-rhLF for our future
studiesas this form is widely available.

4.2 Bioactivity of holo-rhLF towards MC3T3 murine
preosteoblast cells and NHOst primary cells: a
comparative study
4.2.1 Introduction
In vivo studies allow for the analysis of biomolecules on a complete biological
system with a vast array of cell types, growth factors and cytokines. However, in an
isolated in vitro study, the effect of biomolecules is studied on a controlled, artificial
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environment. Therefore, the selection of an isolated cell type to study the effect of a
biomolecule on a particular system may result in pertinent or non-pertinent results.
Thus, it is crucial to select a cell culture system that is pertinent to the organ of clinical
interest and one that will also allow for the accurate study of a biomolecule’s effect on
that organ of interest.
To understand the biological activity of rhLF, we chose to use murine MC3T3
preosteblast cells due to reasons summarized below.

MC3T3 cells are clonal cells

established from newborn mouse calvaria. Compared to primary calvarial cells that
contain a limited percentage of osteoblast precursors capable of forming mineralized foci
(Bellows, Heersche & Aubin 1990), conﬂuent MC3T3 cells form a more continuous layer
of cells and mineralized extracellular matrix (Sudo et al. 1983, Nakano, Addison &
Kaartinen 2007, Wang et al. 1999). Moreover, studies have shown that MC3T3 cells
have the capacity to differentiate into osteoblasts and osteocytes and to form calcified
bone tissue in vitro (Sudo et al. 1983). With good culture maintenance, MC3T3 cells
exhibit very high phenotype stability and biological reproducibility.

In summary,

MC3T3 cells have a long history of being used as a model osteoblast cell to understand
osteoblast behavior (Sudo et al. 1983).

However, while developing biomaterials to

support tissue regeneration, it is important to confirm the translational potential of the
material for applications in humans. Therefore, we compared the bioactivity of holorhLF towards MC3T3 cells and Normal Human Osteoblasts (NHOst) cells to confirm that
rhLF is equally effective towards NHOst and MC3T3 cells.

NHOst cells are primary

cells isolated from human bone tissue. Therefore, the objective of the following studies
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was to evaluate whether holo-rhLF would similarly affect MC3T3 and NHOst cell
proliferation and differentiation.
4.2.2 Methods
4.2.2.1 Proliferation assays

4.2.2.1.1 Thymidine incorporation
The effect of varying concentrations of holo-rhLF on MC3T3 cell proliferation was
measured through thymidine incorporation as described in Section 4.1.2.1. Briefly, the
cell culture was then performed upon supplementation with 0, 10, 100, and 1000 μg/ml of
apo-, pis- and holo-rhLFs and [3H]thymidine for 24 hour incubation at 37°C. Thymidine
incorporation was analyzed; data was normalized to untreated control sample and
expressed as fold change over control.
4.2.2.1.2 MTS assay
NHost cells were plated at a density of 15,000 cells/well in a 48-well plate with basal
media. After 24 hours, treatments were administered at various concentrations (n=4
biological replicates). The cell culture was then performed upon supplementation with 0,
10, 100, and 1000 μg/ml of holo-rhLF for 24 hour incubation at 37°C. The proliferation
of NHOst cells was determined by MTS assay as described in Appendix of Protocols
(Section 7.6.2.1). Data was then normalized to untreated control sample and expressed as
fold changeover control.
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4.2.2.2 Differentiation assays

4.2.2.2.1 Alkaline phosphatase assay
MC3T3 and NHOst cells were plated at a density of 50,000 cells/well in a 24 well plate
with basal media. Cells were grown to confluence in basal medium and then changed to
mineralization media. The cell culture was then performed upon supplementation with 0,
100, and 1000 μg/ml of holo-rhLFs (n=4 biological replicates). Mineralization media
supplemented with and without rhLF treatments was changed every 3 days and samples
were harvested on day 7, 14, 21 and alkaline phosphatase activity was determined as
described in Appendix of Protocols (Section 7.7.2.1).
4.2.2.2.2 Mineralization assay
MC3T3 and NHOst cells were plated at a density of 50,000 cells/well in a 24-well plate
with basal media. Cells were grown to confluence in basal medium and then changed to
mineralization media. The cell culture was then performed upon supplementation with 0,
100, and 1000 μg/ml of holo-rhLF (n=4 biological replicates). Mineralization media with
and without rhLFs was changed every 3 days and samples were harvested on day 7, 14,
21 days the extent of mineral deposition was followed as described in Appendix of
Protocols (Section 7.7.2.2).
4.2.2.3 Protein expression

MC3T3 and NHOst cells were plated at a density of 200,000 cells/plate on 10 cm tissue
culture plates, grown to 90% confluence in basal medium.

The cells were then

maintained in basal serum-free medium overnight. The cell culture was then performed
with supplementation with 0, 100 and 1000 µg/ml of holo-rhLF for 24 hours. Total
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protein was lysed from cells and western blot analysis was performed as described in
Appendix of Protocols (Section 7.2.2.3).
4.2.3 Results
Thymidine incorporation and MTS assay, two traditional cell proliferation assays,
were used to test the effect of holo-rhLF on MC3T3 and NHOst cells, respectively.
Holo-rhLF led to a significant increase in proliferation of MC3T3 cells – concentration of
100 and 1000 µg/ml. Similarly, holo-rhLF led to a significant increase in proliferation of
NHOst cells – at all concentrations tested 10, 100, 1000 µg/ml (Figure 25). Unlike
MC3T3 cells, NHOst showed significant increase with 10 µg/ml holo-rhLF treatment
after 24 hours. 100 µg/ml holo-rhLF treatment led to a 61% and 43% increase in
proliferation over untreated control of MC3T3 and NHOst cells, respectively, after 24
hours treatment.

Figure 25. Effect of holo-rhLF treatment on MC3T3 and NHOst cell proliferation.
Cells were treated for 24 hours in culture. Cell proliferation was measured in MC3T3
and NHOst cells by thymidine incorporation and MTS assay, respectively. Data was
normalized to untreated control sample and expressed as fold change over control.
Statistical significance (p<0.05) is represented as * relative to appropriate control.
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Both cell types, MC3T3 and NHOst cells, demonstrated a significant increase in
ALPase activity after 7, 14, 21 days of holo-rhLF treatment relative to untreated control
samples (Figure 26). MC3T3 cells displayed a dose-dependent increase in ALP activity
at 14 and 21 days. However, this effect was not seen in NHOst cells – 1000 µg/ml holorhLF induced a less significant increase in ALP activity relative to 100 µg/ml holo-rhLF
at 14 and 21 days of culture. Significant increase in calcium deposition by MC3T3 and
NHOst cells was measured by Alizarin Red staining after 14 and 21 days of holo-rhLF
treatment (Figure 27). Trends in increase mineralization (Alizarin Red staining) were
similar in MC3T3 and NHOst cells during the 21 day culture period.
An effect of holo-rhLF on signaling molecule production was exhibited by both
MC3T3 and NHOst cells. As discussed before holo-rhLF can induce phosphorylation of
Akt in MC3T3 cells. Holo-rhLF increase phosphorylation of Akt in MC3T3 cells (Figure
32) and NHOst cells (Figure 28a) after 24 hours treatment relative untreated control
samples. Similarly, activation (de-phosphorylation) of β catenin was increased by holorhLF treatment relative to control in MC3T3 cells (Figure 22) and NHOst cells (Figure
28b) after 24 hours. Equal protein loading was confirmed in western blotting using antitubulin blot
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Figure 26. Alkaline phosphatase activity in MC3T3 and NHOst cells treated with holorhLF.
Alkaline phosphatase assay was performed on MC3T3 and NHOst cells maintained in
mineralization media for 7, 14 and 21 days and treated with 100 or 1000 μg/ml holo-rhLF
or untreated (-). Statistical significance (p<0.05) is represented as * relative to
appropriate control.

Figure 27. Mineral deposition by MC3T3 and NHOst cells treated with holo-rhLF.
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Alizarin Red assay was performed on MC3T3 and NHOst cells maintained in
mineralization media for 7, 14 and 21 days and treated with 100 or 1000 μg/ml holo-rhLF
or untreated (-). Statistical significance (p<0.05) is represented as * relative to
appropriate control.

Figure 28.
Holo-rhLF increases (a) phosphorylation of Akt and (b) activation of β
catenin in NHOst cells after 24 hours of treatment.

4.2.4 Discussion
Bone developmental sequence can be characterized in three stages: (1) osteoblast
proliferation, (2) matrix maturation, and (3) mineralization (Siggelkow et al. 1999). This
sequence has been most extensively studied in the rat calvarial cell system (Aronow et al.
1990b, Collin et al. 1992, Nefussi et al. 1997, Owen et al. 1991, Pockwinse et al. 1995)
and murine MC3T3 cells (Quarles et al. 1992). Differentiation of human osteoblasts is
not as widely characterized, however studies thusfar indicate an analogous process in
developing human bone (Dodds et al. 1994, Mundlos 1994).
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Fetal and neonatal rat calvaria cells are the most widely used source of primary
osteoblasts. These calvarial cells are proteolytically released and in early passage are
heterogeneous and not immortalized. However, enrichment of cultures for committed
osteoblasts can be obtained by proper sub-confluent passaging and 0.1 µM
dexamethasone treatment (Aronow et al. 1990a).

Cells released at later times of

proteolytic digestion have increased osteogenic potential as they express osteoblast
phenotypic markers and form mineralized nodules with time in culture (Kawaguchi et al.
1995).
Clonal osteoblast-like MC3T3 cell line, which is established from newborn
C57B/6 mouse calvaria, provides an excellent in vitro model of bone development. This
system resembles osteogenic cells in numerous ways as it undergoes the three orderly
time-dependent phases characterized by proliferating pre-osteoblasts, hydroxyapatite
crystal matrix deposition by differentiating osteoblasts, which results in the formation of
multilayered bone nodules (Vary et al. 2000). This cell line provides one of the most
convenient and physiologically relevant culture systems for osteoblast studies.

The

MC3T3 cell line is an immortalized cell line selected by the 3T3 passaging protocol
(Sudo et al. 1983). At confluence, this cell line differentiates along the osteoblast linage
and sequentially expresses characteristic osteoblast phenotypic markers (including bone
sialoprotein and osteocalcin) similar to that of primary calvarial osteoblasts cultures of
fractions 3-5 (Vary et al. 2000, Franceschi, Iyer 1992, Franceschi, Iyer & Cui 1994).
Moreover, post-confluent cultures of MC3T3 cells cultured in the presence of ascorbic
acid and β-glycerolphosphate will mineralize and accumulate hydroxyapatite (Sudo et al.
1983).
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passaged accordingly before confluence. This cell line is a physiologically relevant
model commonly used for studying osteoblasts – as it provides a model for signal
transduction cascades and their interactions with osteoblast transcription factors.
MC3T3 and NHOst cells displayed all three stages of the bone developmental
sequence in response to holo-rhLF treatment. A significant increase in MC3T3 and
NHOst cellular proliferation induced by holo-rhLF treatment was measured by thymidine
incorporation and MTS assay, respectively, after 24 hours of treatment. However, unlike
MC3T3 cells, NHOst cells showed a significant increase in cell proliferation with only 10
µg/ml holo-rhLF treatment. Previous studies by Cornish et al. demonstrated similar
effects of rhLF on rat primary osteoblast proliferation via thymidine incorporation after
24 hours treatment at concentrations of 10 and 50 µg/ml (Cornish et al. 2004). Although
the response of MC3T3 cells to many growth factors and hormones mimics that of
primary cultures of rodent osteoblastic cells (Delany, Canalis 1998), studies have
demonstrated differential regulation of growth factors on osteoblast cells based on their
differentiation stage.

For example, FGFs induce immature osteoblastic cells to

proliferate, whereas mature osteoblasts respond by unaltered or decreased proliferation
(Hurley, Marie 2002). This reasoning may be used to explain the more sensitive response
of primary NHOst cells to the lower concentration (10 µg/ml) of holo-rhLF relative to
pre-osteoblastic MC3T3 cells.
Increased osteogenic differentiation was induced by holo-rhLF supplementation
of mineralization media, which included 10 µg/ml L-ascorbic acid and 3 mM βglycerophosphate.

Osteogenic differentiation was assessed by increased alkaline

phosphatase and mineralized matrix deposition at 7, 14 and 21 days.
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Choi et al.

reported the phenotypic increase of alkaline phosphatase activity during early matrix
formation/maturation period (approximately day 10) (Choi et al. 1996). In our studies,
MC3T3 and NHOst cells demonstrated a significant increase in ALP activity during early
matrix formation period of day 7 and 14.

This increase in alkaline phosphatase was

further sustained in both cell types by holo-rhLF at 21 day culture.

A previous study

using MG63 osteoblast-like cells showed similar results as LF treatment led to significant
increase in ALP activity at days 14 and 21 days (Takayama, Mizumachi 2008).
Similar to ALP activity, the presence of holo-rhLF significantly increased the
mineral deposition by MC3T3 and NHost cells at 14 and 21 days of culture in
mineralization media.

Other studies report that mineralization of extracellular matrix,

which marks the final phase of osteoblast phenotypic development, begins approximately
16 days after culture (Quarles et al. 1992). Even at 21 days, the extent of mineralized
matrix formed in the presence of rhLF was significantly higher than the control indicating
the potential of rhLF to produce overall higher amount of matrix compared to control.
Interestingly, there was no statistical significant increase in mineral deposition produced
by 1000 µg/ml holo-rhLF treatment relative to 100 µg/ml.

Thus, the concentration of

100 µg/ml of holo-rhLF is sufficient to induce significant mineral deposition in NHOst
and MC3T3 cells.
These studies also showed similar response of MC3T3 and NHOst cells towards
holo-rhLF treatment regarding Akt phosphorylation and β catenin activation.

These

results concur with results from our previous studies with MC3T3 cells (Section 4.1.3)
and also previously published studies using primary rat osteoblasts and bLF to induce
PI3K-dependent Akt signaling (Grey et al. 2006). The β catenin-dependent signaling
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pathway has been documented as a potential osteogenic signaling pathway (Novak,
Dedhar 1999).
4.2.5 Conclusions
The effect of holo-rhLF on the signaling and functional properties on NHOst and
MC3T3 cells was compared to demonstrate the translational potential of rhLF-based
materials. The study demonstrated NHOst followed the same pattern of transcriptional
factor expression, cell proliferation and differentiation.

The study confirmed that the

bioactivities of rhLF may be reproduced in human cells similar to mouse clonal cells,
thereby demonstrating the translational potential of rhLF based biomaterials.
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4.3 Evaluation of the mechanism behind the anti-apoptotic
and osteogenic activity of rhLF towards MC3T3 cells
4.3.1 Introduction
Cell-based bone tissue engineering encompasses the use of cells and biomaterials
for the regeneration or repair of damaged bone tissue. The challenges in cell-based
therapy are two-fold, which include biological and biomaterial obstacles. The biological
challenges involve the survival of the implanted cells at the defect site (Manassero et al.
2012).

The biomaterial challenge includes localizing the implanted cells at the defect

site for prolonged time, positively modulating the activity of encapsulated cells in the
microenvironment to support accelerated regeneration and maintain the survival of the
cells. The significant cell death and decreased activity of cells after implantation at
orthotopic sites have been demonstrated using various cell-based modalities in small
animals, as well as human clinical trials. A recent study investigated the success of
human mesenchymal stem cell survival after implantation to rat femoral defect.
Unfortunately, less than 2% of the initial cell number was viable after 30 days of
implantation (Figure 29) (Manassero et al. 2012).
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Figure 29. Representative bioluminescence imaging of a mice transplanted with human
mesenchymal stem cells in a critical-size segmental femoral defect and in vivo kinetic
cell survival quantification.

A recent human clinical trial investigated the potency of bone tissue engineering to
reconstruct jaw defects. After 4 months of reconstructing an intra-oral bone defect, bone
formation by implanted stem cells was shown to be feasible in only 1 out of 6 patients by
the tissue-engineered construct (Meijer et al. 2008). To make bone tissue engineering
techniques involving cells suitable for reconstructing an osseous defect, the problem of
cell apoptosis and lack of osteogenic induction must be solved. Biomaterial with inherent
anti-apoptotic and osteogenic properties would be highly beneficial as a cell-delivery
vehicle as it would address the two major existing concerns in cell-based therapy.
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LF has raised significant interest as a bioactive protein due to its wide array of
physiological effects on many different cell types (Amini, Nair 2011c). The diverse list
of LF’s multifunctional roles includes immuno-modulatory, anti-cancer, anti-bacterial,
and anti-viral properties (Spadaro et al. 2008, Legrand et al. 2005). Some of the recent
studies have demonstrated LF as an effector molecule in the skeleton (Cornish, Naot
2010, Cornish 2004), due to its ability to increase osteoblast proliferation, survival and
differentiation (Grey et al. 2006, Cornish et al. 2004, Cornish 2004) and decrease
osteoclast survival (Lorget et al. 2002, Blais et al. 2009).

Many of the biological

activities of LF have been attributed to its ability to induce signal transduction pathways
through cell surface receptors.

LRP1 has been established as one of the putative

receptors in osteoblasts. The activation of this receptor by bLF has been shown to induce
MAPK-mediated osteoblast mitogenesis (Grey et al. 2004). However, the anti-apoptotic
properties of this glycoprotein have been attributed to a PI3K/Akt-independent, and
LRP1-independent pathway (Grey et al. 2006). The anabolic effect of bLF (Cornish
2004) has also been attributed to bLF’s possible positive effects on osteogenic
differentiation (Yagi et al. 2009). Yagi et al. demonstrated the ability of bLF to push the
differentiation of pluripotent mesenchymal stems cells towards the osteoblastic or
chondroblastic lineage, and prevent the differentiation towards myloblastic and or
adipocytic lineages (Yagi et al. 2009).

Furthermore, hLF stimulates keratinocytes

proliferation via MAPK signaling cascade, which is a pathway similar to FGF2stimulated mitogenesis, cell migration and cell survival implying its potential to promote
wound re-epithelialization (Tang et al. 2010). Recent studies indicate the ability of bLF
to promote FGF-2 and VEGF synthesis by osteoblasts via the p44/p42 MAP kinase
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pathway (Nakajima et al. 2011, James et al. 2011). Additionally, bLF has been shown to
inhibit osteoclastogenesis in primary culture of murine bone cells at a concentration as
low as 10 μg/ml (Lorget et al. 2002). Collectively, these studies substantiate LF as a
positive regulator of the skeleton.

Figure 30. Schematic showing the summary of known mechanisms of action of LF in
osteoblasts.
Binding of LF to LRP1 receptor on osteoblasts induces endocytosis of the LF-LRP1
complex as well as activation of the p42/44 MAP kinases signaling pathway. Inhibition of
the MAPK pathway blocks the mitogenic effect of lactoferrin in osteoblasts. LF also
activates the PI3K/Akt signaling pathway and increases mRNA levels of IGF1, Nfatc1
and Ptgs2 but the functional significance of these remains to be determined. The
mechanisms involved in the activities of LF as a survival factor and as a promoter of
osteoblast differentiation are unknown yet. Image was taken from (Cornish, Naot 2010).

Fetal bovine serum, the most widely used serum animal supplement, provides
broad spectrum of macromolecules, carrier proteins, attachment and spreading factors,
low molecular weight nutrients, and hormones and growth factors (Boone et al. 1971).
Serum deprivation has been shown to efficiently induce apoptosis in several cell types
(Aoki et al. 1997, Hara et al. 2012, Braun et al. 2011). Thus, serum deprivation model
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was used to study holo-rhLF effect on cellular apoptosis. Furthermore, we investigated
the osteogenic effect of holo-rhLF on MC3T3 cells. The objective of the following
studies was to test the anti-apoptotic and osteogenic activity of holo-rhLF on MC3T3
cells to evaluate the efficacy of using holo-rhLF as a potential biomaterial to develop
novel injectable cell delivery vehicles. We also went on to investigate the molecular
mechanisms underlying holo-rhLF’s anti-apoptotic and osteogenic effects to gain a better
understanding of the signal transduction pathways induced by this bioactive molecule.
4.3.2 Methods
4.3.2.1 Cell viability/ survival assays

4.3.2.1.1 Serum starvation and cell viability assay
MC3T3 cells were plated at a density of 50,000 cells/well in a 12-well plate with basal
media for 24 hours. Cells were then maintained in serum-free basal media and the cell
culture was then performed upon supplementation with 0 or 100 μg/ml of holo-rhLF.
Live/dead viability assay was then performed as described in Appendix of Protocols
(Section 7.5.2.1).
4.3.2.1.2 Protein expression (Immunocytochemistry)
MC3T3 cells were plated on glass-bottom tissue culture plates (10,000 cells/plate) for 2
days in basal media and then serum starved for 6 hours. Cells were either untreated
(control) or stimulated with holo-rhLF 100 μg/ml for 24 hours. Immunocytochemistry
was performed as described in Appendix of Protocols (Section 7.2.2.5).
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4.3.2.1.3 Wnt signalling pathway
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to
90% confluence in basal media and then serum starved for overnight.

Cells were then

maintained in serum-free basal media overnight and the cell culture was then performed
upon supplementation with 0 or 100 µg/ml of holo-rhLF for 24 hours.

RNA was

extracted, purified and Wnt signaling pathway array was performed as described in
Appendix of Protocols (Section 7.9.2.1).
4.3.2.1.4 Inhibitor studies for signalling pathway probing
4.3.2.1.4.1 Protein expression (Western blot analysis)
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to
90% confluence in basal media and then serum starved for overnight. Inhibitor treatment
of select inhibitors (10 µM LY294002 and 30 µM H-89) for 2 hours was followed by
treatment with 100 µg/ml holo-rhLF or 100 ng/ml Wnt5a for 24 hours. Total protein was
lysed from cells and western blot analysis was performed as described in Appendix of
Protocols (Sections 7.2.2.3 and 7.8.2.1).
4.3.2.1.4.2 Bioluminescent caspase-3 assay
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to
90% confluence in basal media and then serum starved for overnight. Inhibitor treatment
of select inhibitors (10 µM LY294002 and 30 µM H-89) for 2 hour was followed by
treatment with 100 µg/ml holo-rhLF, 100 ng/ml Wnt5a or 100 ng/ml BMP2 for 24 hours.
50 µM Z-VAD-FMK was also used as a positive control apoptosis inhibitor. Total
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protein was lysed from cells and caspase assay was performed as described in Appendix
of Protocols (Section 7.5.2.2).
4.3.2.1.5 Osteogenesis assays
4.3.2.1.5.1 Protein expression
4.3.2.1.5.1.1

Total β catenin expression

4.3.2.1.5.1.1.1 Canonical Wnt signaling pathway activation

MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to
90% confluence in basal media. Cells were then maintained in serum-free basal media
overnight and the cell culture was then performed upon supplementation with 0 or 100
µg/ml of holo-rhLF or 10 mM LiCl for 15 minutes or 100 ng/mlWnt3a for 6 hours. Total
protein was extracted and western blot analysis was performed as described in Appendix
of Protocols (Section 7.2.2.3).
4.3.2.1.5.1.1.2 Time course of β catenin expression

MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to
90% confluence in basal media. Cells were then maintained in serum-free basal media
overnight and the cell culture was then performed upon supplementation with 100 µg/ml
of holo-rhLF for 0, 0.25, 1, 3, 6 and 24 hours. Total protein was extracted and western
blot analysis was performed as described in Appendix of Protocols (Section 7.2.2.3).
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4.3.2.1.5.1.2

Nuclear/cytoplasmic β catenin expression

4.3.2.1.5.1.2.1 Western blot

MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to
90% confluence in basal media. Cells were then maintained in serum-free basal media
overnight and the cell culture was then performed upon supplementation with 0 or 100
µg/ml of holo-rhLF for 24 hours. Total protein was extracted, nuclear and cytoplasm
fractions were separated and western blot analysis was performed as described in
Appendix of Protocols (Sections 7.2.2.3 and 7.2.2.4).
4.3.2.1.5.1.2.2 Immunocytochemistry

MC3T3 cells were plated on glass-bottom tissue culture plates (10,000 cells/plate) for 2
days in basal media and then serum starved for 6 hours. Cells were either untreated
(control) or stimulated with varying iron saturations of 100 μg/ml rhLF for 24 hours.
Immunocytochemistry was performed as described in Appendix of Protocols (Section
7.2.2.5).
4.3.2.1.5.2 RNA expression
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to
90% confluence in basal media. Cells were then maintained in serum-free basal media
overnight and the cell culture was then performed upon supplementation with 0 or 100
µg/ml of holo-rhLF for 0, 12 and 24 hours. RNA was extracted, purified and PCR
analysis was performed as described in Appendix of Protocols (Section 7.3.2.2).
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4.3.2.1.5.3 Inhibitor studies for signaling pathway probing
MC3T3 cells were plated on 10 cm tissue culture plates (200,000 cells/plate), grown to
90% confluence in basal media and then serum starved for overnight. Inhibitor treatment
of select inhibitors (100 ng/ml DKK1 and 30 µM H-89) for 2 hour was followed by
treatment with 100 µg/ml rhLF, 100 ng/ml Wnt5a or 100 ng/ml BMP2 for 24 hours.
Total protein was lysed from cells and western blot analysis was performed as described
in Appendix of Protocols (Section 7.2.2.3).
4.3.3 Results
4.3.3.1 Anti-apoptotic effect of holo-rhLF toward MC3T3 cells

We investigated the ability of holo-rhLF to protect the cells against serum starvation–
induced apoptosis. MC3T3 cell apoptosis was significantly reduced by 100 µg/ml holorhLF over the course of 3 days, as evidenced by the increased ratio of live to dead cells in
the holo-rhLF treated sample relative to control (Figure 31). Furthermore, holo-rhLF
treatment (24 hours) increased Akt phosphorylation over control (Figure 32).
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Figure 31. Viability of serum starved MC3T3 cells after holo-rhLF treatment.
Viability assay demonstrates increased live (green) cells relative to dead (red) cells after
2 days in MC3T3 cells treated with 100 µg/ml holo-rhLF relative to untreated control
during serum starvation.

Figure 32. Increased phosphorylation of Akt in MC3T3 cells after holo-rhLF treatment.
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Immunofluorescence showing the phosphorylation of Akt (FITC-labeled secondary
antibody) in MC3T3 cells treated with 100 µg/ml holo-rhLF treatment relative to
untreated control after 24 hours. Nuclei are stained with propidium iodide.

To elucidate the mechanism by which LF promotes cell survival, Wnt-mediated
signaling transduction pathway array was used (Figure 33). Interestingly, Wnt5a was
stimulated 3.8—fold upon 24-hour holo-rhLF treatment. A signaling pathway reported
to be mediated by Wnt5a’s anti-apoptotic effects is the protein kinase A (PKA)/ cAMP
response element binding protein (CREB) (Torii et al. 2008).

Next, we used PKA

inhibitor, H89, and Akt inhibitor, LY294002, to probe these signaling pathways (Figure
34). We found that rhLF’s increase phosphorylation of Akt was inhibited by both H89
an LY294002 – implicating the dependence of both pathways for holo-rhLF’s
phosphorylation of Akt.

Caspase 3 activity, a marker of cellular apoptosis, was

decreased upon rhLF treatment and then significantly increased upon H-89 inhibitor
treatment – confirming the dependence of rhLF/PKA pathway for cell survival (Figure
35).
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Figure 33. Regulation of Wnt signaling pathway in MC3T3 cells by holo-rhLF.
Wnt Signalling Array was utilized to examine the effect of 100 µg/ml holo-rhLF treatment
(y-axis) relative to untreated control (x-axis). Greater than or equal to 2-fold change
over control was considered to be significantly regulated.
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Figure 34.
30 µM H89 and 10 µM of LY294002 inhibited holo-rhLF-induced
phosphorylation of Akt in MC3T3 cells after 24 hours.
Wnt5a was used as a positive control. Anti-tubulin blot was used as a loading control.

Figure 35. Caspase-3 activity after 24 hours of holo-rhLF treatment with signaling
pathway inhibitors, H89 and LY294002.
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100 ng/ml Wnt-5a and 50 µM Z-FAD-FMK were used as positive controls. Anti-tubulin
blot was used as a loading control.

4.3.3.2 Osteogenic effect of holo-rhLF towards MC3T3 cells

Osteoblast differentiation and mineralization is crucial for a bone regenerative
biomaterial. Alkaline phosphatase activity, an early marker of osteoblast differentiation,
was significantly increased by 100 and 1000 µg/ml holo-rhLF treatment over 14 and 21
days of MC3T3 culture (Figure 26).

Matrix deposition, a later marker of differentiation,

was studied through calcium deposition – which also showed at 14 to 21 days of culture
(Figure 27).

Moreover, 100 and 1000 µg/ml holo-rhLF treatment demonstrated a

statistically significant increase during the late stage of culture, 14 and 21 days over the
control.
4.3.3.2.1 rhLF increases osteogenesis via β catenin signaling pathway.
The potency of LF’s anabolic actions on the skeleton requires better
understanding of its molecular mechanisms.

However, the mechanisms and cell

signaling pathways involved in the transduction of LF’s growth-modulating effects on
osteoblasts have not yet been comprehensively studied. We hypothesize osteogenic
actions induced by rhLF is transduced via β catenin-dependent signaling pathway. HolorhLF treatment has also been demonstrated to increase phosphorylation of Disheveled 2
and Gsk3β (Figure 36). Furthermore, holo-rhLF significantly increased the activation
(de-phosphorylation) of β catenin relative to untreated control (Figure 37).

This

accumulation of β catenin was seen in both the nuclear and cytoplasmic fractions (Figure
38 & 39).
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Figure 36. Increased β catenin signaling cascade by holo-rhLF treatment.
100 µg/ml holo-rhLF increase Disheveled 2, Gsk3β phosphorylation and β catenin
activation in MC3T3 cells after 24 hour treatment.
Anti-tubulin was used as a gel
loading control. 100 ng/ml Wnt 3a and 10 mM LiCl were included as positive controls.

Figure 37. Active βcatenin expression induced in MC3T3 cells by 100 μg/ml holo-rhLF.
Cells were treated with 100 μg/ml holo-rhLF for 0.25 – 24 hours of treatment in culture.
Anti-tubulin blot was used as a loading control.
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Figure 38. Increased accumulation/activation of β catenin in nucleus and cytoplasm of
rhLF treated MC3T3 cells after 24 hours treatment.
10 mM LiCl treatment was used as positive control of activation of β catenin. Anti-actin
blot was used as a loading control. Anti-tubulin was used to test for nuclear/cytoplasmic
contamination.

Figure 39. Increased β catenin in MC3T3 cells treated with 100 µg/ml holo-rhLF.
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10 mM LiCl treatment was used as a positive control for activation of β catenin. Cells
were treated for after 24hours. Propidium iodide was used to stain cell nuclei.

Figure 40. mRNA expression of LRP receptors after holo-rhLF treatment.
β catenin, LRP1, LRP6 mRNA expression was significantly up-regulated by 100 µg/ml
holo-rhLF treatment after 24 hours.

Wnt-mediated signaling transduction pathway array demonstrated a significant
increase in LRP6 and Dvl2 upon 24 hours of rhLF treatment relative to untreated control
(Figure 33). Non-canonical Wnt5a was up-regulated, while canonical Wnts, Wnt2 and 3,
were down-regulated by rhLF treatment. LRP6 up-regulation in MC3T3 cells was also
demonstrated through PCR analysis after 24 hours of 100 µg/ml holo-rhLF treatment
(Figure 40). Similarly, β catenin and LRP1 (a known putative receptor of LF) were also
up-regulated by holo-rhLF treatment. However, LRP5, a co-receptor of the canonical
Wnt signaling pathway was not found to be significantly up-regulated (Figure 40).
In our next study, pharmacological inhibitors, DKK1, and H89 were used to
inhibit the targeted pathways of LRP6 and PKA, respectively (Figure 41).

rhLF’s

increased phosphorylation of LRP6 and activation of β catenin was inhibited by both
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DKK1 and H89. This data suggests the activation of β catenin by rhLF to be dependent
on PKA/LRP6 signalling pathway.

Figure 41. Inhibitor studies (30 µM H89 and 100 ng/ml DKK1) to understand the
osteogenic pathways and β catenin activation.
Inhibitor experiments were performed for 24 hour stimulation of rhLF. Wnt5a and BMP2
were used as positive controls. Anti-tubulin blot was used a loading control.

4.3.4 Discussion
Our studies demonstrated strong protection against serum starvation-induced
apoptosis by holo-rhLF treatment in MC3T3 cells after 3 days (Figure 31) and also
increased phosphorylation of Akt (Figure 32). Akt was used as a marker of cell survival
since a common mechanism by which growth factors promote cell survival is PI3K-
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dependent, Akt phosphorylation. However, the anti-apoptotic properties of bLF have
been demonstrated to increase LRP1-independent, PI3K/Akt phosphorylation (Grey et al.
2006). A previous study has reported that this increased phosphorylation of Akt is not
required by LF to prevent programmed cell death (Grey et al. 2006).

Thus, the

mechanism by which LF prevents cellular apoptosis has not been clearly understood.
PI3K/Akt and PKA signaling transduction pathways are generally strongly
associated anti-apoptotic pathways. Interestingly, previous studies have demonstrated
PI3K/Akt pathway to be activated by Wnt5a treatment (Kawasaki et al. 2007).
Furthermore, non-canonical Wnt5a has been shown to prevent serum starvation-induced
osteoblast apoptosis via Src/Erk and PI3K/Akt-dependent mechanism (Almeida et al.
2005). LF promotes survival of osteoblasts in vitro, but these actions are independent of
Erk/MAPK pathway, which subserves its proliferative actions (Grey et al. 2006).
The Wnt family is comprised of 19 secreted glycoproteins and play essential roles
in embryonic patterning, cell apoptosis, proliferation and differentiation (Logan, Nusse
2004, Miller 2002, Moon et al. 2002, Wodarz, Nusse 1998). In our studies, we utilized a
Wnt signaling array as a tool to elucidate the regulation of Wnts induced by holo-rhLF
treatment in MC3T3 cells (Figure 33). This array was especially selected since the Wnt
family of secreted growth factors are known to regulate developmental processes,
including cell survival (Almeida et al. 2005). The only Wnt molecule that was found to
be up-regulated upon holo-rhLF treatment in MC3T3 cells was Wnt5a. A signaling
pathway reported to be mediated by Wnt5a’s anti-apoptotic effects is the PKA/CREB
(Torii et al. 2008). The use of H89 pharmacological inhibitor allowed for confirmation of
holo-rhLF’s regulation of PKA (Figure 34). We checked CREB phosphorylation, the
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downstream signaling molecule of PKA, to confirm inhibition of PKA by H89 inhibitor.
We included Akt inhibitor, LY294002, in our studies to confirm the previously published
results by Grey et al. that reported that LF’s anti-apoptotic properties are not dependent
on Akt phosphorylation (Grey et al. 2006). Wnt5a was used as a positive control for Akt
phosphorylation in MC3T3 cells. Interestingly, Akt inhibitor, LY294002, inhibited both
holo-rhLF and Wnt5a phosphorylation of Akt. This data confirms that Wnt5a treatment
of MC3T3 cells induces Akt phosphorylation – since cells that were co-treated with
Wnt5a and LY294002 inhibitor did not display increased phosphorylation of Akt.
Furthermore, PKA inhibitor, H89, also inhibited both holo-rhLF and Wnt5a
phosphorylation of Akt. These results confirmed that upon Wnt5a treatment in MC3T3
cells, PKA activation signals downstream to phosphorylate Akt. Similarly, upon holorhLF treatment, PKA signals downstream to phosphorylate Akt. In our next experiment,
we used caspase 3 activity as an indicator for cellular apoptosis upon inhibition with
LY294002 and H89 and stimulation with Wnt5a and holo-rhLF (Figure 35).

This

informative study demonstrated Wnt5a and holo-rhLF to be potent anti-apoptotic
molecules. Furthermore, with LY294002 inhibition of Akt, a partial rescue of caspase 3
activity was induced by Wnt5a and holo-rhLF treatment.

But with H89 inhibition, no

rescue of caspase activity was induced by Wnt5a and holo-rhLF. This proved that cell
survival mechanism of induced by both holo-rhLF and Wnt5a is dependent on PKA
signaling.
The molecular mechanisms underlying the osteogenic properties of holorhLF has been long in question. Wnt molecules are secreted growth factors are known to
regulate osteogenic pathways. Various combinations of Wnts and Fzds transduce two
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distinct intracellular signaling pathways – “canonical” and “non-canonical” Wnt
pathways.

The canonical Wnt signaling pathway is centered on the regulation of

cytoplasmic β catenin levels.

Whereas, non-canonical Wnt pathway is typically

characterized as β catenin-independent signaling often involving Fzd receptors, but not
LRPs or TCF/LEF factors. Key Wnt members in the canonical pathway, which include
Wnt 1, 3a and 8, transduce their signals and play a crucial role in controlling cell
proliferation and differentiation. Central to the canonical pathway is the regulation of β
catenin activity, which depends on its protein cytoplasmic abundance and nuclear
localization. The activation of the canonical Wnt pathway is initiated with the activation
of Disheveled, which leads to the inhibition of Gsk3β and subsequent stabilization of β
catenin.

Accumulation of β catenin in the cytoplasm prompts its translocation to the

nucleus, where it interacts with members of the TCF/LEF family of transcription factors
and induces the transcription of Wnt target genes. Canonical Wnt signaling controls gene
expression by allowing β catenin to accumulate when Wnts are present and by reducing
nuclear β catenin levels when Wnts are absent (Peifer, Polakis 2000, Chan, Struhl 2002,
Sakanaka, Weiss & Williams 1998). Interestingly, in our studies, we found that rhLF
treatment induced significant accumulation of β catenin but down-regulated canonical
Wnts – Wnt2 and 3. Other canonical Wnts, which include Wnt1 and 8, were not found to
be significantly regulated (< 2-fold change) in MC3T3 cells by holo-rhLF.
Non-canonical Wnt pathways are thought to involve Wnt/Ca2+ (Veeman, Axelrod
& Moon 2003, Kuhl et al. 2000, Ma, Wang 2006, Slusarski, Corces & Moon 1997) or the
Wnt/planar cell polarity (PCP) (Veeman, Axelrod & Moon 2003, Adler, Lee 2001) or
other less well-defined pathways (Logan, Nusse 2004, Miller 2002, Moon et al. 2002,
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Wodarz, Nusse 1998, Veeman, Axelrod & Moon 2003). Wnt5a has been considered to
be a representative non-canonical Wnt in several systems, which include stimulation of
intracellular Ca2+ release and activation of PKC and CaMKII (Kuhl et al. 2000, Sheldahl
et al. 1999). Non-canonical Wnt5a has also been suggested to antagonize canonical Wnt
activity in mammalian cells (Torres et al. 1996, Olson, Gibo 1998, Ishitani et al. 2003).
However, direct genetic evidence for this antagonistic interaction is lacking (Topol et al.
2003). Furthermore, even though Wnt5a signaling has been shown to support normal
bone physiology, the biological significance of non-canonical Wnts in osteogenesis is
essentially unknown. It has been just recently found that Wnt5a is a substantial
constituent in BMP2-mediated osteoblast differentiation (Nemoto et al. 2012).
Osteoblastic differentiation mediated by BMP2 is associated with increased expression
of Wnt5a and Ror2 in MC3T3 cells. After silencing the gene expression of Wnt5a and
Ror2 in MC3T3 cells, there was suppression of BMP2-mediated osteoblastic
differentiation, which suggests that Wnt5a and Ror2 signaling are of substantial
importance for BMP2-mediated osteoblastic differentiation (Nemoto et al. 2012).
Our studies demonstrated that LRP6 and Wnt5a were upregulated upon 24 hours
of rhLF treatment relative to untreated control (Figure 33). Although Wnt5a and LRP6
were not previously thought to interact, recent reports have shown that LRP6 can affect
typical non-canonical Wnt processes. These interactions have been shown to modulate
Wnt5a-regulated processes in both Xenopus and mouse (Tahinci et al. 2007, Bryja et al.
2009). Furthermore, non-canonical Wnt signaling and β catenin signaling play a role in
mechanically induced osteogenic cell fate (Arnsdorf, Tummala & Jacobs 2009). Wnt5a
treatment has also been shown to increase integrin expression.
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Wnt5a enhances

osteogenesis through a positive feedback mechanism with integrins through BMP2
signaling (Olivares-Navarrete et al. 2011). In this study, scientists demonstrated the
treatment of HMSCs with Wnt5a increases integrin expression and osteoblast
differentiation.

Furthermore, these results were confirmed using Wnt5a-knockdown

HMSCs – where integrin expression on rough surfaces was decreased.
Biological growth factors, such as parathyroid hormone (PTH), has demonstrated
PKA/LRP6-dependent signalling to increase bone formation in osteoblasts. Teriparatide,
which has the identical sequence of biologically active region of recombinant human
PTH, is FDA-approved as Forteo® for treatment of osteoporosis or high-risk fracture
patients (Sibai, Morgan & Einhorn 2011). Studies have demonstrated the intermittent
administration of PTH stimulates bone formation, but the precise mechanisms
responsible for PTH responses in osteoblasts are incompletely understood. PTH, via the
PTH/PTH-related protein receptor type 1 (PTH1R), couples to the PKA and the canonical
Wnt/β catenin signaling pathway play important roles in bone formation. This study
further utilized H89 inhibitor to confirm the involvement of PKA in PTH signalling,
antagonized PTH stimulation of β catenin levels (Tobimatsu et al. 2006). Studies have
also reported that PKA (Fang et al. 2000) has the ability to stabilize β catenin by
phosphorylating Gsk3β.

Furthermore, Fang et al. showed that PKA-mediated

phosphorylation of serine 9 in Gsk3β activity and up-regulation of β catenin (Fang et al.
2000).
More recently, a study demonstrated that the binding of PTH to its receptor
PTH1R induced association of LRP6 with PTH1R. The formation of the ternary complex
containing PTH, PTH1R, and LRP6 then promoted rapid phosphorylation of LRP6,
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which resulted in the recruitment of axin to LRP6, and stabilization of β catenin (Wan et
al. 2008). This study demonstrated that activation of PKA is essential for PTH-induced β
catenin stabilization.

In vivo studies confirmed PTH treatment increases LRP6

phosphorylation and β catenin accumulation in osteoblasts with a concurrent increase in
bone formation. These studies correspond with our findings of LF-induced, PKA/LRP6dependent β catenin stabilization.
With the acknowledgment that osteoblast survival influences bone formation and
skeletal integrity (Manolagas 2000, Weinstein et al. 1998), great likeliness is LF’s antiapoptotic activity plays a role in its ability to stimulate bone formation in vivo (Grey et al.
2006, Cornish et al. 2004). In our studies, we found LF’s ability to activate β catenin and
inhibit serum starvation-induced apoptosis to be both dependent on PKA signaling
transduction pathway (Figure 42). However, the receptor through which LF is activating
PKA pathway is still unknown.
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Figure 42. Schematic of signaling pathways induced by holo-rhLF in MC3T3 cells.

4.3.5 Conclusions
The bioactivity of holo-rhLF was investigated in our in vitro cell culture model.
Holo-rhLF treatment decreased cellular apoptosis in response to serum starvation.
Furthermore, this bioactive protein up-regulated osteogenic markers, including collagen 1
and OCN, in MC3T3 cells. Our results demonstrated the novel discovery that holorhLF’s anti-apoptotic actions and β catenin activation are dependent on PKA signaling
cascade.
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5 Preparation and characterization of injectable holorhLF and gelatin gels
5.1 Development and characterization of bioactive holo-rhLF
injectable gel via enzymatic crosslinking
5.1.1 Introduction
Cell-based therapy has emerged as a promising strategy to repair and/regenerate
lost, damaged or degenerative tissue using the principles of tissue engineering and
regenerative medicine. Pluripotent and multi-potent cells along with tissue-specific cells
are being investigated to develop novel cell based regenerative therapies. The therapeutic
efficacy of local cell based strategies depends on several factors, including the ability to
retain implanted cells at the defect site and present the cells in a three-dimensional
manner without adversely affecting its performance (Zhao et al. 2011). Hydrogels are
promising candidates due to their unique tissue-mimetic properties and their ability to
allow gas and nutrient diffusion throughout the matrix, which is crucial for maintaining
the viability of the encapsulated cells (Nicodemus, Bryant 2008, Annabi et al. 2010).
Eventhough both performed and injectable hydrogels have been considered for
biomedical applications, injectable gels are preferred as cell delivery vehicles – as
discussed previously in Section 2.1.2.2.1.

Injectable scaffolds undergo mild and

cytocompatible gelation, allow for homogeneous distribution of cells or molecules at the
injection site, and have the ability to fill irregular defects (Slaughter et al. 2009).
Moreover, they can be implanted by simple injection (Yu et al. 2008). Various polymers
with stimuli sensitive properties and novel cross-linking chemistries are investigated to
develop injectable hydrogels (Hennink, van Nostrum 2002). These include thermosensitive and pH-sensitive polymers, which can undergo sol-gel transition at or near
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physiological conditions (Nair et al. 2007, Jiang et al. 2008), self-assembling peptides
(Kopecek, Yang 2009), photo or thiol-mediated polymerization of acrylated polymers
(Rydholm, Bowman & Anseth 2005) and enzyme-mediated crosslinking of polymers
with appropriate functional groups (Davis et al. 2010). Polymers functionalized with
tyramine, tyrosine or aminophenol side groups can form in situ gels by phenol or aniline
derivative coupling using H2O2 and HRP as the oxidant and enzyme, respectively
(Kurisawa et al. 2005, Kobayashi, Uyama & Kimura 2001, Jin et al. 2007, Lee, Chung &
Kurisawa 2009). This biologically compatible system has several advantages as the
physical properties of the gel may be fine tuned by varying the degree of tyramine
substitution, polymer and enzyme concentration (Jin et al. 2010, Sakai et al. 2009, Hu et
al. 2009, Darr, Calabro 2009).
The objective of this study was to investigate the feasibility of developing
injectable hydrogels from holo- rhLF gel and characterize the gel properties in terms of
its gelation time, mechanical properties, water uptake and morphology.

An

understanding of the physical properties of gels is crucial for determining the range of
their biomedical applications. Since LF-based biomaterials have been recently developed,
the understanding of the structure-property relationships in this class of materials is
limited. Such understanding would provide molecular design principles to tailor material
properties, allowing the materials to be optimized for clinical applications or tuned
systematically to address fundamental biological questions. Depending on various
parameters, such as the gelation mechanism and polymer concentration, the gels can
exhibit different mechanical properties. We hypothesize that varying concentrations of
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the gel precursors, HRP, modified rhLF and H2O2, will directly affect the gelation rate,
mechanical strength and morphology of the rhLF gels.

5.1.2

Methods

5.1.2.1 Synthesis of holo-rhLF tyramine conjugates (modified holo-rhLF)

Modified holo-rhLF was prepared as described in Appendix of Protocols (Section
7.9.2.1.1).
5.1.2.2 Preparation of holo-rhLF gels

Holo-rhLF gels were prepared by the HRP-mediated oxidative coupling of modified
holo-rhLF molecules in the presence of H2O2 as described in the Appendix of Protocols
(Section 7.9.2.1.2.2). Various concentrations of modified holo-rhLF ranging from 10
mg/ml to 50 mg/ml were dissolved in 10 U/ml HRP and gelation was initiated by the
addition of 0.25% aqueous H2O2.
5.1.2.3 Quantification of tyramine modification

Holo-rhLF was modified with varying reaction times (0.5 – 24 hours) and tyramine
concentration was then examined as a function of modification reaction time as described
in Appendix of Protocols (Section 7.9.2.1.1.1). A tyramine standard curve was used to
determine the concentration of a tyramine in the modified holo-rhLF samples.
5.1.2.4 Gelation time

Sol to gel time was determined via vial inversion method. The effect of modified holorhLF (10 – 50 mg/ml), HRP (10 – 50 U/ml) and 0.25% H2O2 (1 - 10 µl) concentration on
gelation time was investigated. 10mg/ml modified holo-rhLF in 100 µl of 10/ml U HRP
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+ 1 µl of 0.25% H2O2 represents the standard gelling conditions.

Variables were

individually varied and tested for effect on gelatin time.
5.1.2.5 Soluble holo-rhLF protein release from holo-rhLF gel

10 mg/ml holo-rhLF gel was incubated in PBS at 37oC. Aliquots were taken from each
sample every 24 hours for 5 consecutive days and phenolic content was measured via UV
spectrophotomer at 275 nm. Details of the protocol were described in Section 7.9.2.3.
5.1.2.6 Percentage water uptake

The percentage of water uptake of the injectable gels was determined as described in
Appendix of Protocols (Section 7.9.2.2.4).

Briefly, 400 µl of holo-rhLF gel were

prepared in 24-well plastic inserts (n=4).
5.1.2.7 Morphology

The morphology of the holo-rhLF gels formed from modified holo-rhLF solutions of
different concentrations (10, 25, 50 mg/ml) was visualized by scanning electron
microscope (JEOL 6335 Field Emission Scanning Electron Microscope) to evaluate the
effect of solution concentrations on gel microstructure – as described in Appendix of
Protocols (Section 7.9.2.2.3). Measurements (n=50) of pore size and pore wall width
were obtained using Image J program.
5.1.2.8 Rheological analysis

A rheometer is an ideal instrument that may be used to measure the gel strength. The
holo-rhLF gels were subjected to rheological measurements to assess the viscoelastic
properties at varying component concentrations at 25ºC and 37ºC. Briefly, the modified
holo-rhLF/HRP and H2O2 mixture were introduced in a parallel plate rheometer (ARES-
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LS, TA instruments). Stress sweeps at a constant frequency of 1 Hz were first performed
to obtain the linear viscoelastic region for collecting subsequent data. Dynamic frequency
sweeps were then performed in the linear viscoelastic region to determine values of the
storage (G’) and loss (G”) modulus to compare the mechanical strength of gels with
different concentrations of holo-rhLF.
5.1.2.9 Biomaterial degradation in vivo

Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) (12-16 weeks) were
used. 10 mg/ml holo-rhLF were injected subcutaneously to form the gels in situ. The
animals were cared for according to the procedures approved by the Animal Care and
Use Committee at the University of Connecticut Health Center, and following the
guidelines established by the U.S. National Institutes of Health. At 4 and 12 weeks, rats
were sacrificed and the tissue surrounding the injection sites were excised using blunt
dissection technique. Samples were fixed in 10% formalin solution (Surgipath, USA)
and embedded in paraffin, sectioned and hematoxylin and eosin (H&E) was performed.
5.1.3 Results
We investigated tyramine concentrations as a function of chemical modification
time. The phenolic content of unmodified holo-rhLF is due to the presence of tyrosine.
After 24 hours of tyramine modification, the phenolic concentration increased from 0.158
µg/ml to 0.181 µg/ml. This increase in phenolic concentration of the modified holo-rhLF
led to decreased gelation time as in the case of bLF gel (Section 3.1.3.1) (Figure 43).
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Figure 43. Inverse effect of tyramine modification time (over 24 hours) on phenolic
content and gelation time of rhLF.
The standard gel precursor concentrations, 10 mg/ml modified rhLF dissolved in 100 µl
of 10 U/ml HRP plus 1 µl of 0.25% H2O2, were used to test gelation time.

Sol-to-gel time of the holo-rhLF gels was determined via vial inversion method
(Figure 44).

The flexibility of fast or slow gelation time is possible through the

manipulation of the concentration of the gel precursors – HRP, modified holo-rhLF and
H2O2 (Figure 45). HRP and holo-rhLF polymer concentration had a direct effect on
gelatin time, whereas, H2O2 concentration did not have this similar trend on gelation
time. Lower amounts of H2O2 (0.5-5 µl of 0.25% H2O2) decreased gelation time of holorhLF gel; whereas, higher amounts of H2O2 (10 µl of 0.25% H2O2) actually increased the
gelation time. Based on the study, the standard precursor concentrations was determined
as follows: modified rhLF (10 mg/ml) dissolved in 100 µl of 10 U/ml HRP and 1 µl of
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0.25% H2O2 in water/PBS mixture– these conditions yielded a gelation time of
approximately 1 minute.

Figure 44. Gelation time of rhLF gel upon addition of dilute H2O2 as determined by the
vial inversion technique.

Figure 45. Effect of gel precursors (modified rhLF, HRP, H2O2) concentration on
gelation time.
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The standard conditions for approximately 1 minute gelation time is 10 mg/ml modified
rhLF dissolved in 100 µl of 10 U/ml HRP plus 1 µl of 0.25% H2O2. To study the effect of
each gel component, one component was varied and the concentrations of other
components were held at the standard conditions.

To test whether a substantial amount of polymer was un-crosslinked, we
measured the amount of protein that was released (un-crosslinked polymer) from the gel
into PBS buffer over 5 days at 37°C (Figure 46). After 24 hours, only 4.2 ng/ml of
protein was released from 10 mg/ml holo-rhLF. By 5 days, a cumulative amount of 10.1
ng/ml of modified holo-rhLF protein was released in the PBS buffer.

The study

demonstrated that enzyme mediated crosslinking of modified rhLF lead to a fully
crosslinked matrix

Figure 46. Soluble holo-rhLF release from crosslinked 10 mg/ml holo-rhLF gel as a
function of time.
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The crosslinked rhLF gel displayed a highly porous microstructure as indicated in
Figure 47 and Figure 48). Changes in holo-rhLF polymer, HRP enzyme and H2O2
oxidant concentrations did not result in a significant change in pore size of the
crosslinked gel (Figure 48). The average pore size of holo-rhLF gels was 8.51 ± 2.97
µm. Figure 45 shows the storage modulus of the gel as a function of rhLF concentration.
An increase rhLF polymer concentration led to corresponding increase in storage
modulus, G’ (Figure 49). rhLF gels with polymer concentrations of 10, 25, 50 mg/ml
resulted in storage moduli of 102.8 ± 8.5, 429.2 ± 31.8, 997.9 ± 204.6 Pa, respectively.
We also investigated the effect of gelation temperature on the storage modulus of the
gels. As shown in Figure 45b, the 50 mg/ml holo-rhLF gels formed at temperatures of
25°C and 37°C showed storage moduli of 997.9 ± 204.6 Pa and 899.8 ± 93.4 Pa,
respectively, indicating that temperature of gelation does not have any effect on gel
mechanical properties.

Figure 47. Morphology of 10 mg/ml holo-rhLF gel.
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Figure 48. Morphology of holo-rhLF gel at various gel precursor concentrations

Figure 49. A) Effect of holo-rhLF polymer concentration on hydrogel mechanical
strength as a function of storage moduli, G’. B) Effect of temperature (25°C vs. 37°C) on
storage moduli, G’, of 50 mg/ml holo-rhLF gel.
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Data is expressed in Pascal (Pa). * indicates p<0.05; # indicates p>0.05

Another physical property investigated was the extent of water uptaken by the
gels. Figure 50 shows the extent of water uptake of gels made from different polymer
concentration.

Although there was a trend towards increasing water uptake as the

polymer concentration increased, there was no statistically significant differences
between the weights of the gels at 0 day and after 8 days of incubation in buffer (Figure
50-52).

Similar trends were observed with gels prepared at different HRP and H2O2

concentration (Figure 51 &52). No significant increase in water uptake was observed
with any of the gels as a function of incubation time in PBS.

Figure 50. Effect of holo-rhLF concentration on holo-rhLF gel water uptake over 8 days.
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Figure 51. Effect of HRP concentration on holo-rhLF gel water uptake over 8 days.

Figure 52. Effect of H2O2 concentration on holo-rhLF gel water uptake over 8 days.
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Figure 53 shows the H&E-stained subcutaneous tissue surrounding the gel (10
mg/ml holo-rhLF gel) implantation 4 and 12 weeks past implantation. At 4 weeks, the
presence of injectable gel was evident at the site of injection. Significant cell infiltration
mainly composed of macrophages and lymphocytes was observed within the gel.
Interestingly, no sign of fibrous capsule formation was observed. At 12 weeks post
implantation, the no evidence of gel was observed in the subcutaneous tissue indicating
the complete degradation of the gel at that time point.

Figure 53. In vivo degradation of 10 mg/ml holo-rhLF gel in rat subcutaneous tissue
after 4 and 12 weeks.

Attempts were also made to characterize the ability of rhLF gel to serve as a cell
delivery vehicle.

Cell delivery vehicle should be able to encapsulate cells under

physiological condition, support cell adhesion, spreading and proliferation. Figure 54
shows the Live/Dead staining of MC3T3 cells encapsulated in holo-rhLF gels. Three
different rhLF gel concentration was studied to understand the effect of polymer
concentration on cell behavior. As shown in the figure, irrespective of the polymer
concentration, rhLF gels were able to maintain MC3T3 cell viability. However, the
extent of cell spreading and proliferation seems to be negatively affected by increase in
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polymer concentration.

Among the samples studied, 10 mg/ml holo-rhLF gel allowed

for the most extensive cell spreading after 14 days of encapsulation.

Figure 54. Cellular spreading in 10, 25 and 50 mg/ml holo-rhLF gel over 14 days of
encapsulation using live/dead assay.

5.1.4 Discussion
In situ formation of injectable biomaterials allows for the biomaterial to fill
irregular 3D shapes of clinically relevant defects. The synthesis of our in situ—forming,
biodegradable holo-rhLF crosslinked gel utilizes modified rhLF. Standard carbodiimide
mediated coupling of amino groups of tyramine with the carboxyl groups of holo-rhLF
was used to develop the modified rhLF (Sakai et al. 2009, Amini, Nair 2012b). Although
holo-rhLF contains phenolic amino acids, such as tyrosine, the phenolic content holorhLF is much lower than what is needed to develop an effectively crosslinked matrix via
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the enzyme-catalyzed coupling. The reaction of holo-rhLF with tyramine could increase
the extent of polymer cross-linking by increasing the number of phenolic groups (Figure
11, Figure 12). Since there is significant species homology between bLF and hLF (van
Berkel et al. 2002) (Figure 1), the substitution process of hLF similar to that used for
developing bLF (section 3.1.3.1).

Holo-rhLF gels were obtained by enzymatic

crosslinking of the modified holo-rhLF in the presence of HRP, as the catalyst, and H2O2,
as the oxidant (Figure 13). Enzymatic crosslinking driven by HRP and H2O2 allows for
a mild, cell-friendly gelation process. The advantages of HRP-mediated crosslinking
include its ability to take place at physiological pH and temperature. Moreover, the
gelation time can be modulated to a great extent by varying the reagent concentrations,
making this a potential route to form injectable cell and protein delivery vehicles (Sakai
et al. 2009, Hu et al. 2009, Amini, Nair 2012b).
Gelation time of HRP-mediated enzymatic crosslinking of holo-rhLF yields a
protein-based hydrogel that may be controlled by the concentration of the reactants.
Although increased concentration of modified holo-rhLF (polymer) and HRP (catalyst)
led to decreased gelation time of holo-rhLF gel – this effect was not seen with the
increase of H2O2 (oxidant).

It has been reported that HRP can be oxidized to an

inactivated form upon exposure to an excess amount of H2O2 (Arnao et al. 1990, Baynton
et al. 1994). Moreover, the use of low amounts of H2O2 is advantageous, since H2O2 may
give cytotoxicity problems.

Fast gelation time is preferred especially for in situ—

forming gels, since slow gelation in vivo may result in diffusion of gel precursors or
bioactive molecules to the surrounding areas or failure of gel formation. The optimal
gelation time was determined to be in the range of 1 minute.
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Storage moduli of biomaterials has been shown to have an influence on several

cellular behaviors, including cell adhesion, spreading, proliferation, morphology and
differentiation of stem cells (Lo et al. 2000, Pelham, Wang 1997, Cukierman et al. 2001).
Previous data reports a wide range in substrate stiffness with a soft gel (1 kPa), a stiff gel
(8 kPa), and a rigid substrate (66 kPa) (Engler et al. 2004). The degree of stiffness in
physiological human tissue varies dramatically between tissues: brain is about 0.1-1 kPa;
striated skeletal muscle is approximately approximately 8-17 kPa and pre-calciﬁed bone
is 25-40 kPa (Engler et al. 2006, Tse, Engler 2010). Human bone exhibits unique
mechanical properties – both elastic and semi-brittle behavior. There are two types of
bone, compact or cortical, and cancellous or trabecular (spongy) bone. Compact and
trabecular bone have mechanical strengths in the range of 131 - 224 MPa and 5 – 10
MPa, respectively (Yaszemski et al. 1996, Athanasiou et al. 2000, Currey 1998, Currey
1970, Currey 1999). However, the storage modulus of holo-rhLF gels (10-50 mg/ml) was
in the range of 100-1000 Pa. The low storage modulus of holo-rhLF makes it an
excellent cell delivery vehicle for non-load bearing applications and for load bearing
applications with external support.
Another very important parameter that needs to be evaluated while developing an
injectable biomaterial is the extent of water uptake of the formed gel once exposed to
aqueous environment. Significant water uptake of the gel can adversely affect the
performance of the injectable gel. As in the case of mechanical properties, several
parameters, such as polymer concentration and cross-linking density, can directly affect
the extent of water uptake. In our gel studies, holo-rhLF gels demonstrated water uptake
percentage of about 10% of original gel weight after 8 days of PBS buffer incubation at
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37°C physiological temperature.

This percentage of water uptake did not seem to

adversely affect the performance of the encapsulated cells.
Biomaterial morphology is an important characteristic to investigate when
designing a cell delivery vehicle. Hydrogels are porous biomaterials that allow for in
situ-delivery of encapsulated cells. Porous interconnectivity also allows for uniform cell
seeding and necessary diffusion of nutrients and waste. In our studies, all concentrations
of holo-rhLF gel that were investigated displayed a porous interconnected structure.
Osteoblasts require a delivery vehicle that not only maintains cell viability but
also supports cell attachment and spreading for three-dimensional cellular organization.
The highly porous structure of holo-rhLF gel allowed for cellular spreading, which was
inversely regulated with polymer concentration of the gel (Figure 54). Decreased cell
spreading at high polymer concentration gels may be attributed to the decreased cell
proliferation at higher concentrations (Huang et al. 2008). Porous biomaterial hydrogels
are favorable since they support vascular ingrowth for oxygen transport. Pore size of
holo-rhLF gel (10-50 mg/ml) was averaged at approximately 5-10 µm. However, the
average size of an osteoblast is approximately 20-25 µm (Puckett, Pareta & Webster
2008). Porosity and interconnected pores allow for the diffusion of nutrients and gases
for enhancing cell viability. In our cell encapsulation studies, holo-rhLF gel allowed for
high percentage of live to dead cell ratio. However, a decrease in cell spreading and
density was seen in the MC3T3 cells encapsulated in 50 mg/ml holo-rhLF gel (relative to
10 and 25 mg/ml holo-rhLF gel). As described below, these results may be explained
through a variety of different reasonings – decrease cell spreading and density due to 1)
increased mechanical strength decreasing cell proliferation and spreading or 2) high
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concentration holo-rhLF adversely affecting the encapsulated cell proliferation and
spreading.
Hydrogels, which may act as the ECM that surrounds encapsulated cells, are
known to contain biochemical information that may regulate cell functions, including
adhesion, spreading, migration, proliferation, survival, and differentiation (Khatiwala,
Peyton & Putnam 2006). A recent study reported an injectable HRP/H2O2 hydrogel
scaffold system with tunable mechanical properties for controlling the proliferation rate
and differentiation of human mesenchymal stem cells (Wang et al. 2010). The scientists
found that the hydrogel stiffness inversely affected the cell proliferation rates – an
increase in stiffness led to a decrease in cellular proliferation.
Another possible reason for the decreased cell spreading in holo-rhLF gels of
higher LF concentrations is that LF being a bioactive protein can adversely affect cellular
behavior. In our studies, we only investigated the proliferative effect of 1000 µg/ml holorhLF, which showed an increase in cell proliferation (Figure 19). However, Huang et al.
tested concentrations up to 50,000 µg/ml holo-rhLF in HT29 intestinal cells. In these
studies, holo-rhLF increase thymidine incorporation in HT29 cells at concentrations of
10-1,000 µg/ml, however 10,000 and 50,000 µg/ml holo-rhLF treatment led to a
significant decrease in thymidine incorporation (Huang et al. 2008). The decrease in
cellular performance at high concentrations of holo-rhLF treatments in Huang’s study
may support our findings of decreased cell number and spreading at 50 mg/ml holo-rhLF
gel.
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5.1.5 Conclusions
The study demonstrated the feasibility of developing injectable rhLF gels by the
enzymatic coupling of tyramine-modified rhLF.

The gelation time of the gels

significantly depended on the reagent concentrations. Through the optimization of the
concentrations of the gel components, a clinically viable gelation time of ~1 minute was
developed. However, the gel physical properties, such as morphology and water uptake,
was not significantly affected by the change in reagent concentrations. Increase in rhLF
concentration significantly increased the storage modulus of the gels. Based on the
storage modulus, the gels were characterized as soft gels. rhLF-encapsulated MC3T3
cells in various concentrations of rhLF gel maintained high viability, demonstrating the
cyto-compatibility of the gels. However, rhLF gels of higher concentration tended to
decrease cell spreading and density.

Since even 50 mg/ml rhLF showed a porous

structure and storage modulus, the decreased cellular activity in rhLF gels with higher LF
concentrations is presumed to be due to the bioactivity of the gels.
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5.2 Enzymatically crosslinked injectable gelatin gel as an
osteoblast delivery vehicle
5.2.1 Introduction
The study discussed in section 5.1 demonstrated the feasibility of developing
rhLF gel and the cytocompatibility of the gel as a potential cell delivery vehicle. Based
on the demonstrated bioactivities of rhLF (sections 4.1- 4.3), we hypothesize that rhLF
gels will retain the unique bioactivities of soluble rhLF protein and could serve as a
bioactive cell delivery vehicle with anti-apoptotic and osteogenic properties.

To

demonstrate the bioactivity of rhLF gel towards encapsulated gel, a control gel system
needs to developed. The objective of the proposed study is to test if injectable gelatin gel
may serve as a three dimensional control gel matrix to evaluate the bioactivity of rhLF
gels.
Injectable hydrogels based on proteins are highly preferred as they can favorably
interact with the encapsulated cells via specific peptide epitopes and also undergo cellmediated enzymatic degradation (Nguyen, Lee 2010). Therefore, ECM-derived proteins,
such as collagen, gelatin, laminin and elastins are potential candidates to develop cell
delivery vehicles (Stenzel, Miyata & Rubin 1974). Compared to collagen, gelatin is more
economical and possesses more integrin binding domains for cell attachment due to its
less ordered structure.

Furthermore, gelatin is a denatured protein, making it less

immune-reactive than collagen (Dreesmann, Ahlers & Schlosshauer 2007, Liu et al.
2009, Spotnitz, Burks 2008). The good cell-adhesivity of gelatin is particularly useful in
developing cell delivery vehicles for anchorage dependent cells such as osteoblasts,
epithelial cells and smooth muscle cells (Kwon, Peng 2002).
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Several preformed and injectable gelatin formulations have been developed
(Young et al. 2005, Singh et al. 2010, Lai, Li 2010, Kuwahara et al. 2010, Chen et al.
2003). These include chemical cross-linking using the carboxyl or amino groups of
gelatin with polymers having appropriate reactive groups (Balakrishnan, Jayakrishnan
2005), and photo cross-linking of acrylated gelatin either alone or in the presence of other
biocompatible polymers. Yamamoto et al. used glutaraldehyde to crosslink acidic and
basic gelatins with iso-electric points of 5.0 and 9.0, respectively (Yamamoto, Takahashi
& Tabata 2006). The study demonstrated the ability of chemically crosslinked acidic
gelatin gels to retain growth factors and function as a sustained delivery vehicle. The
spatial and temporal control of the photo-curing process provides unique advantages for
developing controllable in vitro systems. However, the need to use photo initiators and
UV light has raised concerns with respect to in vivo applicability (Fukaya et al. 2009,
Okino et al. 2002, Hoshikawa et al. 2006, Terao et al. 2003). As discussed before,
enzyme-catalyzed reactions have recently gained interest due to the ability to use mild,
cell-friendly natural processes to develop injectable gels.

Several enzymatically-

catalyzed reactions were developed to form gelatin gels. Transglutaminase cross-linked
gelatin was developed as a cell delivery vehicle in which covalent N-ε(γ-glutamyl) lysine
amide bonds are formed between the gelatin molecules in the presence of the enzyme
(Yung, Bentley & Barbari 2010) (Figure 55).

Cross-linking phenol derivatives of

polymers in the presence of H2O2 and HRP is another potential route to develop
injectable gels (Lee, Chung & Kurisawa 2009, Sakai et al. 2009). Injectable gelatin gels
using the HRP-H2O2 oxidative coupling reaction has been reported (Sakai et al. 2009, Hu
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et al. 2009, Park et al. 2011). Recently, gelatin–poly(ethylene glycol)–tyramine (GPT)
injectable hydrogel was developed to support tissue regeneration (Sakai et al. 2009).

Figure 55.
Schematic representation of the enzymatic crosslinking of gelatinpoly(ethylene glycol) tyramine (GPT) conjugates and the image of the in situ GPT
hydrogel formation using a dual syringe.
The dual syringe contained: (a) 3wt % GPT dissolved in 0.0025 mg/ml HRP in 0.01 M
HRP and (b) 3wt% GPT dissolved in 0.0125wt % H2O2 in 0.01 M PBS. Image adapted
from (Park et al. 2011).

Several parameters such as chemical and biological properties of the polymer,
pore size, pore structure, stiffness and permeability of the scaffold are known to affect
cell performance (Kim et al. 2010). In order to develop the appropriate control for rhLF
gels, tyramine conjugated gelatin was used for HRP mediated crosslinking similar to
rhLF gels. We evaluated the effects of gelatin concentration on the microstructure of the
injectable gel and the long-term viability and spreading of encapsulated MC3T3 cells.
The bioactivity of the modified and unmodified gelatin towards MC3T3 was evaluated by
whether the protein can induce the phosphorylation of ERK and the expression of active
β catenin and Runx2. Immunocytochemistry was used to investigate if the gel matrix can
modulate the osteogenic functions of the encapsulated cells.
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5.2.2 Methods
5.2.2.1 Preparation of gelatin gel

5.2.2.1.1 Synthesis of gelatin tyramine conjugates (modified gelatin)
Modified gelatins were prepared as described in Appendix of Protocols (Section
7.9.2.1.1). The extent of tyramine-substitution in modified gelatin was followed by UVspectrophotometer at 275 nm and the concentration of the phenolic group in the solutions
was determined from a standard curve.
5.2.2.1.2 Preparation of gelatin gels
Different concentrations of water-soluble modified gelatin (10, 25 and 50 mg/ml) were
dissolved in HRP solution (10 U/ml) in distilled H2O and gelation was initiated by the
addition of 0.25% H2O2.
5.2.2.2 Morphology

The morphology of the gelatin gels formed from modified gelatin solutions of different
concentrations (10, 25, 50 mg/ml) was visualized by SEM as described in Appendix of
Protocols (Section 7.9.2.2.3).
5.2.2.3 Rheological analysis of gelatin gels

The gelatin gels were subjected to rheological measurements to assess the viscoelastic
properties at varying component concentrations at 25ºC as described in Appendix of
Protocols (Section 7.9.2.2.2).

50 µl of modified gelatin/HRP solution was first

introduced in a parallel plate rheometer. Next, 50 µl of modified gelatin/H2O2 solution
was added during pre-shear step of 50 rad/second for 10 seconds. Dynamic frequency
sweeps were then performed in the linear viscoelastic region to determine values of the
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storage (G’) and loss (G”) modulus to compare the mechanical strength of gels with
different concentrations of gelatin. Rheology testing conditions were as follows: angular
frequency of 1 rad/second; 3% strain; 1000 µm gap width; 100 µl volume load.
5.2.2.4 Cell encapsulation in gelatin gel

The water-soluble modified gelatin (10, 25 and 50 mg/ml) was dissolved in 10U/ml
HRP in distilled water. Cell suspension on media (500,000 cells) were added and resuspended in 100 µl each of the modified gelatin/HRP solutions followed by the addition
of aqueous H2O2 (1 µl of 0.25% solution). The encapsulated cells were then cultured in
basal MEMα medium at 37ºC.
The water/PBS soluble modified gelatin (10, 25 and 50 mg/ml) was dissolved in
10U/ml HRP in 50:50 water/PBS mixture. Cell pellet (500,000 cells) was added and resuspended in 100 µl each of the modified gelatin/HRP solutions followed by the addition
of aqueous H2O2 (1 µl of 0.25% solution). The encapsulated cells were then cultured in
basal MEMα medium at 37ºC.
5.2.2.4.1 Cell viability and spreading
500,000 cells/ml MC3T3 cell encapsulated in the two different types of gelatin gels were
incubated at 37°C in basal medium for a time course of 21 days and then imaged every 7
days using live/dead viability assay as described in Appendix of Protocols (Section
7.5.2.1).
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5.2.2.5 Bioactivity of gelatin and modified gelatin

5.2.2.5.1.1 Western blot analysis
MC3T3 cells were plated on 10 cm2plates (250,000 cells/plate) and grown to 90%
confluence in basal media. Cells were serum starved for 6 hours and treated with gelatin
or modified gelatin (dissolved in PBS) or with PBS (control) for 15 minutes in serum-free
media. For long time-course study, cells were plated at low density (200,000 cells/well)
on 6-well plate and grown to 90% confluence in basal media and then treated with gelatin
or modified gelatin or with PBS (control) for 21 days in mineralization media. Media
and treatments were changed every 3 days.

Total protein was lysed from cells and

western blot analysis was performed as described in Appendix of Protocols (Section
7.2.2.3).	
  
5.2.2.5.1.2 Alkaline phosphatase activity
For alkaline phosphatase studies, MC3T3 cells were plated on 24-well plates at a low
density (10,000 cells/well) and grown for 1 day in basal media and then treated with
gelatin or modified gelatin or with PBS (control) for 14 days in mineralization media
(n=4) and samples were analyzed for alkaline phosphatase activity as described in
Appendix of Protocols (Section 7.7.2.1).
5.2.2.5.1.3 Mineralization assay
For mineralization studies, MC3T3 cells were plated on 24-well plates at a low density
(10,000 cells/well) and grown for 1 day in basal media and then treated with gelatin or
modified gelatin or with PBS (control) for 14 days in mineralization media (n=4) and
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samples were analyzed for calcium deposition using Alizarin Red staining method as
described in Appendix of Protocols (Section 7.7.2.2).
5.2.2.6 Bioactivity of gelatin gels

MC3T3 cells (500,000 cells/ml) were encapsulated in 10 mg/ml gelatin gel dissolved in
distilled water and were maintained in basal media for 2 days and the
immunocytochemistry was used to detect the regulation of Erk phosphorylation and
active β catenin.

Soluble factors, 30 ng/ml insulin and 10 mM LiCl, were added

separately to the medium of gelatin gel–encapsulated cell samples for 2 hours following 2
days incubation period. Immunocytochemistry was performed as described in Appendix
of Protocols (Section 7.2.2.5).
5.2.2.7 Statistical data analysis

All data are presented as mean ± SD (standard deviation) for n = 3, unless stated
otherwise. Statistical analyses were performed by t-test, and p < 0.05 was considered
statistically significant.
5.2.3 Results
5.2.3.1.1 Synthesis of gelatin-tyramine conjugates
Figure 56 shows the phenolic content of tyramine modified and unmodified water
soluble gelatin as a function of reaction time under the described reaction conditions. The
phenolic content of the modified gelatin was approximately four times higher than of the
unmodified gelatin. Moreover, under the reaction conditions used, no significant increase
in phenolic group was found after 25 minutes of reaction at room temperature.
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Figure 56. Extent of phenolic group substitution in gelatin as a function of reaction time
under the conditions used in the study.
(n) Gelatin treated with tyramine in the presence of EDC; (☐) Gelatin treated with EDC in
the absence of tyramine.

5.2.3.1.2 Preparation of gelatin gels
The concentrations of the reagents (modified gelatin, H2O2 and HRP) play an
important role in determining the gelation time as well as the properties of the resulting
gel.

Irrespective of the concentration of the water-soluble modified gelatin (10-50

mg/ml), H2O2 (0.75-2 µL of 0.25% w/v stock concentration) and HRP (5-10 U/mL) all
the solutions gelled in less than 10 seconds. Unlike rhLF gels discussed in section 5.1.3,
the reagent concentrations did not significantly affect the gelation time.
5.2.3.1.3 Morphology
The morphology of flash frozen and lyophilized gels prepared from modified gelatin
solutions of different concentrations are shown in Figure 57. The gels formed from 10

	
  

199

mg/ml and 25 mg/ml gelatin solutions presented a macro-porous structure with
interconnected pores.

Even though both 10 and 25 mg/ml presented a porous

microstructure, the average pore width and pore wall thickness was significantly higher
in the case of gels formed from 25 mg/ml solution compared to that formed from
10mg/mL (Figure 58). On the other hand, the highest concentration solution (50 mg/ml)
presented a dense, less-porous structure. In order to investigate the effect of H2O2
concentration on hydrogel morphology, gels were made from modified gelatin solutions
of 50 mg/ml in the presence of different concentrations of H2O2. Irrespective of H2O2
concentrations, the gels showed a dense less-porous structure at 50 mg/ml concentration.
It is presumed that at 50 mg/ml concentration, the pore wall thickness increased to the
extent that the matrix collapsed to form a structure with limited porosity.

Figure 57. SEM images of 10-50 mg/ml gelatin gels.
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Figure 58. Average pore width and pore wall thickness of gelatin gels.
Gels were formed from solutions of 10mg/ml and 25mg/ml gelatin concentrations. A)
Average pore width; B) Average pore wall thickness.
* indicates p<0.05 statistical
significance.

5.2.3.1.4 Rheological Analysis
Storage modulus of gelatin gels (10, 25 and 50 mg/ml) were measured – 220.88 ± 25.70
Pa, 1579.21 ± 272.49 Pa and 5568.74 ± 543.48 Pa, respectively.

Figure 59. Rheological testing of 10, 25 and 50 mg/ml gelatin gel.
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5.2.3.2 Cell-Gelatin Interactions

5.2.3.2.1 Cell viability and spreading
In the present study, the effect of modified gelatin concentration on osteoblast
viability and spreading in the gels as a function of encapsulation time was investigated.
The viability and morphology of MC3T3 pre-osteoblast cells encapsulated in two
different gelatin gels of different polymer concentrations and times in basal media are
shown in Figure 60 A&B. The viable cells are indicated by green calcein fluorescent
labeling and the dead cells by red ethidium homodimer-1 fluorescent labeling. Cell
suspension encapsulated in water soluble gelatin gels (Figure 60A) exhibited high
viability while the extent of cell spreading was dependent on the gelatin concentration.
The MC3T3 cells encapsulated in 10 mg/ml gels with the lowest storage modulus
displayed the greatest spreading and number of cells throughout the culture. The gels
from 25 mg/ml gelatin also showed good cell spreading with extended filopodia rich
morphology while cells encapsulated in 50 mg/ml gelatin had a round morphology with
limited spreading throughout the 21 day culture. The increase in storage moduli of the
gels prepared at 10, 25, 50 mg/ml gelatin concentrations was presumed to be one of the
reasons for the limited spreading and lack of network formation by the cells in 50 mg/ml
modified gelatin compared to the 10 and 25 mg/ml compositions.

However, cells

encapsulated in the 50 mg/ml gels started showing some cell spreading by day 21 (arrow,
Figure 60A).
However, since the control gelatin gels were prepared to evalaute the biological
activity of LF gel, we developed a modified protocol to develop gelatin gel that can be
formed from a water/PBS mixture (similar to the LF gel protocol) and cell pellet was
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encapsulated rather than cell suspension.

Cell pellet were used in lactoferrin gel

encapsulation studies to remove the contribution of FBS in the media which may exhibit
some biological activity. The cell pellets encapsulated in gelatin gels prepared from
water/PBS mixture also showed good cell viability, however, showed a lack of cell
spreading (Figure 60B). Irrespective of the polymer concentration, none of the gels
showed the potential of cell spreading over the 21 days culture period studied. Compared
to the gelatin gel, cell pellet encapsulated in 10mg/mL of lactoferrin gel under similar
culture condition showed good cell spreading within 24 hours.

A.
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B.

Figure 60. Photomicrographs of MC3T3 cells encapsulated in gelatin gels of different
concentrations (10-50 mg/ml) as a function of time. (A) Gels prepared by dissolving
gelatin in H2O. (B) Gels prepared by dissolving gelatin in 1:1 H2O:PBS solution.
Images taken at 20x magnification.
Cells were stained by a Live/Dead stain: green fluorescence indicating live cells and red
fluorescence indicating dead cells.

5.2.3.2.2 Bioactivity of gelatin and modified gelatin
We probed different functional markers of osteoblasts, such as phosphorylation of
Erk, activation of β catenin and phosphorylation of Runx2 after exposing the cells to
media, media containing gelatin or media containing water soluble modified gelatin. The
western blot analysis using specific phospho-Erk and active β catenin antibodies
displayed no differences (Figure 61A) in phosphorylation of Erk or accumulation of
active β-catenin in the cell lysate from cultures exposed to gelatin, modified gelatin or
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control media. The non-osteogenic activity of the modified gelatin was further confirmed
by the expression of Runx2 protein, an osteogenic marker after 21 days in culture in
mineralization media (Figure 61B). No significant up-regulation of Runx2 was observed
in cells exposed to gelatin or modified gelatin compared to cells given mineralization
media alone. These studies clearly demonstrated the lack of inherent osteogenic activity
of modified gelatin.

Figure 61. Bioactivity of gelatin and modified gelatin.
(A) MC3T3 cells were stimulated with 100µg/mL gelatin (+), modified gelatin (+*) or PBS
(-) for 15 min in basal media A) or for 21 days in mineralization media B). Anti-tubulin
blots were used as loading controls.
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Figure 62. Alkaline phosphatase activity of MC3T3 cells treated with gelatin and holorhLF (modified and unmodified).
Alkaline phosphatase assay was performed on samples maintained in mineralization
media for 14 days. Statistical significance (p<0.05) is represented as * relative to
appropriate control.

Figure 63. Calcium deposition of MC3T3 cells treated with gelatin and holo-rhLF
(modified and unmodified).
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Alizarin red assay was performed on samples maintained in mineralization media for 14
days. Statistical significance (p<0.05) is represented as * relative to appropriate control.

5.2.3.2.3 Bioactivity of injectable gelatin gels
We investigated the effect of three-dimensional encapsulation of MC3T3 cells in
10 mg/ml gelatin gel in cellular function by following the collagen I deposition as well as
activating intercellular signaling by following the induction of Erk and β-catenin
activation using immunocytochemistry. Propidium iodide (red) was used to label the cell
nuclei and secondary antibodies were FITC-conjugated (green). Shown in Figure 64
A&B, no positive antibody staining (green) of active β catenin and Erk phosphorylation
was observed in the MC3T3 cells encapsulated in water soluble and water/PBS gelatin
gels. The addition of soluble molecules, 30 ng/mL insulin and 10 mM LiCl, to the media
of the gelatin gel—encapsulated cells, led to the expression of active β catenin and
phospho-Erk, after only a 2 day treatment. These studies confirmed that although the
enzymatically cross-linked gelatin gel at 10mg/ml supported the adhesion, spreading,
proliferation and collagen deposition of MC3T3 cells, the three dimensional organization
of the osteoblast cells in the gel did not induce the phosphorylation of Erk or activation of
β catenin indicating a lack of inherent osteogenic activity. However, the increased
expression of active β catenin and phospho-Erk by the cells cultured in the presence of
bioactive molecules indicated that the porous structure of this matrix allowed diffusion of
soluble bioactive molecules to activate intercellular signaling pathways in the
encapsulated cells.

A.
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B.

Figure 64. Phosphorylation of Erk in MC3T3 cells encapsulated in 10 mg/ml gelatin gel.
MC3T3 cells were encapsulated in 10 mg/ml gelatin gel and maintained in basal media 2
days. Activation of β catenin and phosphorylation of ERK were probed using
immunocytochemistry. FITC-labeled secondary antibodies (green) and propidium iodide
(red) were used to detect positive antibody staining and nuclei, respectively. Gelatin gel–
encapsulated MC3T3 cells did not express activation of βcatenin or phospho-Erk after 2
days of encapsulation (absence of green fluorescence). Positive expression of
activation of β-catenin and phospho-ERK occurred after the addition of 10 mM LiCl or 30
ng/mL insulin, respectively, for 2 hours to the medium following 2 day encapsulation of
MC3T3 cells in gelatin gel.
A) Gels were preared by dissolving gelatin in H2O B) Gels were prepared by dissolving
gelatin in 1:1 H2O:PBS solution Images taken at 20x magnification.
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5.2.4 Discussion
Gelatin possesses several desirable features for tissue engineering applications
such as excellent biocompatibility, biodegradability and low immunogenicity. Standard
carbodiimide mediated coupling of amino groups of tyramine with the carboxyl groups of
gelatin was used to modify gelatin (Sakai et al. 2009). Natural gelatin contains phenolic
amino acids, such as tyrosine, depending on its origin and purity. However, the phenolic
content of natural gelatin has been reported to be much lower than what is needed to
develop an effectively crosslinked matrix via enzyme-catalyzed coupling. The reaction of
gelatin with tyramine or hydroxyphenylpropionic acid enhances polymer cross-linking by
increasing the number of phenolic groups in gelatin (Sakai et al. 2009, Hu et al. 2009).
Several methods such as colorimetric, spectrophotometric and chromatrographic methods
can be used to detect the phenolic content of polymers such as gelatin
Kenchington & Ward 1962).

(Cobbett,

In our studies, we detected phenolic concentration of

gelatin after tyramine concentration via spectrophotometry. Phenolic content of the
modified gelatin increased over 24 hours of reaction time with tyramine.
Pore size and structure of the scaffold has an affect cell performance when cells
are seeded on microporous hydrogels. Betz et al. cultured human mesenchymal stem
cells on a porous hydrogel (100-250 µm pore size) up-regulated BMP2 expression which
favored osteogenic differentiation Betz et al. 2010). The viability and proliferation of
cells is presumed to be favorably influenced by the microporous structure of the scaffold
due to increased nutrient and gaseous permeability (Hwang et al. 2010). The enzymatic
crosslinking of 10 mg/ml gelatin gel led to microporous structures of approximately 30
µm pore size, which is sufficent since the average size of an osteoblast is approximately
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20-25 µm (Puckett, Pareta & Webster 2008). In our cell encapsulation studies, gelatin gel
allowed for high percentage of live to dead cell ratio. However, a decrease in cell
spreading and density was seen in the MC3T3 cells encapsulated in 50 mg/ml gelatin gel
(relative to 10 and 25 mg/ml holo-rhLF gel). These results may be explained through a
variety of different reasons – decrease cell spreading and density due to 1) increased
mechanical strength decreasing cell proliferation and spreading or 2) collapsed pore
structure adversely affecting the encapsulated cell proliferation and spreading. Although
gelatin has cell adhesive domains, several three-dimensional hydrogel matrices developed
from gelatin show poor cell viability and spreading (Hoshikawa et al. 2006, Grinnell et
al. 2003). Other parameters, including storage moduli and pore structure, may also be
playing crucial roles in determining the fate of the encapsulated cells.
Mechanical testing revealed significant storage modulus increases upon increased
polymer concentration. The storage moduli of the gelatin gels were measured to range
from approximately 200 – 5000 Pa for gelatin polymer concentrations of 10-50 mg/ml.
As mentioned previously in section 5.1.4, hydrogel stiffness inversely affected the cell
proliferation rates (Wang et al. 2010). Perhaps the significant storage moduli of 50
mg/ml gelatin gel resulted in a decrease proliferation rate of the encapsulated cells.
Unlike porous 10 mg/ml and 25 mg/ml gelatin gels, SEM analysis of the 50
mg/ml gelatin gel revealed a collapsed gel structure. This collapsed structure may not
present as a conducive environment for cellular spreading and proliferation of the
encapsulated cells. However, cells encapsulated in the 50 mg/ml gels started showing
some cell spreading by day 21 (Figure 60). This may be presumably due to some cell
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mediated degradation of the matrix, as gelatin has the same biodegradable epitopoes as
collagen (Atkinson et al. 1992).
Since the modified lactoferrin solutions were made in water/PBS mixture,
modified gelatins were prepared that are highly soluble in water/PBS mixture. Cell
pellets instead of cell suspension were used for cell encapsulation in LF gels to prevent
the potential biological activity of serum in the media. The cell pellets encapsulated in LF
gels maintained high cell viability. However, the absence of serum completely prevented
cell spreading in gelatin gels. The poor cell spreading observed with higher gelatin
concentrations in the previous study (Figure 60A) as well the present study (Figure 60B)
can therefore be attributed to the inferior properties of aqueous gelatin solution in the
absence of serum. Thus, the lack of cell spreading in gelatin gel presents limitation in
using gelatin gels as proper 3D control systems for LF based gels. Future studies need to
focus on developing appropriate intert control gels that can support cell adhesion similar
to lactoferrin gels to quantitatively evalaute the increase in biological activity of
lactoferrin gels.
An ideal cell delivery vehicle should allow for homogeneous mixing of cells
within the solution before the sol-gel transition and promote favorable cell-matrix
interactions particularly for anchorage dependent cells, such as osteoblasts (Wang,
Varshney & Wang 2010).

Gelatin is derived from natural extracellular matrix and

exhibits a wide range of bioactivity (Alvarez-Perez et al. 2010, Peng et al. 2010).
Previous studies report favorable effects of gelatin on cell adhesion. Furthermore, some
of the recent studies have indicated that an increase in MC3T3 cell proliferation and
differentiation via the activation of the Erk signaling pathway may be induced by gelatin
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or chemically/biologically modified gelatin (Lee et al. 2010, Ge et al. 2007). Recently,
the ability of gelatin nanostructures to induce Erk activation and the expression of cell
adherent molecules, focal adhesion kinase, secreted protein acidic and rich in cysteine
(SPARC) and VEGF in MC3T3 cells was reported (Ge et al. 2007). Similarly, the
efficacy of micro-porous hydrogels in up-regulating osteogenic signal expression when
cells are seeded on the gel was reported (Betz et al. 2010).
Unlike modified LF, our studies did not indicate any increased bioactivity in
MC3T3 cells treated with gelatin, tyramine modified gelatin and gelatin gel.

We

investigated the bioactivity of soluble gelatin and its tyramine-modified form to test
whether tyramine modification affects gelatin’s bioactivity on MC3T3 cells. In our
studies, we probed different functional markers of osteoblasts, including phospho-Erk, β
catenin, Runx2, ALP activity and mineral deposition.

Our analysis displayed no

differences in the regulation of the functional markers from MC3T3 cell cultures exposed
to gelatin, modified gelatin or control media (Figure 61).

Furthermore, holo-rhLF and

tyramine-modified holo-rhLF samples were included in these studies as positive controls.
There was no significant difference in bioactivity induced by holo-rhLF and modified
holo-rhLF. In summary, this study confirmed positive bioactivity of holo-rhLF and inert
bioactivity of gelatin. Moreover, it demonstrated that tyramine modification did not alter
the bioactivity of gelatin or holo-rhLF. In our next study, we investigated the bioactivity
of gelatin gel-encapsulated MC3T3 cells.

No positive expression of our functional

markers (phospho-Erk and β catenin) were expressed in the gelatin gel-encapsulated
MC3T3 cells. These studies also demonstrated that exogeneous bioactive factors such as
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insulin, LiCl and LF may be used to increase bioactivity of inert gels. These results
demonstrate the applicability of gelatin gel as an inert osteoblast cell delivery vehicle.
5.2.5 Conclusions
Gelatin, an ECM-derived protein, is an excellent candidate for developing cell
delivery vehicle due to its biocompatibility and biodegradability. The use of aqueous
gelatin solutions in developing enzymatic gels presented limitations in terms of cell
spreading. The absence of inherent osteogenic activity of the modified gelatin and
gelatin gel indicated the need to include exogenous bioactive molecules to modulate the
functions of the encapsulated cells.
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5.3 Evaluation of the bioactivity of holo-rhLF gel as a novel
cell delivery vehicle
5.3.1 Introduction
As a highly specialized and complex organ, the skeleton is composed of extensive
vasculature, bone cells and mineralized organic matrix.

Bone possesses the intrinsic

capacity for regeneration and remodeling – a constant formation and resorption of 5-15%
total bone mass per year under normal physiological conditions (Davies, Hosseini 2000).
Growth factors, cytokines, hormones, bone matrix proteins and mechanical forces act as
modulators of essential homeostatic cellular functions, including cell survival,
proliferation and differentiation, through the induction of specific cell signaling pathway
cascades. The lengthy list of essential signaling molecules during bone regeneration
include IL1, IL6, TNFα, TGFβ, PDGF, BMP, FGF, IGF, MMP, VEGF and angiopoietin
(Fernandez-Tresguerres-Hernandez-Gil et al. 2006, Devescovi et al. 2008).
The temporal release of signaling molecules and activation of signaling pathways
are responsible for the coordinated biological processes involved in bone regeneration –
which include cell mitogenesis, survival and differentiation. Precise regulation of Wnt/
β-catenin signaling plays a disparate role in the facilitation of pluripotent mesenchymal
stem cell differentiation into osteoblasts and enhancing bone formation (Silkstone, Hong
& Alman 2008, Chen et al. 2007). Erk, a member of the MAPK family, is activated by
growth factors, such as FGF2, to increase osteoblast proliferation (Chaudhary, Avioli
2000, Lai, Cheng 2002, Xiao et al. 2000). Multiple signaling pathways, including ERK,
have been shown to converge and lead to the activation and phosphorylation of
osteoblast-specific transcription factor, Runt-related transcription factor 2 (Runx2)
(Franceschi et al. 2003), which plays a fundamental role in osteoblast differentiation and
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bone formation (Komori 2002).

Runx2 induces osteoblast and chondrocyte

differentiation and enhances their migration by coupling with PI3K-Akt signaling (Fujita
et al. 2004), which has been implicated as a critical pathway for the differentiation and
cell survival of skeletal component cells including chondrocytes, osteoblasts, myoblasts,
and adipocytes (Kaliman et al. 1996, Sakaue et al. 1998, Ghosh-Choudhury et al. 2002,
Hidaka et al. 2001).
In the case that bone is not able to self heal, bone tissue engineering is needed to
regenerate the damaged bone (Rose, Oreffo 2002).

Autologous transplantation, the

current gold standard procedure for bone repair, holds significant drawbacks including
possible donor site morbidity. Tissue-engineering strategies utilize biocompatible
scaffolds with specific combinations of cells and bioactive factors (Vaccaro 2002,
Carson, Bostrom 2007). Tissue regeneration may be enhanced by the introduction of
biochemical signals, in the form of growth factors, cytokines and genetics, which directs
cellular responses.

However, administration of growth factors also present with

significant shortcomings. For example, recombinant human BMP2 (rhBMP2) (Infuse®),
the first approved complete bone graft substitute for spinal fusion, presents drawbacks as
a regenerative bone factor since the proteins have the propensity to denature, may lead to
ectopic bone formation, entail high cost, requires high doses to induce adequate bone
formation, and possesses large variations in response among patients (Hawkins 2010).
Due to the multitude of growth factors and cell-cell interactions involved in bone
regeneration, scientists have begun to investigate novel bioengineering systems that have
the ability to release or bind to multiple growth factors. For example, dual delivery of
VEGF and BMP2 from gelatin microparticles for enhanced angiogenesis and
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osteogenesis in critical-sized defect bone regeneration (Patel et al. 2008).

This

multifactorial technique has presented itself with strong limitations including lack of
spatial and temporal control of growth factor release from biomaterial scaffold.
Thorough testing of the pharmakinetics of the released agents and elucidation of the
efficacy of the carrier systems must be performed on this type of bioengineering
approach.

Even so, each in vivo biological system presents its own individuality.

Therefore, even with complete characterization of the bioengineering system, it still may
not be fit for different biological systems.
In summary, the current biomaterials systems present a cytocompatible
microenvironment to support cell adhesion and growth, they lack specific bioactivities to
modulate the host/donor cell functions. Attempts were made to increase their bioactivity
by incorporating biological molecules such as growth factors, cytokines and chemokines.
However, those approaches also present various limitations.

These include issues

regarding inability to retain these bioactive molecules at the defect site due to the
uncontrolled diffusion of protein from the matrices as well as the inability to present
multiple bioactive molecules in a spatial and temporal controlled manner which plays a
very important role in achieving optimal regenerative outcome (as described in section
2.1.3.2).
As discussed previously in section 2.1.3.5, cell-based strategies, on the other
hand, are raising significant interest lately due to the ease of isolation of autologous
mesenchymal stem cells and their ability to undergo osteogenic differentiation. Several
other potential cell sources with good regenerative ability are also currently been
investigated. Despite encouraging results from extensive preclinical studies on cell-based
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bone tissue engineering, key biological and engineering challenges still need to overcome
for its successful clinical translation. Some of the critical challenges include poor cell
survival and inability to control cellular processes such as proliferation and
differentiation due to the inability to present appropriate microenvironment with
bioactive molecules to the transplanted cells (as described in section 4.3). Nevertheless,
such transient bioactive microenvironments are expected to be necessary for the
successful regeneration of functional tissue.

Thus, the key for a successful regenerative

biomaterial for bone regeneration lies in its ability to interact with the surrounding
environment and activate specific cell signaling pathways to support cell survival and
functions. LF’s influential role in bone morphogenesis has been accredited to its wide
array of effects on bone cells – including proliferative and anti-apoptotic actions of
osteoblasts and inhibition of osteoclast function (Amini, Nair 2011, Cornish 2004,
Cornish et al. 2004, Gonzalez-Chavez, Arevalo-Gallegos & Rascon-Cruz 2009). Based
on the unique biological activities of LF, we hypothesize that an injectable biomaterial
developed from rhLF will retains its bioactivities (as described in section 4) and will be
able to present an artificial microenvironment capable of modulating encapsulated cell
functions. The objective of the studies described in this chapter is to evaluate the
biological activities of injectable holo-rhLF gel compared to the gelatin gel (which has
shown to have no osteoblast-specific bioactivity towards encapsulated cells as discussed
in section 5.2 to understand its efficacy as a bioactive cell delivery vehicle.

Cellular

proliferation analysis methods were investigated in the 2D model using EdU
incorporation and Ki67 protein expression.

Ki67 protein expression was then used to

investigate cellular proliferation in MC3T3 encapsulated cells (3D model).
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Figure 65. Schematic showing cell encapsulation in holo-rhLF gel.
Chemical modification of holo-rhLF using standard carbodiimide reaction. Followed by
the homogenous mixture of HRP and cells plus H2O2 to yield cell-laden holo-rhLF gel.

5.3.2 Methods
5.3.2.1 Determination of optimal cell seeding density for cell encapsulation in
hydrogel

MC3T3 cells of various cell-seeding densities (2.5 x 106 cells/ml, 1.25 x 106 cells/ml and
0.5 x 106 cells/ml) were encapsulated in 100 µl of 10 mg/ml holo-rhLF gel as described
in Appendix of protocols (Section 7.9.2.4). Holo-rhLF gel component concentrations:
100 µl of 10 mg/ml holo–rhLF gel, 10 U/ml HRP, 0.75 µl of 0.25% H2O2.Cells were then
maintained in basal media for 1 day and imaged using live/dead assay as described in
Appendix of protocols (Section 7.5.2.1).
5.3.2.2 Mitogenic Activity

5.3.2.2.1 EdU incorporation
MC3T3 cells were plated on glass-bottom tissue culture plates (50,000 cells/plate) and
then serum starved for 6 hours. Cells were either untreated (control) or stimulated with
holo-rhLF 100 µg/ml for 8 hours. Click-it EdU Cell Proliferation Assay was performed
as described in Appendix of Protocols (Section 7.6.2.3).
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5.3.2.2.2 Protein expression (2D Immunocytochemistry)
MC3T3 cells were plated on glass-bottom tissue culture plates (10,000 cells/plate) for 2
days in basal media and then serum starved for 6 hours. Cells were either untreated
(control) or stimulated with holo-rhLF 100 μg/ml for 24 hours. Immunocytochemistry
was performed as described in Appendix of Protocols (Section 7.2.2.5).
5.3.2.2.3 Protein expression (3D Immunocytochemistry)
MC3T3 cells (500,000 cells/ml) were encapsulated in 100 µl of 10 mg/ml holo-rhLF gel
as described in Appendix of protocols (Section 7.9.2.4). Holo-rhLF gel component
concentrations: 100 µl of 10 mg/ml holo–rhLF gel (10 U/ml HRP, 0.75 µl of 0.25%
H2O2. Immunocytochemistry was performed to investigate the phosphorylation of Erk
and Ki67 expression as described in Appendix of protocols (Section 7.2.2.5).
5.3.2.2.4 Long term culture of encapsulated cells in the gels
MC3T3 cells (500,000 cells/ml) were encapsulated in 100 µl of 10 mg/ml holo-rhLF gel
as described in Appendix of protocols (Section 7.9.2.4). Cells were then maintained in
basal media for 20 days and imaged using live/dead assay as described in Appendix of
protocols (Section 7.5.2.1).
5.3.2.3 Anti-apoptotic effect of rhLF gels

5.3.2.3.1 Serum starvation-induced apoptosis
500,000 cells/ml in 100 µl of 10 mg/ml holo–rhLF and gelatin gel (10 U/ml HRP, 0.75 µl
of 0.25% H2O2). Cells were encapsulated and then grown in basal medium for 24hours.
Cells were then maintained in serum free media to induce apoptosis and imaged using
live/dead assay as described in Appendix of protocols (Section 7.5.2.1).
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5.3.2.3.2 Protein expression
MC3T3 cells (500,000 cells/ml) were encapsulated in 100 µl of 10 mg/ml holo-rhLF and
gelatin gels as described in Appendix of protocols (Section 7.9.2.4). Holo-rhLF gel
component concentrations: 100 µl of 10 mg/ml holo–rhLF gel (10 U/ml HRP, 0.75 µl of
0.25% H2O2. Gelatin gel component concentrations: 100 µl of 10 mg/ml gelatin gel (10
U/ml HRP, 1 µl of 0.25% H2O2. Immunocytochemistry was performed as described in
Appendix of protocols (Section 7.2.2.5).
5.3.2.3.3 Holo-rhLF/ gelatin composite gels
The protocol for the following gel biomaterials is described below: 10 mg/ml gelatin gel
+ 10 mg/ml holo-rhLF; 10 mg/ml gelatin gel + 10 mg/ml tyrosinated holo-rhLF; and 10
mg/ml holo-rhLF gel + 10 mg/ml tyrosinated holo-rhLF.

Encapsulated cells were

maintained in basal media for 6 hours and then serum starved for 2 days. Viability was
tested using live/dead assay as described in Appendix of protocols (Section 7.5.2.1).
Phosphorylation of Akt was examined using immunocytochemistry as described in
Appendix of protocols (Section7.2.2.5).
10 mg/ml gelatin gel + 10 mg/ml holo-rhLF gel
•

To make 1 ml of 10 mg/ml gelatin/HRP solution: dissolve 10 mg modified in 1ml
of 10 U/ml HRP (dissolved in H2O) and then mix well.

•

To make 1 ml of 10 mg/ml holo-rhLF/HRP solution: dissolve 10 mg tyrosinated
holo-rhLF in 500 µl of 10 U/ml HRP (dissolved in H2O) and then mix well. Add
500 µl of 10 U/ml HRP (dissolved in PBS).
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•

Mix 50 µl of gelatin/HRP solution and 50 µl of holo-rhLF/HRP solution. Add
500,000 cells/ml and mix well to a 35 mm glass bottom plate. Next, add 1 µl of
0.25% H2O2to gel.

10 mg/ml gelatin gel + 10 mg/ml holo-rhLF (non-tyrosinated)
•

To make 1 ml of 10 mg/ml gelatin/HRP solution: dissolve 10 mg modified in 1ml
of 10 U/ml HRP (dissolved in H2O) and then mix well.

•

Next, add 10 mg holo-rhLF to gelatin/HRP solution.

•

Add 500,000 cells/ml to 100 µl gelatin/holo-rhLF/HRP solution and mix well to a
35 mm glass bottom plate. Next, add 1 µl of 0.25% H2O2 to gel.

10 mg/ml holo-rhLF gel + 10 mg/ml holo-rhLF (non-tyrosinated)
•

To make 1 ml of 10 mg/ml holo-rhLF/HRP solution: dissolve 10 mg tyrosinated
holo-rhLF in 500 µl of 10 U/ml HRP (dissolved in H2O) and then mix well. Add
500 µl of 10 U/ml HRP (dissolved in PBS).

•

Next, add 10 mg holo-rhLF to holo-rhLF/HRP solution.

•

Add 500,000 cells/ml to 100 µl holo-rhLF/HRP solution and mix well to a 35 mm
glass bottom plate. Next, add 1 µl of 0.25% H2O2 to gel.

5.3.2.4 Cell differentiation

5.3.2.4.1 Protein Expression
500,000 MC3T3 cells/ml were encapsulated in 100 µl of 10 mg/ml holo–rhLF gel (10
U/ml HRP, 0.75 µl of 0.25% H2O2) and 100 µl of 10 mg/ml gelatin gel (10 U/ml HRP,
7.5 µl of 0.025% H2O2). Cell culture was maintained in basal medium for 1 day and then
changed to mineralization media and cultured for for 21 days. Immunocytochemistry
was performed as described in Appendix of protocols (Section 7.2.2.5).
	
  

221

5.3.3 Results
We first tested the optimal cell seeding density for biomaterial encapsulation.
MC3T3 cells were encapsulated in 10 mg/ml holo-rhLF gels at densities of 2,500,000
cells/ml 1,250,000 cells/ml and 500,000 cells/ml (Figure 66).

Optimal cell seeding

density was determined after 24 hours of incubation in basal media using live/dead assay.
500,000 MC3T3 cells/ml allowed for distinct cell imaging and therefore was determined
to be the optimal cell seeding density for biomaterial encapsulation for evaluating the
expression of transcription factors, growth factors and matrix deposition.

Figure 66.Various cell seeding densities of MC3T3 cells encapsulated in 10 mg/ml holorhLF gel.
Imaged after 24 hours of encapsulation using live/dead assay using confocal microscopy
(5x and 10x magnification).

	
  

222

5.3.3.1 Effect of holo-rhLF and holo-rhLF gel encapsulation on MC3T3 cell
proliferation

Previous findings have reported rhLF to increase thymidine incorporation in primary rat
osteoblast cultures (Huang et al. 2008). Similarly, our studies demonstrated holo-rhLF to
significantly increase MC3T3 and NHOst cell proliferation at concentrations of 100 and
1000 µg/ml (Figure 25). Different proliferation markers, including Ki67, pErk, EdU and
thymidine incorporation were used to follow the extent of cell proliferation cultured in
the presence and absence of holo-rhLF. We found increased Ki67 protein expression and
EdU incorporation by MC3T3 cells significantly increased after 8 hours of rhLF
treatment (Figure 67) relative to control.

Since one cycle of MC3T3 cell division

typically takes 24 hours, we chose to use an earlier time point (8 hours) to visualize cell
proliferation rate via EdU incorporation. As seen in top left panel of Figure 67, 100
µg/ml holo-rhLF treatment increased EdU incorporation.

Furthermore, p42/p44 Erk

phosphorylation and Ki67 expression increased after 24 hours of 100 µg/ml holo-rhLF
treatment (bottom left panel of Figure 67, Figure 68). In these immunocytochemistry
figures, nuclei (first panel) was stained using propidium iodide (red), protein expression
(second panel) was visualized using FITC-label secondary antibodies (green) and the
merged/overlayed images are displayed in the third panel – which demonstrates
cytoplasmic/nuclear protein localization.
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Figure 67. 100 µg/ml holo-rhLF increases EdU incorporation and Ki67 protein
expression in MC3T3 cells after 8 hours treatment.
Cells were treated for 8 hours in culture. The images of EdU incorporation (blue; top left
panel), PI nuclei staining (red; top right panel), Ki67 protein expression (FITC-green,
bottom left panel) were merged to yield bottom right panel.
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Figure 68. Increased phosphorylation of Erk and increased Ki67 protein expression in
MC3T3 cells treated with 100 µg/ml holo-rhLF.
Cells were treated for 24hours and protein expression was compared relative to
untreated control MC3T3 cells. Propidium iodide was used to stain the cell nuclei.

Figure 69 shows the pERK and Ki67 expression of cells encapsulated in rhLF
gels (left panel) and gelatin gels (middle and right panels). As demonstrated in the
figure, the proliferative effect of holo-rhLF on MC3T3 cells was retained by the
crosslinked gel form. Cell proliferation was counted using live dead assay and Image J
program after culturing the cells in the holo-rhLF gel for an extended culture period.
11.2—fold increase of cell number occurred after 20 days of encapsulation in holo-rhLF
gel (Figure 70).
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Figure 69. Phosphorylation of Erk and Ki67 expression in (A) holo-rhLF gel—
encapsulated MC3T3 cells. (B) Gelatin gels were dissolved in H2O (C) Gelatin gels
were dissolved in 1:1 H2O:PBS solution
Cells were encapsulated for 2 days in culture. Protein expression was compared to that
of gelatin gel—encapsulated cells. Propidium iodide was used to stain the cell nuclei.

Figure 70. Cell number and h viability of MC3T3 cells encapsulated in 10mg/mL of holo
rhLF gels as a function of time.
Live/dead assay was used to investigate cell viability.
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5.3.3.2 Anti-apoptotic effect of holo-rhLF gel

Holo-rhLF gel encapsulated MC3T3 cells demonstrated stimulation of Akt
phosphorylation after 2 days, which is a common marker in the survival signaling
cascade (Figure 71). P-Akt protein expression of MC3T3 cells-encapsulated in holorhLF and gelatin gel was visualized using FITC-labeled secondary antibody (green).
Cell nuclei were stained with propidium iodide (red). In the following experiment, we
encapsulated MC3T3 cells in holo-rhLF and gelatin gels and then exposed them to
serum-free media to investigate the ability of holo-rhLF gel to protect against serum
starvation-induced cellular apoptosis. Significant cell survival was seen using live/dead
assay in MC3T3 cells encapsulated in holo-rhLF gel after serum starvation for 3 days
(Figure 72). After 3 days of serum starvation – induced apoptosis, MC3T3 cells
encapsulated in holo-rhLF gel exhibited a 76% live (green) to dead (red) cells.

Figure 71. Akt phosphorylation in MC3T3 cells encapsulated in (A) 10 mg/ml holo-rhLF
gel. (B) Gels were preared by dissolving gelatin in H2O (C) Gels were prepared by
dissolving gelatin in 1:1 H2O:PBS solution
Immunofluorescence testing the phosphorylation of Akt (FITC-labeled secondary
antibody) in MC3T3 cells treated with 10 mg/ml holo-rhLF treatment relative to untreated
control after 24 hours. Nuclei are stained with propidium iodide.
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Figure 72. Viability in MC3T3 cells encapsulated in (A) 10 mg/ml holo-rhLF gel during
serum starvation. (B) Gels were prepared by dissolving gelatin in H2O (C) Gels were
prepared by dissolving gelatin in 1:1 H2O:PBS solution Images taken at 20x
magnification.
Live/dead assay was used to investigate cell viability.

Since a certain number of crosslinking sites are required for crosslinking, the
concentration of bioactive may be higher than what is needed for optimal bioactivity.
Composite gels of bioactive holo-rhLF and inert gelatin allow manipulation of
concentration of bioactive holo-rhLF in the gel encapsulating cells.

To test this

hypothesis, we made a composite gel of 1:1 ratio of 10 mg/ml tyrosinated holo-rhLF and
10 mg/ml tyrosinated gelatin to yield a 10 mg/ml holo-rhLF/gelatin composite gel which
contained only half as much bioactive tyrosinated holo-rhLF protein as pure 10 mg/ml
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holo-rhLF gel. In other words, we were able to maintaine sufficient crosslinking sites
(total polymer concentration) while we decreased the amount of bioactive, tyrosinated
holo-rhLF protein by replacing it with inert, modified gelatin. Interestingly, 10 mg/ml
holo-rhLF/gelatin composite gel also supported cell survival as visualized by live/dead
assay (Figure 73c) and phosphorylation of Akt (Figure 74c) after 2 days of encapsulation.
However, the addition of holo-rhLF (non-tyrosinated) to gelatin gel did not support cell
survival (Figure 73b) and phosphorylation of Akt (Figure 74b) after 2 days of
encapsulation.

This observation supports the notion of tyrosination of holo-rhLF

increases crosslinking and retention of the bioactive protein surrounding the encapsulated
cells.
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Figure 73. Live/dead assay of serum-starved encapsulated cells in the gels.
Imaged on day 2 of serum starvation via confocal microscopy (10x magnification). Dead
cells (first column) were visualized using ethidium homodimer (red) and live cells
(second column) were stained using calcein AM (green). The first and second column
images were merged to yield the third column to visualize the live/dead ratio.
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Figure 74. Phospho-Akt expression of serum-starved encapsulated cells in the gels.
Imaged on day 2 of serum starvation via confocal microscopy (20x magnification). Cell
nuclei (first column) were visualized using propidium iodide (red) and pAkt expression
(second column) were stained using FITC-labeled antibody (green). The first and
second column images were merged to yield the third column to visualize the
localization of the pAkt protein expression in the encapsulated MC3T3 cells. (A-C) Gels
prepared from gelatin dissolved in H2O. (F-G) Gels prepared from gelatin dissolved in
1:1 H2O:PBS solution Images taken at 20x magnification.
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5.3.3.3 Effect of holo-rhLF gel encapsulation on MC3T3 cell osteogenesis

Holo-rhLF gel biomaterial retained the osteogenic properties of the protein. The
activation of β catenin was retained by the gel crosslinked form of holo-rhLF. (Figure
75). Collagen 1 and osteocalcin protein expression (Figure 76) were observed in cells
encapsulated in holo-rhLF gel and cultured for 21 days in mineralization media.

Figure 75. Active β catenin expression in MC3T3 cells encapsulated in (A) 10 mg/ml
holo-rhLF gel and gelatin gel. (B) Gelatin gels were dissolved in H2O (C) Gelatin gels
were dissolved in 1:1 H2O:PBS solution Images taken at 20x magnification.

Nuclei are stained with propidium iodide. Cells were encapsulated for 2 days.
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Figure 76. Collagen 1 and OCN expression in MC3T3 cells encapsulated in 10 mg/ml
holo-rhLF gel and gelatin gel. A. Gels prepared from gelatin dissolved in 1:1 H2O: PBS
solution. B. Gels prepared from gelatin dissolved in H2O. Images taken at 20x
magnification.

Nuclei are stained with propidium iodide. Cells were encapsulated for 21 days.

5.3.4 Discussion
The challenges of this chapter stemmed from the porous structure of the rhLF
biomaterial gel and also the strong affinity of LF to negatively charged molecules.
Conventional methods were not selected due to the physical structure and porosity of the
gels inhibiting accurate measurements of mineralization and proliferation. Therefore, the
methodologies for this aim were selected carefully and took these points in to
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consideration. Cellular proliferation was measured via Ki67 and pErk protein expression
instead of thymidine incorporation as used in the 2D studies for soluble rhLF treatment
on MC3T3 cells. Protein expression of collagen 1 and OCN, two key specific ostoegenic
markers, were used to evaluate osteogenic differentiation rather than conventional
Alizarin Red, which was used for the 2D studies of holo-rhLF on MC3T3 cells.
Furthermore, cell number for gel encapsulation was optimized to 500,000 cells/ml of gel
since this cell density allowed for distinct cell imaging for evaluating the expression of
transcription factors and growth factors.
Based on the previous gel characterization studies (section 5.1), 10 mg/ml holorhLF gel concentration was in our biological studies of the gel. This gel concentration
yielded a clinically-feasible gelation time of approximately 1 minute.

Also, 10 mg/ml

holo-rhLF gel allowed for excellent cell spreading and viability and also provided
sufficient mechanical strength to serve as an encapsulating cell delivery vehicle.
The mitogenic effects of LF have been clearly reported in our previous studies
(Figure 25) and also previously published studies (Huang et al. 2008). However, it was
not clear whether the crosslinked matrix would retain the properties of the soluble
protein.

Since bioactive proteins may activate cellular processes cell internalization or

receptor-mediated signal transduction – it is therefore not known if an immobilized
polymer, which is incapable of being endocytosed, will be bioactive or not. Grey et al.
reported that LF internalization by osteoblastic cells is not necessary for activation of
mitogenic signaling (Grey et al. 2004).

Therefore, we could conclude that the

crosslinked matrix has the potential to retain the protein’s inherent bioactive activity.
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Different proliferation markers, including Ki67, pErk, EdU and thymidine
incorporation were used to follow the extent of cell proliferation cultured in the presence
and absence of holo-rhLF.

Ki67 protein expression is a marker that is expressed by

proliferating cells in all phases of active cell cycle (G1, S, G2 and M phase). pErk is a
signaling marker that is often seen in proliferating cells.

In addition to following

mitogenic markers, viable cell number in the gel after long-term culture was followed as
a function of time by fluorescent live/dead staining. Our previous data (Figure 25)
indicated increased cell proliferation in MC3T3 cells treated with holo-rhLF. Similarly,
our long-term culture of the MC3T3 encapsulated cells in holo-rhLF gel demonstrated
that this gel presents a conducive microenvironment to promote cell proliferation. This
data shows that rhLF gel is mitogenic towards the encapsulated MC3T3 cells and
immunocytochemistry is a very good tool to follow the mitogenic activity.
Our previous data demonstrated that holo-rhLF has potent anti-apoptotic effect on
MC3T3 cells serum-starved in culture (Figure 31).

Cornish et al. found pAkt, a

common signaling molecule activated during cell survival events, to be increased by LF
treatment. However, they also reported that this phosphorylation event is not required for
LF-induced cell survival (Grey et al. 2006). In our studies, we discovered that this
biological property of holo-rhLF to be dependent on PKA signaling pathway (section
4.3.3.1).

Cells encapsulated in holo rhLF gels showed good viability upon serum

starvation for 3 days. The cells in gelatin gel however did not show cell survival even at
24 hours. This can be attributed to the lack of biological activity of gelatin as well as the
inability of the gel to support cell spreading. Future studies need to compare the
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antiapoptotic effect of lactoferrin gels to control gels that allow cell spreading (Figure
72).
To address the question of whether it is the crosslinked holo-rhLF matrix that is
showing bioactivity or some remaining/uncrosslinked holo-rhLF we measured the
amount of protein that was released (un-crosslinked polymer) from the gel into PBS
buffer over 5 days at 37°C (Figure 46). By 5 days, a cumulative amount of 10.1 ng/ml of
modified holo-rhLF protein was released in the PBS buffer. However, in Figure 19, we
demonstrated that a minimum of 100 µg/ml rhLF was required for statistically significant
thymidine incorporation (Cornish et al. 2004).

Therefore, we concluded the bioactivity

induced in the MC3T3 cells encapsulated in holo-rhLF was a result of the crosslinked
matrix not the small amount of un-crosslinked, modified holo-rhLF protein. To further
confirm our theory, we designed an experiment where modified and unmodified holorhLF was encapsulated in gelatin gel. In this experiment, the modified holo-rhLF became
crosslinked in the gelatin gel – forming a bioactive, holo-rhLF/gelatin crosslinked
composite matrix.

However, the unmodified holo-rhLF was not crosslinked in the

gelatin gel and therefore did not induce any bioactivity in the encapsulated MC3T3 cells
– as measured by pAkt expression and also live/dead assay upon serum starvation.
After confirming the mitogenic and anti-apoptotic effect of the holo-rhLF gel,
attempts were made to understand the osteogenic activity of holo-rhLF.

Thus far, no

previously published data has revealed any molecular mechanisms underlying LF’s
osteogenic effects. In our studies, we found LF increases Disheveled/ Gsk3β / β catenin
signaling cascade.

Furthermore, through inhibitor studies, we discovered LF-induced

PKA/LRP6 is responsible for β catenin accumulation. The cells encapsulated in holo
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rhLF gels showed a positive expression for β catenin as well as express osteogenic
markers – collagen I and OCN – after 21 days culture in osteogenic media.
There is a great need for a bioactive, biocompatible cell delivery vehicle.
Furthermore, in the field of orthopedics there no existing biomaterial that provides
effective cell delivery, survival, proliferation and increased osteogenesis.

Current

paradigms in tissue engineering involve the synthesis of novel biomaterials that mimic
essential aspects of the physiological niche. Ideally, scaffold design is tailored towards
reproducing required signals to foster and direct cellular attachment, proliferation and
specific cellular differentiation. To accomplish that several factors must be taken in to
account, including the fabrication and implantation of scaffolding material, the physical
structures and their biological activity. To date, no studies report cells differentiating into
osteogenic linage without any exogenous soluble differentiation factors using hydrogel
biomaterials in vitro.

As demonstrated in the rpesent study, the enzymatically

crosslinked LF gel presents a conducive environment to support cell viability,
proliferation and differentiation and support phosphorylation/dephosphorylation of
proteins demonstrating a potential avenue for developing cell instructive injectable
materials.

5.3.5 Conclusions
The proposed studies were aimed to increase our understanding of the effect of holorhLF in modulating skeletal cells and further establish holo-rhLF crosslinked gel as an
excellent candidate for a skeletal regenerative biomaterial. In our studies, the bioactive
holo-rhLF gel matrix is used as a cell delivery vehicle and further promotes cell survival,
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proliferation, differentiation and mineralization. The positive effects of holo-rhLF gel on
cellular processes supports the notion that holo-rhLF gel is a strong candidate for bone
tissue engineering.
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6 Future studies
6.1 Molecular mechanism underlying LF
Grey et al. confirmed that LRP1 is a mitogenic receptor for LF in osteoblastic cells
(Grey et al. 2004) and that LF inhibits osteoblast apoptosis via a LRP1-independent
pathway (Grey et al. 2006). Several questions still remained unanswered such as what
pathways are involved inLF’s anti-apoptotic effects in osteoblasts.

Our recent studies

have demonstrated that LF induces PKA-dependent survival in MC3T3 preosteoblast
cells. However, the mechanism and receptor by which LF induces PKA is still unknown.
Numerous studies have reported LF’s osteogenic effects (Cornish et al. 2004). Our
studies confirmed the activation of β catenin as it is the penultimate osteogenic signaling
molecule.

Further investigation revealed that PKA upregulation and LRP6

phosphorylation.

Identification of LRP6 as LF’s osteogenic receptor should be

confirmed through DKK1 inhibitor studies and also knockout model. LRP6-knockout
mice develop to term (Kelly, Pinson & Skarnes 2004) and therefore would allow for the
investigation of its role in LF’s osteogenic induction.

Testing of osteogenic

differentiation potential of primary osteoblast cells from LRP6 knockout mice by LF
would confirm the LF’s dependence on LRP6 for osteogenic differentiation.

6.2 LF composite gels
For sufficient number of available crosslinking sites, LF gels required
approximately 10 mg/ml of tyrosinated LF. However, in order to study concentration-
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dependent effects of LF on the encapsulated cells, lower concentrations of LF should be
used. Composite mixture with inert proteins or polymers (ie. gelatin) will allow for the
study lower concentrations of crosslinked LF gels.

Furthermore, addition of other

polymers to LF gel may be used to modify the physical properties such mechanical
strength and gelation time.

6.3 Holo-rhLF gel bone regeneration study in vivo
Maintenance of the skeletal system consists of a dynamic interplay between boneforming osteoblasts and bone-resorbing osteoclasts. LPS-induced periodontitis models
provide an excellent way to study the interactions between immune and bone cells
(Yamano et al. 2010).

This inflammatory disease ultimately leads to increased

osteoclastogenesis and destruction of the periodontium (Clowes, Riggs & Khosla 2005,
Weitzmann, Pacifici 2007).

LF may affect this model multifold: inhibition of

osteoclastogenesis, increased osteoblast activity and inhibition of periodontopathic
bacteria growth.

We hypothesize that localized LF gel injections will decrease the

inflammation and thus inhibit osteoclastogenesis and destruction of the periodontium.
Inflammatory markers, such as IL1α and TNFα, from the saliva may be used to monitor
the inflammatory state of the animal model.

Alveolar bone levels may be monitored

through live x-ray scanner. Calcein green labeling may be used to monitor new bone
growth as described previously (Cornish et al. 2004).
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7 Appendix of Protocols
7.1 Cell culture
7.1.1 Materials

	
  

•

MC3T3-E1 Clone 4 cells (ATCC CRL-2593)

•

MEMα medium (Gibco; Grand Island, NY)

•

10% FBS (Gibco; Grand Island, NY)

•

1% Pencillin/Streptomycin (Gibco; Grand Island, NY)

•

2.5% Trypsin/EDTA (Gibco; Grand Island, NY)

•

L-ascorbic acid (Fisher Scientific; Pittsburg, PA)

•

β-glycerophosphate (Sigma-Aldrich; St. Louis, MO)

•

Clonetics Normal Human Osteoblasts (NHOst) cells (Lonza; Walkersville, MD)

•

Osteoblast Basal Medium (Lonza; Walkersville, MD)

•

Single Quots (Lonza; Walkersville, MD)

•

ReagentPack Subculture Reagents (Lonza; Walkersville, MD)

•

Differentiation SingleQuots (Lonza; Walkersville, MD)

•

Bovine LF, native hLF and LiCl (Sigma; St. Louis, MO)

•

rhLFs (endotoxin level: <1.5 EU/mg) (InVitria; Fort Collins, CO)

•

Gelatin Type A (MP Biomedicals; Solon, OH)

•

rhWnt3a, rhWnt5a and rhBMP2 (R&D Systems; Minneapolis, MN)
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7.1.2 Methods
7.1.2.1 MC3T3 cell culture

MC3T3-E1 (passages 18-35) were maintained 37oC, 5% CO2 humidified incubator.
MC3T3 cells were plated on 75cm2 flasks at the recommended density of 5,000 cells/cm2
with 0.2 ml/cm2 basal media consisted of MEMα medium supplemented with 10% FBS
and 1% Pencillin/Streptomycin. At 80% confluency, the MC3T3 cells were subcultured
using 2.5% Trypsin/EDTA.

Mineralization media consisted of supplemented MEMα

media additionally supplemented with 10 µg/ml L-ascorbic acid and 3 mM βglycerophosphate.
7.1.2.2 Human osteoblast cell culture

Clonetics Normal Human Osteoblasts (NHOst) cells (passages 2-4) were maintained
37oC, 5% CO2 humidified incubator. NHOst cells were plated on 75 cm2 flasks at the
recommended density of 5,000 cells/cm2 with 1 ml/ 5 cm2 Osteoblast Basal Medium
supplemented with Single Quots, which includes FBS, Gentamycin and Ascorbic Acid.
At 80% confluency, the NHOst cells were subcultured using ReagentPack Subculture
Reagents, which includes Trypsin/EDTA, Trypsin Neutralizing Solution and HEPESBSS. To differentiate the NHOst cells to mineralizing bone cells, the supplemented
Osteoblast Basal Medium were further supplemented with Differentiation SingleQuots,
which includes Hydrocortisone-21-hemisuccinate (200 nM final concentration) and βGlycerophosphate (10 mM final concentration).
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7.2 Protein analysis
7.2.1 Materials
•

CellLytic M and Protease Inhibitor (Sigma; St. Louis, MO)

•

Western blot analysis reagents (BioRad; Hercules, CA)

•

BCA Protein Assay Reagent (Peirce; Rockford, IL)

•

ReadyPrep Cytoplasmic/Nuclear Protein Extraction kit (Fisher Scientific;
Pittsburg, PA)

•

Glass bottom culture plates, 35 mm uncoated (MatTek; Ashland, MA)

• Primary	
  Antibodies	
  
Phospho-‐Akt	
  (Ser473)	
  
Phospho-‐p44/42	
  MAPK	
  (Erk1/2)	
  
Phospho-‐p44/42	
  MAPK	
  (Erk1/2)	
  
anti-‐phospho-‐CREB	
  (Ser133)	
  
	
  
LRP1	
  (5A6)	
  
Phospho-‐LRP1	
  
LRP5/6	
  (1A12)	
  
LRP5/6	
  (1A12)	
  
Phospho-‐LRP6	
  
	
  
VEGF	
  
VEGF	
  
IL6	
  
	
  

Company,	
  Catalog	
  number	
  
Cell	
  Signalling	
  4060	
  
Cell	
  Signalling	
  4370	
  
Millipore	
  05-‐481	
  
Millipore-‐06-‐519	
  

Dilution	
  
1:1000	
  (western)	
  
1:1000	
  (western)	
  
1:100	
  (immunocytochemistry)	
  
1:1000	
  (western)	
  

Santa	
  Cruz	
  sc57351	
  
Upstate	
  30628	
  
Abcam	
  ab257250	
  
Santa	
  Cruz	
  sc57354	
  
Millipore	
  07218	
  

1:1000	
  (western)	
  
	
  
1:1000	
  (western)	
  
	
  
1:1000	
  (western)	
  

Santa	
  Cruz	
  sc65617	
  
Abcam	
  ab1316	
  
Abcam	
  ab6672	
  

1:1000	
  (western)	
  
1:100	
  (immunocytochemistry)	
  
1:100	
  (immunocytochemistry)	
  

Phospho-‐Dishevelled	
  2	
  
Phospho-‐Gsk3β	
  
β	
  catenin	
  
Active	
  β	
  catenin	
  

Millipore	
  ab5972	
  
Millipore	
  ab05643	
  
BD	
  610153	
  
Millipore	
  05-‐665	
  
	
  
Santa	
  Cruz	
  sc8566	
  
Santa	
  Cruz	
  sc10758	
  
Abcam	
  ab76956	
  
Santa	
  Cruz	
  sc30045	
  

1:1000	
  (western)	
  
1:1000	
  (western)	
  
1:2000	
  
1:1000	
  (western)	
  

Abcam	
  ab292	
  

1:100	
  (immunocytochemistry)	
  

Millipore	
  05661	
  
Abcam	
  ab8227	
  
Abcam	
  ab15580	
  

1:1000	
  (western)	
  
1:1000	
  (western)	
  
1:100	
  (immunocytochemistry)	
  

Santa	
  Cruz	
  SC-‐14434	
  

1:1000	
  (western)	
  

Runx2	
  (C-‐19)	
  
Runx2	
  
Runx2	
  
Osteocalcin	
  (FL-‐95)	
  
Collagen	
  1	
  
	
  
Tubulin	
  
β	
  -‐	
  actin	
  
Ki67	
  
	
  
Anti-‐Lactoferrin	
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1:1000	
  (western)	
  
	
  
1:100	
  (immunocytochemistry)	
  
1:100	
  (immunocytochemistry)	
  

	
  
Secondary	
  Antibodies	
  
Goat	
  Anti-‐Rabbit	
  IgG	
  Conjugate	
  
Goat	
  Anti-‐Mouse	
  IgG	
  Conjugate	
  
Goat	
  Anti-‐Rat	
  IgG	
  Conjugate	
  
Donkey	
  Anti-‐Goat	
  IgG-‐FITC	
  
Goat	
  Anti-‐Rabbit	
  IgG-‐FITC	
  
Goat	
  Anti-‐Mouse	
  IgG-‐FITC	
  

KPL	
  #474-‐1516	
  
KPL	
  #474-‐1806	
  
KPL	
  #474-‐1612	
  
Abcam	
  sc-‐2024	
  
Abcam	
  ab6717	
  
Abcam	
  ab6785	
  

Table 6.
Primary and secondary
immunocytochemistry studies.

antibodies

1:3000	
  (western)	
  
1:3000	
  (western)	
  
1:3000	
  (western)	
  
1:200	
  (immunocytochemistry)	
  
1:200	
  (immunocytochemistry)	
  
1:200	
  (immunocytochemistry)	
  

used

for

western

blot

and

7.2.2 Methods
7.2.2.1 Extraction

Media was aspirated from cells and washed briefly with PBS. 500 µl of CellLytic M and
Protease Inhibitor at a 1000:1 ratio were added to cells and then incubated at 4°C for 30
minutes. Cells were removed by mechanical scrapping and spun down at 10,000 rpm for
5 minutes.
7.2.2.2 Bicinchoninic Acid (BCA) total protein assay

Protein concentrations were measured using BCA Protein Assay Kit. BCA Protein Assay
Reagent (Bicinchoninic Acid) contains BCA Reagent A (500 mL), BCA Reagent B (25
ml), Albumin Standard (2 mg/ml). Working BCA reagent was prepared by mixing 50
parts of BCA reagent A with 1 part of BCA reagent B. 10 µl of each unknown sample or
standard (i.e., diluted with 1% Triton X100 solution) was pipette to a 96 well plate. 90 µl
of the working reagent was then added to each well and plate was mixed
thoroughly. The absorbance of the samples were measured at 562 nm after 30 minute
incubation at 37°C. BSA standards were calculated according to Table 7.
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Vial	
  

Volume	
  of	
  diluent	
  	
  (μl)	
  

Volume	
  &	
  Source	
  of	
  BSA	
  

Final	
  BSA	
  concentration	
  

A	
  
B	
  
C	
  
D	
  
E	
  
F	
  
G	
  

450	
  
300	
  
300	
  
360	
  
300	
  
320	
  
400	
  

150	
  μl	
  of	
  stock	
  
300	
  μl	
  of	
  A	
  
300	
  μl	
  of	
  B	
  
240	
  μl	
  of	
  C	
  
300	
  μl	
  of	
  D	
  
80	
  μl	
  of	
  E	
  
0	
  

500	
  μg	
  /ml	
  
250	
  μg	
  /ml	
  
125	
  μg	
  /ml	
  
50	
  μg	
  /ml	
  
25	
  μg	
  /ml	
  
5	
  μg	
  /ml	
  
blank	
  

Table 7. Diluted albumin (BSA) standards.

7.2.2.3 Western blot analysis

Each sample was prepared with Laemmli Sample Buffer and samples were boiled for 5
minutes. 25 µg of each sample were run on 4-15% Tris-HCl Ready Gels for western blot
protein electrophoresis.

Mini-PROTEAN Tetra System, 10x Tris/Glycine/SDS Buffer,

Precision Plus Protein Dual Color Standard were used and gels were run at a constant 100
Volts. Gels were transferred at a constant 100 Volts for 2 hours using 10x Tris/Glycine
Buffer, Mini Trans-Blot Electrophoresis Transfer Cell, Blot Papers and 0.2 µm
Nitrocellulose Membrane.

Membranes were blocked for 2 hours at 4°C in 10%

milk/TBS-T solution (10x Tris-Buffered Saline, 0.1% Tween-20). Membranes were
washed with TBS-T solution after each incubation.

Membranes were incubated

overnight with primary antibodies diluted in 5% milk/TBS-T solution at 4°C. Next,
membranes were incubated for 45 minutes with secondary antibody diluted in 5% milk/
TBS-T solution at 4°C and then washed three times with TBS-T. List of primary and
secondary antibodies used for western blot are contained in Table 6. Super Signal West
Pico Chemiluminescent Substrate was used for detection, and CL-XPosure Film was used
for exposure of the membranes.
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7.2.2.4 Nuclear/ cytoplasmic protein extraction

ReadyPrep Cytoplasmic/Nuclear Protein Extraction kit enabled the stepwise separation
and preparation of cytoplasmic and nuclear extracts from cell samples. Cells were
harvested with trypsin-EDTA and then centrifuged at 500 × g for 5 minutes. Cells were
washed by suspending the cell pellet with PBS. 1-10 × 106 cells were transferred to a 1.5
mL microcentrifuge tube and pelleted by centrifugation at 500 × g for 2-3 minutes. A
pipette was used to carefully remove and discard the supernatant, leaving the cell pellet
as dry as possible. This protocol was scaled depending on the cell pellet volume and the
volume ratio of CER I: CER II: NER reagents was maintained at 200:11:100 µL,
respectively (	
  
Packed	
  cell	
  volume	
  (μl)	
  
10	
  
20	
  
50	
  
100	
  

CER	
  I	
  (μl)	
  
100	
  
200	
  
500	
  
1000	
  

CER	
  II	
  (μl)	
  
5.5	
  
11	
  
27.5	
  
55	
  

NER	
  (μl)	
  
50	
  
100	
  
250	
  
500	
  

CER	
  I	
  (μl)	
  
100	
  
200	
  
500	
  
1000	
  

CER	
  II	
  (μl)	
  
5.5	
  
11	
  
27.5	
  
55	
  

NER	
  (μl)	
  
50	
  
100	
  
250	
  
500	
  

Table 8).
	
  
Packed	
  cell	
  volume	
  (μl)	
  
10	
  
20	
  
50	
  
100	
  

Table 8. Reagent volumes for different packed cell volumes.

Ice-cold CER I was added to the cell pellet. The tube was vigorously vortexed on the
highest setting for 15 seconds to fully suspend the cell pellet and then incubated on ice
for 10 minutes. Ice-cold CER II was added to the tube and then vortexed for 5 seconds
on the highest setting, followed by 1 minute incubation on ice. Samples were centrifuged
for 5 minutes at maximum speed in a microcentrifuge (~16,000 × g). The supernatant
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(cytoplasmic extract) was then transferred to a clean pre-chilled tube and samples were
placed stored at -80°C until use. The insoluble (pellet) fraction, which contains nuclei,
was suspended in ice-cold NER and vortex on the highest setting for 15 seconds. The
samples were placed on ice and continued vortexing for 15 seconds every 10 minutes, for
a total of 40 minutes. The samples were then centrifuged at maximum speed (~16,000 ×
g) in a microcentrifuge for 10 minutes. The supernatant (nuclear fraction) was then
immediately transferred to a clean pre-chilled tube and stored at -80°C until use.	
  
7.2.2.5 Immunocytochemistry

Cells were cultured on sterile glass bottom culture plates, 35 mm uncoated. Washed
briefly with PBS and then fixed using -10ºC methanol for 5 minutes. Next, methanol was
aspirated and allow to air dry. Samples were washed in three changes of PBS. Sufficient
reagent was used to cover the specimen (approximately 200 µl per slide). Samples were
incubated in 10% normal blocking serum in PBS for 20 minutes to suppress non-specific
binding of IgG. Blocking serum ideally should be derived from the same species in
which the secondary antibody is raised and then washed with PBS.

Next, the samples

were incubated with primary antibody overnight in 1% normal blocking serum. Washed
with three changes of PBS for 5 minutes each. Incubated in dark chamber for 45 minutes
with fluorochrome-conjugated secondary antibody diluted to in PBS with 1% normal
blocking serum and washed with three changes of PBS. List of primary and secondary
antibodies used for immunocytochemistry are contained in Table 6. Mounted coverslip
with Vectashield Mounting Medium with Propidium Iodide (nuclear stain) and imaged
via confocal microscopy.
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7.3 Gene expression analysis
7.3.1 Materials
•

Clontech Sprint RT Complete cDNA synthesis kit (Clontech; Mountain View,
CA)

•

BioRad MyiQ2 Two-Color Real-Time PCR Detection System, 2x iQ real-time
PCR Supermix (BioRad; Hercules, CA)

•

TaqMan® Gene Expression Assay Probes (Applied Biosystems; Carlsbad, CA)

•

Microseal 96-Well PCR Plates (BioRad; Hercules, CA)

•

Illumina TotalPrep RNA Amplification Kit (Ambion, Carlsbad, CA)

•

Illumina MouseWG-6 v2.0 Expression BeadChip (Ambion, Carlsbad, CA)

7.3.2 Methods
7.3.2.1 RNA extraction and purification

RNeasy Mini RNA Isolation kit was used to isolate and purify the RNA. Cells were first
disrupted by adding Buffer RLT and removed by mechanical scrapping. Lysate was
homogenize for 30 seconds using a rotor–stator homogenizer. 1 volume of 70% ethanol
was added to the homogenized lysate, and mixed well by pipetting and then added to an
RNeasy spin column placed in a 2 ml collection tube and centrifuged for 15 seconds at
≥8000 x g. Flow-through was discarded. 700 µl Buffer RW1 was added to the RNeasy
spin column and then centrifuged for 15 seconds at ≥8000 x g to wash the spin column
membrane. Flow-through was discarded. 500 µl Buffer RPE was added to the RNeasy
spin column and samples were centrifuged for 15 seconds at ≥8000 x g to wash the spin
column membrane. Flow-through was discarded. 500 µl Buffer RPE was added to the
RNeasy spin column and centrifuged for 2 min at ≥8000 x g to wash the spin column
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membrane. RNeasy spin column was placed in a new 1.5 ml collection tube. 30–50 µl
RNase-free water was added directly to the spin column membrane and centrifuged for 1
minute at ≥8000 x g to elute the RNA.
7.3.2.2 Real time PCR analysis

For cDNA synthesis, 2 µg total RNA was used as a template for Clontech Sprint RT
Complete cDNA synthesis kit in a total volume of 20 µl. For quantitative real time PCR,
BioRad MyiQ2 Two-Color Real-Time PCR Detection System, 2x iQ real-time PCR
Supermix, TaqMan® Gene Expression Assay Probes were loaded in Microseal 96-Well
PCR Plates. Each well contained 10 µl of iQ real-time PCR Supermix, 1 ul of TaqMan®
Gene Expression Assay probe and 9 µl of diluted cDNA. Threshold cycle values of
target genes was standardized against GAPDH expression and normalized to the
expression in the control culture. The –fold change in expression was calculated using the
ΔΔCt comparative threshold cycle method.
7.3.2.3 Microarray analysis

Three biological replicates were tested for each sample (n=3). Illumina TotalPrep RNA
Amplification Kit was used for RNA amplification. RNA Nano Chip on Agilent 2100
Bioanalyzer was used to detect quality of RNA and labelled cRNA. Samples were
hybridized to Illumina MouseWG-6 v2.0 Expression BeadChip.

The multi-sample

format includes 45,200 transcripts and six samples simultaneously on a single BeadChip,
which dramatically increases throughput while decreasing experimental variability. The
MouseWG-6 beadchip exhibits a dynamic range of > 3 logs; detectable fold change <
1.35 fold and reproducibility CV < 10%.
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The ratio of the signal intensity of each

experimental sample and the signal intensity of untreated control was represented as the
fold change relative to control.
7.3.2.4 Mouse Wnt signaling pathway array

Quantitative real time PCR was employed to assess the influence of the 100 µg/ml holorhLF (n=3) on Wnt signaling pathway in MC3T3 preosteoblast cells. Total RNA was
isolated using the Qiagen RNeasy Mini Kit according to the manufacturer's instructions.
For cDNA synthesis, 2 µg total RNA was used as a template for Clontech Sprint RT
Complete cDNA synthesis kit in a total volume of 20 µl.

BioRad MyiQ2 Two-Color

Real-Time PCR Detection System was utilized to measure expression profiles of 84
genes related to WNT-mediated signal transduction on cells treated with of holo-rhLF
relative to untreated control. The RT² Profiler™ PCR Arrays includes built-in positive
control elements for the proper normalization of the data, for the detection of genomic
DNA contamination, for the quality of RNA samples, and for general PCR performance.

7.4 Cell Imaging
7.4.1 Materials
Alexa Fluor 488 phalloidin (Molecular Probes; Grand Island, NY)
7.4.2 Methods
7.4.2.1 Cell morphology

7.4.2.1.1 Actin staining via Alexa Fluor 488 phalloidin
Cells were cultured on sterile glass bottom culture plates, 35 mm uncoated (MatTek
P35G-1.0-14-C). Washed briefly with PBS and then fixed using 4% paraformaldehyde
for 30 minutes at 37°C. Next, aspirate and rinse with PBS. Incubate samples in 0.1%
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Triton X-100 in PBS for 3 to 5 minutes. Wash two or more times with PBS. Samples
were then stained with Alexa Fluor 488 phalloidin to visualize the actin filaments. To
prepare the stock solution of Alexa Fluor 488 phalloidin, the vial was dissolved in 1.5
mL methanol to yield a final concentration of 200 units/mL, which is equivalent to
approximately 6.6 µM. When staining with any of the fluorescent phallotoxins, dilute 5
µL methanolic stock solution into 200 µL PBS for each coverslip to be stained. To reduce
nonspecific background staining with these conjugates, add 1% bovine serum albumin
(BSA) to the staining solution. Place the staining solution on the coverslip for 20 minutes
at room temperature in dark incubator. Wash two or more times with PBS. Image via
confocal microscopy (excitation/emission: 495nm/518nm).
7.4.2.1.2 Nuclear staining via propidium iodide
To stain the nuclei, mount coverslip with Vectashield Mounting Medium with Propidium
Iodide (nuclear stain) and image via confocal microscopy (excitation/emission: 535 nm/
617 nm).

7.5 Cell survival and viability
7.5.1 Materials
•

Live/Dead Viability/Cytotoxicity Kit (Molecular Probes; Grand Island, NY)

•

CaspACE assay (Promega; Madison, WI)

7.5.2 Methods
7.5.2.1 Live/Dead Viability assay

Samples were stained using Live/Dead Viability/Cytotoxicity Kit to test viability of the
cells.
	
  

2 µM calcein AM and 4 µM Ethidium homodimer-1 was added to PBS. The
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polyanionic dye calcein was used since it is well retained within live cells, producing an
intense uniform green fluorescence in live cells (excitation/emission: 495 nm/ 515 nm).
EthD-1 was included since it enters cells with damaged membranes and undergoes a 40fold enhancement of fluorescence upon binding to nucleic acids, thereby producing a
bright red fluorescence in dead cells (excitation/emission: 495 nm/ 635 nm). Zeiss LSM
510 Confocal Microscope was utilized to image the samples.
7.5.2.2 Colorimetric CaspACE assay

CaspACE assay was used to measure the activity of caspase-3, a member of the cysteine
aspartic acid-specific protease family. Grow cells on 10cm tissue culture plates to 90%
confluence. Add serum-free media to MC3T3 cells as a positive (induced apoptosis)
control. For inhibited apoptosis samples, add the Z-VAD-FMK inhibitor to the cells
(final concentration of 50 µM). Prepare negative controls using untreated cells. Incubate
overnight at 37°C in a humidified, 5% CO2 atmosphere.

Cells were harvested by

centrifugation at 450 x g for 10 minutes at 4°C. Keep the cell pellet on ice. Wash 1X
with ice-cold PBS, and resuspend in Cell Lysis Buffer at a concentration of 108 cells/ml.
Lyse cells by freeze-thaw, then incubate on ice for 15 minutes (repeat freeze thaw cycles
as needed to ensure complete cell lysis). Cell lysates were centrifuged at 15,000 x g for
20 minutes at 4°C, and the supernatant fraction was collected. Caspase-3 activity was
measured in cell extracts from at least 1 x106 cells/assay. Cell extracts were used as an
enzyme source. In a flat-bottom, clear polystyrene 96-well plate 20 µl of cell extract (75
µg total protein) was added to each reaction. Prepare replicate wells (n=3) containing
blank (no cell extract), negative control (extract from untreated cells), induced apoptosis
(extract from induced cells) and inhibited apoptosis (extract from induced, inhibitor	
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treated cells) samples (according to Table 9). Add 2 µl of DEVD-pNA Substrate (10mM
stock) to all wells. Samples were incubated at 37°C overnight and then the absorbance
was read at 405 nm.

	
  

Blank	
  
32	
  μl	
  

Negative	
  
Control	
  
32	
  μl	
  

Induced	
  
Apoptosis	
  
32	
  μl	
  

Inhibited	
  
Apoptosis	
  
32	
  μl	
  

Caspase	
  Assay	
  Buffer	
  
DMSO	
  
DTT,	
  100	
  mM	
  
Untreated	
  cell	
  extract	
  

2	
  μl	
  
10	
  μl	
  
-‐	
  

2	
  μl	
  
10	
  μl	
  
20	
  μl	
  

2	
  μl	
  
10	
  μl	
  
-‐	
  

2	
  μl	
  
10	
  μl	
  
-‐	
  

Induced	
  apoptosis	
  extract	
  

-‐	
  

-‐	
  

20	
  μl	
  

-‐	
  

Inhibited	
  apoptosis	
  extract	
  

-‐	
  

-‐	
  

-‐	
  

20	
  μl	
  

Deionized	
  water	
  to	
  final	
  
volume	
  

98	
  μl	
  

98	
  μl	
  

98	
  μl	
  

98	
  μl	
  

Table 9. Caspase assay control sample preparation.

7.6 Proliferation assays
7.6.1 Materials
•

Click-it EdU Cell Proliferation Assay Kit (Invitrogen; Carlsbad, CA)

•

MTS assay (Promega; Grand Island, NY)

7.6.2 Methods
7.6.2.1 MTS assay

Cells were plated at a density of 15,000 cells/well in a 48-well plate with basal media.
After 24 hours, treatments were administered at various concentrations (n=4 biological
replicates). The proliferation of MC3T3 cells was determined by MTS assay. 1000 µl of
culture medium was incubated with 200 µl of Cell Titer 96 AQueous One Reagent for 2
hours at 37°C and the absorbance was measured at 492 nm.
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7.6.2.2 Thymidine incorporation

Cells were plated and then incubated at 37°C for 6 hours to allow proper cell adhesion
and maintained in serum-free medium overnight. The cell culture was then performed
with supplementation of treatments and [3H]thymidine for 24 hour incubation (n=4
biological replicates). Incorporation of [3H]thymidine radioactivity was counted for 30
seconds in a liquid scintillation counter and expressed as disintegrations per minute
(dpm) per microgram of DNA. Data was then normalized to untreated control sample
and expressed as fold change over control.
7.6.2.3 EdU incorporation

Click-it EdU Cell Proliferation Assay Kit protocol involves 4 main steps: preparation of
stock solutions, EdU labeling, EdU detection and counter nuclear staining.
7.6.2.3.1 Preparation of stock solutions
10 mM stock solution of EdU (Component A) was prepared by adding 2 mL of DMSO
(Component C) to EdU (Component A). Next, a working solution of the Alexa Fluor®
azide (Component B) was prepared by adding 70 µL of DMSO (Component C) to
Component B. A working solution of 1X Click-iT® EdU reaction buffer (Component D)
was prepared by diluting the 4 ml of Component D to 36 ml of deionized water.

A 10X

stock solution of the Click-iT® EdU buffer additive (Component F) was made by adding
2 mL of deionized water to the Component F vial.
7.6.2.3.2 EdU labeling
Cells were cultured on sterile glass bottom culture plates, 35 mm uncoated and allow
cells to adhere for 6 hours in basal media. 2X working solution of EdU (Component A)
was prepared in serum free basal media from the 10 mM stock solution. A suggested
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starting concentration is 10 µM. An equal volume of the 2X EdU solution was added to
the volume of serum free basal media containing cells to be treated to obtain a 1X EdU
solution (final EdU concentration = 10 µM).

Concurrently, we added 0 or 100 µg/ml

holo-rhLF to the cell cultures. The time of EdU exposure to the cells allowed for direct
measurement of cells synthesizing DNA. After incubation, media was removed and 1
mL of 3.7% formaldehyde in PBS was added to each sample and incubated for 15
minutes at room temperature. Next, the fixative was removed and the cells were washed
well twice with 1 mL of 3% BSA in PBS. Next, 1 mL of 0.5% Triton® X-100 in PBS
was added to each well and incubated at room temperature for 20 minutes.
7.6.2.3.3 EdU detection
First, 1X Click-iT® EdU buffer additive was prepared by diluting the 10X solution 1:10
in deionized water.

Click-iT® reaction cocktail was prepared according to Table 10.

Click-iT® reaction cocktail was used within 15 minutes of preparation (as
recommended).
Reaction	
  
components	
  

Number	
  of	
  samples	
  
1	
  
430	
  μl	
  

2	
  
860	
  μl	
  

4	
  
1.8	
  mL	
  

5	
  
2.2	
  mL	
  

10	
  
4.3	
  mL	
  

25	
  
10	
  mL	
  

50	
  
21.4	
  mL	
  

CuSO4	
  

20	
  μl	
  

40	
  μl	
  

80	
  μl	
  

100	
  μl	
  

200	
  μl	
  

500	
  μl	
  

1	
  mL	
  

Alexa	
  Fluor	
  azide	
  

1.2	
  μl	
  

2.5	
  μl	
  

5	
  μl	
  

6	
  μl	
  

12.5	
  μl	
  

31	
  μl	
  

62	
  μl	
  

Reaction	
  buffer	
  
additive	
  

50	
  μl	
  

100	
  μl	
  

200	
  μl	
  

250	
  μl	
  

500	
  μl	
  

1.25	
  ml	
  

2.5	
  ml	
  

Total	
  volume	
  

500	
  μl	
  

1	
  ml	
  

2	
  ml	
  

2.5	
  ml	
  

5	
  ml	
  

12.5	
  ml	
  

25	
  ml	
  

1x	
  Click-‐iT	
  reaction	
  
buffer	
  

Table 10. Click-iT reaction cocktails.

Permeabilization buffer was removed and the cells were washed twice with 1 mL of
3% BSA in PBS. Remove the wash solution.
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Next, 0.5 mL of Click-iT® reaction

cocktail was added to each sample and incubated for 30 minutes at room temperature,
protected from light. The reaction cocktail was removed and then the samples were
washed with 1 mL of 3% BSA in PBS.
7.6.2.3.4 Counter DNA stain
Samples were covered with Vectashield Mounting Medium with Propidium Iodide
(nuclear stain) and image via confocal microscopy (excitation/emission: 535/617nm).
Alexa Fluor® 647 EdU staining may be image via confocal microscopy
(excitaton/emission: 650/670 nm).

7.7 Cell differentiation assays
7.7.1 Materials
•

Alkaline Phosphatase Substrate Kit (BioRad; Hercules, CA)

7.7.2 Methods
7.7.2.1 Alkaline phosphatase assay

Alkaline phosphatase activity was determined using the Alkaline Phosphatase
Substrate Kit. In this assay, the early phenotypic marker ALP, from osteoblasts in
culture, converts p-nitrophenyl phosphate (p-NPP) into p-nitrophenol (p- NP). The rate of
p-NP formation is directly proportional to the ALP activity and can be measured
colorimetrically.
At the end of each timepoint, the samples were washed twice with PBS to remove
any unattached cells. The samples then incubated in 1% Triton X100. For a volume of
100 µL of cell lysate, a 400 µL of p-NPP substrate solution and buffer mixture was added
and incubated at 37 °C for 30 min. The reaction was stopped by adding 500 µL of 0.4 N
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NaOH. Subsequently, the ALP induced p-NP production can be estimated by measuring
the absorption at 405 nm the TECAN. The results of ALP activity was normalized to the
total protein content (i.e., BCA assay) from each individual sample.
7.7.2.2 Alizarin red (Calcium staining)

Calcium deposition was determined using Alizarin Red staining.
Reagents were first prepared as follows.
4 M Alizarin Red –1.369 grams of alizarin red powder dye was dissolved in 100 ml of
DD1 H2O; 1 N NaOH was used to adjust pH to 4.32
10mM Na2PO4 –0.142 grams was dissolved in 100ml H2O
10% (w/v) Cetylpyridinium Chloride (CPC) –10 grams was dissolved in 100ml of
10mM Na2PO4; 1N HCl was used to adjust pH to 7.0
Mineralized matrix synthesis was analyzed with Alizarin Red staining method for
calcium deposition. This technique used a colormetric analysis based on stabilizing the
red matrix precipitate with Cetylpyridinium Chloride (CPC) to yield a purple solution.
Briefly, the protocol is as follows: cells were rinsed twice with PBS- to remove any
unattached cells and then fixed with 70% ethanol for 1 hour at 4°C. Ethanol was then
removed and cells were air-dried and then rinse with DDI water. Cells were then
incubated with 4 M Alizarin Red for 10 minutes at room temperature. Samples were
wash five times with DDI water and then incubated with 10% CPC for 15 minutes at
room temperature. Sample absorbance was read at 562 nm.

7.8 Signalling pathway probing
7.8.1 Materials
•
	
  

H-89 (Cell Signaling; Danvers, MA)
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•

LY294002 (Cell Signaling; Danvers, MA)

•

DKK1 (R&D Systems; Minneapolis, MN)

7.8.2 Methods
7.8.2.1 Pharmalogical pathway inhibitors

Cells were pretreated with pharmalogical inhibitors (10 µM LY294002, 30 µM H-89 or
100 ng/ml DKK1) for 2 hours and then stimulated with treatment of choice for 24 hours.
7.8.2.2 Wnt signalling array

*See above protocol section 7.3.2.4.

7.9 Biomaterial studies
7.9.1 Materials
•

2-(N-morpholino) ethanesulfonic acid (MES) buffer (Sigma-Aldrich; St. Louis,
MO)

•

N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) (SigmaAldrich; St. Louis, MO)

•

N-Hydroxysuccinimide (NHS) (Sigma-Aldrich; St. Louis, MO)

•

Tyramine (Sigma-Aldrich; St. Louis, MO)

•

Standard Regenerated Cellulose Dialysis Tubing MWCO 10,000 (Spectrum Labs;
Rancho Dominguez, CA)

	
  

•

UV-Vis Spectrophotomer (Thermo Scientific Evolution 60)

•

100U/ml HRP (Sigma-Aldrich; St. Louis, MO)

•

30% H2O2 (Sigma-Aldrich; St. Louis, MO)

•

PBS (Gibco; Grand Island, NY)
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•

ARES-LS Parallel plate rheometer (TA Instruments; New Castle, DE)

•

JEOL 6335 Field Emission Scanning Electron Microscope (JEOL; Peabody, MA)

7.9.2 Methods
7.9.2.1 Formation of protein crosslinked hydrogels

7.9.2.1.1 Synthesis of protein-tyramine conjugates
LF–tyramine conjugates were synthesized by a carbodiimide/active-ester coupling
reaction. 500 mg protein was dissolved in 50 ml of 1 M MES buffer. To this solution,
500 mg of EDC, 150 mg NHS and 300 mg tyramine were added. The mixture was
allowed to react for 24 hours at room temperature under gentle stirring. The modified
polymer was purified by dialysis against excess deionized water using Standard
Regenerated Cellulose Dialysis Tubing MWCO 10,000. Following dialyzation to remove
unreacted tyramine, EDC, NHS, the remaining solution was subsequently frozen at -20°C
and then lyophilized to give LF-tyramine conjugates.

Water soluble gelatin-tyramine conjugates were synthesized by the carbodiimide/activeester coupling reaction. 500 mg protein was dissolved in 50 ml of 1 M MES buffer. To
this solution, 500 mg of EDC, 150 mg NHS and 300 mg tyramine were added. The
mixture was allowed to react for 24 hours at room temperature under gentle stirring. The
modified polymer was purified by dialysis against excess deionized water using Standard
Regenerated Cellulose Dialysis Tubing MWCO 10,000. Following dialyzation to remove
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unreacted tyramine, EDC, NHS, the remaining solution was subsequently frozen at -20°C
and then lyophilized to give the water soluble gelatin-tyramine conjugates.

Water/PBS soluble gelatin–tyramine conjugates were also synthesized by the
carbodiimide/active-ester coupling reaction. 875 mg protein was dissolved in 55 ml of 1
M MES buffer and 20 mL of H2O. To this solution, 510 mg of EDC, 150 mg NHS and
510 mg tyramine were added. The mixture was allowed to react for 24 hours at room
temperature under gentle stirring. The modified polymer was purified by dialysis against
excess deionized water using Standard Regenerated Cellulose Dialysis Tubing MWCO
10,000. Following dialyzation to remove unreacted tyramine, EDC, NHS, the remaining
solution was subsequently frozen at -20°C and then lyophilized to give gelatin-tyramine
conjugates.

7.9.2.1.1.1 Quantification of tyramine modification
Protein was modified with varying reaction times and tyramine concentration was then
examined as a function of reaction time. Tyramine concentration was measured at 275
nm using UV-Vis Spectrophotomer. A tyramine standard curve was used to determine
the concentration of a tyramine in the modified bLF samples (Figure 77).

Standard

curve stock was made by diluting 10.5 mg tyramine in 2 ml MES buffer (n = 4 biological
replicates). 0 - 40 µl of standard curved stock was diluted in increments of 5 µl further
in 900 µl MES buffer (n=4) and diluted samples were measured by spectrophotomer at
275 nm.
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Figure 77. Tyramine Concentration Standard Curve.

7.9.2.1.2 Preparation of protein crosslinked gels
Hydrogels were prepared by the HRP-mediated oxidative coupling of protein-tyramine
conjugated molecules in the presence of dilute H2O2. Hydrogel samples were prepared in
vials at 25oC. 100 U/ml HRP and 30% H2O2 were individually dissolved at varying
concentrations in PBS or DDI H2O. HRP solution was added at desired concentrations
with sufficient agitation and time to ensure the rhLF-Tyr solution was fully hydrated.
7.9.2.1.2.1 Gelatin gel
7.9.2.1.2.1.1

Gelatin Gel (dissolved in H2O)

To make gelatin gel, first dissolve tyramine-modified gelatin in 10 U/ml HRP (diluted in
H2O) and mix well. To form gel, at diluted H2O2 and mix well.

For example, the

following is the protocol to make 10 mg/ml gelatin gel. To make 1 ml of 10 mg/ml
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gelatin/HRP solution: dissolve 10 mg modified in 1 ml of 10 U/ml HRP (dissolved in
H2O) and then mix well. Finally, to make 10 mg/ml gelatin gel: 100 µl of gelatin/HRP
solution + 1 µl 0.25% H2O2.

7.9.2.1.2.1.2

Gelatin Gel (dissolved in 1:1 PBS:H2O ratio)

To make gelatin gel, first dissolve tyramine-modified gelatin in 10 U/ml HRP (diluted in
1:1 PBS:H2O ratio) and mix well. To form gel, at diluted H2O2 and mix well.

For

example, the following is the protocol to make 10 mg/ml gelatin gel. To make 1 ml of 10
mg/ml gelatin/HRP solution: dissolve 10 mg modified in 1 ml of 10 U/ml HRP (diluted
in 1:1 PBS:H2O ratio) and then mix well. Finally, to make 10 mg/ml gelatin gel: 100 µl
of gelatin/HRP solution + 1 µl 0.25% H2O2.

7.9.2.1.2.2 LF gels
To make LF gels, first dissolve tyramine-modified LF in half the total volume of 10 U/ml
HRP (dissolved in H2O) and mix well. Next, add the second half of the total volume of
10 U/ml (dissolved in PBS) and mix well. To form gel, at diluted H2O2 and mix well.
For example, the following is the protocol to make 10 mg/ml LF gel. To make 1 ml of 10
mg/ml LF/HRP solution: dissolve 10 mg modified LF in 500 µl of 10 U/ml HRP
(dissolved in H2O) and then mix well. Add 500 µl of 10 U/ml HRP (dissolved in PBS).
Finally, to make 10 mg/ml LF gel: 100 µl of LF/HRP solution + 1 µl 0.25% H2O2.
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7.9.2.2 Characterization of hydrogels

7.9.2.2.1 Gelation time
Sol to gel time was determined via vial inversion method (Menger, Caran 2000).

10

mg/ml protein-tyramine conjugate in 100 µl of 10 U/ml HRP + 1 µl of 0.25% H2O2
represents the standard gelling conditions for LF and gelatin gels.

Variables were

individually varied and tested for effect on gelatin time.
7.9.2.2.2 Rheological testing
A rheometer is an ideal instrument that may be used to measure the gel strength. The
holo-rhLF gels were subjected to rheological measurements to assess the viscoelastic
properties at varying component concentrations at 25ºC. Briefly, the 150 μl of modified
holo-rhLF/HRP and 1 μl H2O2 mixture was mixed together in an eppendorf tube and then
immediately introduced in a parallel plate rheometer and started the rheological testing
program. Dynamic frequency sweeps were then performed in the linear viscoelastic
region to determine values of the storage (G’) and loss (G”) modulus to compare the
mechanical strength of gels with different concentrations of holo-rhLF.

Rheology

testing conditions were as follows: angular frequency of 1 rad/sec; 3% strain; 1000 µm
gap width; 100 µl volume load.
7.9.2.2.3 Gel morphology
The morphology of the hydrogels was visualized by scanning electron microscope to
evaluate the effect of solution concentrations on gel microstructure. The gels were flash
frozen by immersing in liquid nitrogen for 1 minute followed by 24 hour lyophilization
and then observed under the SEM. Prior to imaging, the samples were mounted on
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aluminum stubs and samples were platinum coated for improved conductivity. The
samples were viewed at an accelerating voltage of 10kV and 12 µA. Measurements
(n=30) of pore size were obtained using Image J program (U.S. National Institutes of
Health, Bethesda, MD).
7.9.2.2.4 Percentage of water uptake
The percentage of water uptake of the injectable gels (n=4 biological replicates) was
determined as follows. Briefly, holo-rhLF gels were prepared in plastic inserts, flash
frozen with liquid nitrogen and then lypholyzed.

The weight of the samples was

determined (W1) before incubating them in phosphate buffer solution at 37°C. At each
time point, the samples were taken out, dabbed dry with a paper towel and their wet mass
(Wwet) was determined. The percentage water uptake of the samples was determined as
[% water uptake = [(Wwet-W1)/W1) ×100].
7.9.2.2.5 Degradation of holo-rhLF biogels in vivo
Sprague Dawley rats (Charles River Laboratories, Wilmington, MA) (12-16 weeks) were
used 10 mg/ml holo-rhLF were injected subcutaneously to form the gels in situ. The
animals were cared for according to the procedures approved by the Animal Care and
Use Committee at the University of Connecticut Health Center, and following the
guidelines established by the U.S. National Institutes of Health. At 4 and 12 weeks, rats
were sacrificed and the tissue surrounding the injection sites were excised using blunt
dissection technique. Samples were rinsed with PBS solution, washed with deionized
water, fixed in 10% formalin solution (Surgipath, USA) and embedded in paraffin,
sectioned and hematoxylin and eosin (H&E) was performed.
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7.9.2.3 Soluble holo-rhLF protein release from holo-rhLF gel

100 µl of 10 mg/ml holo-rhLF gel was formed in a 1.5 ml eppendoff tube (n=5). 1 mL
PBS was added above the holo-rhLF gel and incubated at 37oC. 150 µl aliquots were
taken from each sample every 24 hours for 5 consecutive days. Phenolic content was
measured via UV Spectrophotomer at 275 nm.
7.9.2.4 Cell encapsulation in hydrogel

Protein-tyramine conjugate was dissolved in 10 U/ml HRP. Appropriate number of cells
were resuspended in protein-tyramine conjugate/HRP solution followed by the addition
of H2O2. The encapsulated cells were then maintained in medium at 37ºC.
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